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Many proteins require prenylation in order to be biologically functional.  Some such 
proteins include the small Ras and Rho GTPase superfamilies, nuclear lamins A and B, and the 
kinesin motor proteins CENP-E and F. Prenyltransferase (PTase) inhibition is currently being 
explored as a possible treatment not only for cancer but for a wide variety of other diseases.  
Clinical studies revealed that the effectiveness of farnesyltransferase inhibitors (FTIs) to 
treat Ras-dependent tumors is determined by which isoform of Ras is overactive.  Unfortunately 
the majority of Ras-dependent tumors have a mutation in either the N- or K-Ras isoforms; both of 
these isoforms can be alternatively prenylated by GGTase-I and, therefore, do not respond to FTI 
treatment. This sparked our interest in developing GGTase-I inhibitors and exploring 
requirements needed for alternative prenylation by GGTase-I.  
Clinical studies also brought about the discovery that FTIs were effective toward some 
Ras-independent tumors (e.g. breast cancer, chronic & acute myeloid leukemia, multiple 
myeloma, and advanced myelodyplastic syndrome).  Presumably, these results are due to the 
prenylation of one or more essential proteins required for tumorigenesis.  The identity of the 
protein(s) responsible for the observed antitumor affect in Ras-independent tumors remains 
elusive.  Identifying tumors reliant on proteins that are solely prenylated by one prenyltransferase 
could open up new avenues for therapeutic intervention by FTIs or GGTIs.   Thus, identifying 
xix 
 
prenylated proteins and the prenyltransferase(s) required for this modification is of great interest 
and importance. 
Chemical tools capable of modulating prenylation of specific proteins would allow 
researchers to more precisely investigate proteins’ individual roles in the cell as well as the 
function of their lipid moieties.  To this end we use a combinatorial approach in which we screen 
isoprenoid pyrophosphate analogs against a synthetic Dansyl-GCaaX peptide library (the minimal 
recognition sequence of PTases; Dansyl-G = Dansyl-glycine, C = Cys, a = aliphatic amino acid, 
X = a small subset of amino acids, which in general designates which PTase modifies the CaaX 
sequence).  This approach revealed that for each pyrophosphate analog, both FTase and GGTase-
I exhibit unique patterns of reactivity among various CaaX sequences.  Our laboratory has also 
developed a tagging-via-substrate proteomic method to identify farnesylated proteins within cells.  
The aim of this research focuses not only on extending our current techniques into the realm of 
geranylgeranylation in order to study the enzymatic requirements of GGTase-I, but also on 
developing cellular probes that would allow for the identification of geranylgeranylated proteins.  
The initial goal of this project was to advance our knowledge of GGTase-I substrate 
specificity in terms of both prenyl and protein substrates and to investigate GGTase-I versus 
FTase substrate specificity. The overall goal of this project was the development of biologically 
useful chemical tools that could in the future be developed into proteomic probes for GGTase-I in 
order to identify and characterize geranylgeranylated proteins. 
1 
 
CHAPTER 1.   INTRODUCTION 
 
1.1    Posttranslational Modifications 
 
Posttranslational modifications are chemical modifications that proteins undergo 
following their biosynthesis resulting in enhanced protein biodiversity.  The human genome 
predicts 30,000 genes; however, due to posttranslational modifications, the human proteome is 
hypothesized to contain 300,000 – 3,000,000 different forms of proteins.1  The dynamicity of 
proteins and their ability to change in the presence of various cellular stimuli via posttranslational 
modifications are what dictate various cellular functions and activities.   
Posttranslational modifications can be classified into two general groups: covalent 
modifications and covalent cleavage.    The majority of covalent modifications (e.g. acetylation, 
glycosylation, methylation, lipidation, phosphorylation, and ubiquitination) can be categorized in 
accordance with the type of amino acid side chain modified, the extent of reversibility of the 
modification, and classification of the modifying enzyme.1  Covalent cleavage or hydrolytic 
cleavage of peptide backbones in proteins is catalyzed by proteases or, less commonly, by 
autocatalytic cleavage.1    
Protein lipidation is a posttranslational modification that aids in membrane targeting by 
covalently attaching at least one lipid anchor to a protein.  Many proteins involved in human 
diseases are modified by the covalent linkage of fatty acids or isoprenoid groups.  The attachment 
of hydrophobic groups to proteins aids in regulating protein structure and function.
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Major types of protein lipidation include: N-myristoylation, S-acetylation, S-prenylation, 
palmitylation, and the attachment of glycosyl phosphotidylinositol anchors.1 
 
1.2    Protein Prenylation 
 
After protein prenylation’s first appearance in the late 1970’s in fungal peptide 
pheromones, it was realized in the late 1980’s that the Ras superfamily of proteins underwent 
protein prenylation, a type of posttranslational modification, which localized the proteins to the 
plasma membrane.2, 3  Many proteins require prenylation in order to be biologically functional; 
these proteins include critical proteins such as the small Ras and Rho GTPase superfamilies, 
nuclear lamins A and B, and the kinesin motor proteins CENP-E and F.4   
Protein prenylation, a type of lipidation, occurs on a cysteine four residues from the C-
terminus.  Prenylated proteins contain a C-terminal “CaaX box” sequences, where ‘C’ denotes 
cysteine, ‘a’ is typically an aliphatic amino acid, and ‘X’ represents a small subset of amino acid 
residues.5  Proteins containing a CaaX box are recognized by prenyl transferases located in the 
cytosol.  The prenyl transferase enzymes catalyze the formation of a thioether bond between the 
cysteine residue of the CaaX box and isoprenyl lipids.6  There are three categories of 
prenyltransferases in mammalian cells: farnesyl transferase (FTase), geranylgeranyl transferase-I 
(GGTase-I), and geranylgeranyl transferase-II (GGTase-II aka RabGGTase).  FTase and 
GGTase-I are CaaX prenyltransferases.  FTase catalyzes the covalent attachment of a 15-carbon 
farnesyl isoprenoid (farnesyl pyrophosphate, FPP)7 while GGTase-I catalyzes the attachment of a 
20-carbon geranylgeranyl isoprenoid (geranylgeranyl pyrophosphate, GGPP) to cysteine.8  Both 
isoprenoid chains are derived from the mevalonate pathway.  In comparison, GGTase-II catalyzes 
the attachment of two 20-carbon geranylgeranyl isoprenoids to a C-terminal CXC or CC motif.9  
The three types of protein prenylation modifications are shown in Figure 1.1.  After covalent 
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attachment of the isoprenoid(s), the protein then relocates to the endoplasmic reticulum where it 
undergoes proteolytic cleavage of the “-aaX” residues by the endoprotease Ras-converting 
enzyme-1 (Rce-1).2, 5  To eliminate the charge of the free carboxylate, the C-terminal cysteine is 
methyl-esterified by isoprenylcysteine carboxyl methyl transferase (Icmt), utilizing S-adenosyl 
methionine as the methyl donor.10, 11  Upon completion of these modifications, the newly 
isoprenylated protein can be anchored in the membrane and regulate various cellular functions 
(Figure 1.2) such as cell signaling (Ras & others), cell division (CENP-E & CENP-F), and 
organelle structure (lamins).12  
 
Figure 1.1.  Post-translational modifications of CaaX or CXC-containing peptides by 



























































Figure 1.2.  Post translational modifications of Ras proteins by FTase & GGTase-I and a 
simplified version of the Ras signaling pathway.  Ras signals downstream to the MEK/MAPK 
pathway.  
 
1.3    Ras Family of Proteins 
 
 It has been estimated that approximately 0.5-2% of all mammalian proteins are 
prenylated, but roughly only 60 proteins have been identified thus far.13  Of the known prenylated 
proteins, many exhibit a plethora of cellular functions including cell signaling, cell mobility, cell 
division, organelle structure, and vascularization.14-20  Due to its diverse functionalities, it is not 
surprising that protein prenylation is currently being explored as possible treatments not only for 
cancer but for a wide variety of other diseases such as neurodegradation, Progeria, 
arteriosclerosis, as well as parasitic and viral infections. 
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The RAS superfamily of GTPases is a well-studied class consisting of over one hundred 
small monomeric G proteins that act as molecular switches.2  Members of this superfamily 
include the Ras family of proteins: H-Ras, N-Ras, & K-Ras (K-Ras4a & K-Ras4b). In addition to 
prenylation, all three isoforms of Ras require additional modifications for proper membrane 
localization.  H-Ras and N-Ras both require palmitoylation for membrane localization while K-
Ras does not need to be alternatively lipidated.21  Instead, K-Ras has a polylysine sequence 
located near the prenylated cysteine residue that offers additional membrane affinity for 
localization to the plasma membrane.   
 Ras acts as a molecular switch and cycles between an active-GTP bound and an inactive-
GDP bound state that is controlled predominately by guanine nucleotide exchange factors 
(GEFS).22  In its active-GTP bound state Ras localizes to the inner leaflet of the plasma 
membrane where it can interact with other cofactors and initiate a signaling cascade.  At the 
plasma membrane, growth factors bind to membrane-bound receptor tyrosine kinases (RTK) 
which results in RTK phosphorylation.  This allows for docking proteins, such as growth factor 
receptor-bound protein 2 (GRB2), to bind to the phosphorylated RTK via Src-homology 2 (SH2) 
domains.  Next, via an SH3 domain, GRB2 can associate with Son of Sevenless (SOS), a GEF, 
thus activating SOS.  Activated SOS converts the membrane-anchored, inactive-GDP bound Ras 
to the active-GTP bound Ras. Activated Ras can then associate with, and in turn activate, Raf-1 
which leads to the upregulation of cell growth and proliferation via the MAPK pathway (Figure 
1.2).23 
Oncogenic Ras is stabilized in an active GTP-bound state that promotes cellular signaling 
and, consequently, tumorigenesis.  The constitutive activation of these proteins was linked to a 
single point mutation in the Ras gene and implicates the Ras proteins in a number of cancers.24, 25   
Approximately 30% of all tumors have an activating mutation in one of the RAS genes with high 
incidence rates in pancreatic (~90%), colon (~50%), lung (~40%) and acute myeloid leukemia 
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cancers (~20%).26-28  The constitutive activation of Ras contributes to deregulation of tumor-cell 
growth, programmed cell death, invasiveness, and angiogenesis.  Moreover, Ras farnesylation  is 
required for proper cell signaling and was implicated as the cause of oncogenic transformations in 
cells.29     
 
1.4    Targeting Protein Prenylation & Alternative Prenylation in Cancer 
 
When it was discovered that the Ras family of proteins is farnesylated and their function 
depends on their association with the inner face of the plasma membrane, FTase as a drug target 
along with its biochemical mechanisms became of great interest among the scientific community. 
Over the past two decades, several FTase inhibitors (FTIs) have been developed and evaluated as 
potential cancer therapeutics in an effort to treat Ras-dependent tumors.  These FTIs include: 1) 
FPP analogs (non-peptidomimetic) that compete with the isoprenoid substrates,30-32 2) 
peptidomimetic inhibitors that mimic the CaaX sequence of target proteins such as Ras,33-35 and 
3) bisubstrate analogs which mimic both the isoprenoid and the CaaX sequence.36-38 
 Several FTIs showed promising results, both in vitro and in vivo, in preclinical 
experiments with low nanomolar IC50 values; however, clinical trials brought about more 
questions than answers.39 These studies revealed that the effectiveness of FTIs to treat Ras-
dependent tumors is reliant upon which isoform of Ras is overactive.  FTIs are general effective 
toward H-Ras diseases.  This is a consequence of the fact that H-Ras can only be prenylated by 
FTase.  Unfortunately, the majority of Ras-dependent tumors have a mutation in either the N- or 
K-Ras isoforms; in particularly, K-Ras4B is the main oncogenic form of Ras.40  It was discovered 
that both of these isoforms of Ras can be alternatively prenylated by GGTase-I.41  Due to 
alternative prenylation, N- and K-Ras tumors do not respond to FTI treatment.   
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Moreover, preclinical studies brought about the revelation that although FTIs are not 
effective for treating the Ras-dependent tumors they were originally envisioned for (due to 
alternative prenylation), FTIs were effective toward some Ras-independent tumors (e.g. breast 
cancer, chronic & acute myeloid leukemia, multiple myeloma, and advanced myelodyplastic 
syndrome).4, 27, 42  Presumably, these results are due to the prenylation of one or more essential 
proteins required for tumorigenesis. This finding sparked the quest to identify “Protein X,” the 
true target(s) responsible for the observed antitumor effects in Ras-independent tumors.  The 
identity of the proteins(s) responsible for the observed antitumor affect in Ras-independent 
tumors remains elusive.  
 
1.5    The CaaX Prenyltransferase Enzymes 
 
 In the early 1990’s, two enzymes were identified that catalyze the CaaX protein 
prenylation reactions: farnesyltransferase and geranylgeranyltransferase-I.  As previously 
mentioned, the primary functions of these cytosolic enzymes are to covalently attach isoprenoid 
chains to the sulfur of a C-terminal cysteine via a thioether linkage.  This posttranslational 
modification serves as a method to localize and anchor proteins to cellular membranes, or other 
cellular locations, to ensure proper cellular functioning.   
FTase catalyzes the transfer of a 15-carbon isoprenoid onto a cysteine residue.  
Mammalian FTase is a heterodimeric protein consisting of a 46 kD α-subunit and a 48 kD β-
subunit that, as revealed by X-ray crystal structure, are predominantly alpha-helical.5, 7  The active 
site of this enzyme is located in a groove found between the α- and β-subunits; thus, both subunits 
are essential for substrate binding and catalysis.  For protein recognition, FTase uses a C-terminal 
“CaaX” motif.  Generally, the “X” residues control enzyme-substrate recognition between FTase 
and GGTase-I.  The “X” residues that designate farnesylation are serine, methionine, or 
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glutamine.  On the other hand, GGTase-I recognizes protein substrates where the “X” residues are 
typically leucine, phenylalanine, and occasionally methionine.5, 6, 8, 43 A list of some known 
farnesylated and geranylgeranylated proteins can be found in Table 1.1. 
Mammalian GGTase-I is also a heterodimeric zinc metalloenzyme consisting of a 46 kD 
α-subunit and a 43 kD β-subunit that are predominantly alpha-helical.4, 6  In fact, FTase and 
GGTase-I have the same α-subunit but differ in their β-subunits.  The extensive interface at the α- 
and β-subunits essentially buries ~20% of the accessible surface area of each subunit.6  Unlike 
most subunit interfaces, the α/β-interface of both FTase and GGTase-I exhibits greater 
hydrophilic character resulting in nearly double the number of hydrogen bonds.   
Although the β-subunits share only ~25% sequence homology, they have very similar 
structures consisting of 14 α-helices in FTase and 13 α-helices in GGTase-I (Figure 1.3).6  The α-
α barrel shown in Figure 1.3C is made up of twelve of these α-helices.  The core of this barrel 
consists of six parallel helices while the other six helices are parallel with each another but 
antiparallel in regard to the core helices and form the outside of the barrel.  In both enzymes, one 
end of the α-α barrel is open to solvent while the opposing end is blocked by a loop formed from 
the C-terminal residues of the β-subunit.  This conformation creates the active site which is a 
deep, funnel-shaped cavity in the center of the barrel.  The active site cavity has a depth of 14Å 




Figure 1.3.  Structural representation of FTase (A) and GGTase-I (B) with the α-subunit shown 
in red.  (C) Overlay of the β-subunits of FTase (blue) and GGTase-I (yellow).6 
 
1.5.1    Mechanism of Catalysis and Kinetics of CaaX Prenyltransferases 
 
Both FTase and GGTase-I have been identified in a number of various species including 
mammals,44, 45 protists,46, 47 plants,48, 49 and fungi.50, 51  The CaaX prenyltransferases are essential 
for the function of these organisms and elimination of these enzymes have severe detrimental 
effects and in some instances, lethality.50, 52-54  As mentioned previous, both FTase and GGTase-I 
are cytosolic heterodimeric zinc metalloenzymes with unique, yet similar, kinetics of binding and 
catalytic mechanisms.  In fact, all three prenyltransferases have a conserved prenyl binding site 
and have an ordered binding mechansim.6-8, 55  The catalytic cycle begins with the binding of the 
pyrophosphate substrate (FPP or GGPP depending on the enzyme) to the active site located at the 
interface of the α- and β-subunits.  Following FPP/GGPP binding, the CaaX protein or peptide 
binds to the active site to form a ternary complex.8, 56, 57  It is believed that the CaaX protein binds 
to the active site as the thiol but is rapidly deprotonated and binds tightly to the zinc atom as the 
thiolate.58-60 
In the case of FTase, the zinc atom is embedded within the active site in the β-subunit and 
coordinates to three important amino acids in the β-subunit (D297β, C299β, and H362β) and is 
located 2.5 Å from the cysteine sulfur of the CaaX box.6, 8  The Zn2+ atom is present in 
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stoichiometric amounts and has been shown to be crucial for enzyme activity.58, 61  In addition to 
Zn2+, Mg2+ is also present in the mechanism of action.  Although it is not essential for enzyme 
catalysis, Mg2+ has been shown to enhance the rate of FTase activity by several hundred fold.62  It 
is believed that the catalytic role of Zn2+ in farnesylation is to generate and coordinate to the 
cysteine thiolate, while the Mg2+ plays the important role of positioning the FPP substrate prior to 
catalysis.56, 63, 64  There are also implications that Mg2+ aids in the stabilization of the diphosphate 
leaving group that results from the chemical lipidation with farnesyl pyrophosphate.62  Taken 
together, Zn2+ and Mg2+ ensure the efficient function of FTase by properly orienting FPP and 
forming/activating the cysteine thiolates (Figure 1.4). 
Analogous to FTase, the Zn2+ atom in GGTase-I also coordinates to three strictly 
conserved residues (D269β, C271β, and H321β), as well as to the thiolate group of the cysteine 
residue of the CaaX box.8  Kinetic studies revealed that although FTase requires millimolar 
amounts of Mg2+ for full catalytic efficiently, GGTase-I is Mg2+ independent.65  It has been 
hypothesized that FTase requires Mg2+ in order to stabilize the negative charge on the phosphate 
group that develops as the bond between the α-phosphate and the C1 atom of the farnesyl group 
breaks.62  In fact, structural studies show that the Mg2+ coordinates to residue D352β of FTase and 
the pyrophosphate moiety of FPP.6  Sequence alignment of FTase and GGTase-I revealed that the 
D352β residue of FTase corresponded to a lysine residue in GGTase-I (K311β).8  FTase and 
GGTase-I superimposition revealed that the lysine residue of GGTase-I adopts a conformation 
that positions the positively charged side chain amine (Nε) at the site of the Mg
2+ in FTase.6  
Mutagenesis studies confirm these theories.63, 66  Mutating the D352β residue of FTase to a lysine 
abolished Mg2+ dependence while mutating the K311β of GGTase-I to either alanine or aspartate 
introduced Mg2+ dependence (Figure 1.4).66 
After the binding of the pyrophosphate and CaaX protein to the enzyme, the following 
chemical step proceeds quickly via a mechanism that is still highly controversial.  This chemical 
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step consists of the formation of the thioether linkage between the isoprenoid chain and the 
cysteine thiolate with the pyrophosphate acting as the leaving group.62, 67 The rate limiting step of 
protein prenylation is the product release.68  To induce product release, a second molecule of the 
isoprenoid pyrophosphate must bind to the active site.69, 70  This causes the newly added prenyl 
motif of the CaaX protein to move into the “exit groove” located in the β-subunit where it is then 
transferred to the endoplasmic reticulum for further modifications by RCE-1 and ICMT (Figures 
1.5 & 1.6).  
 
Figure 1.4.  Transition state model of protein prenylation. Hydrogen bonds are shown as dashed 
red lines.  Red amino acid residues correspond to GGTase-I & blue amino acid residues 


















































Figure 1.5.  Reaction pathway of farnesylation (PDB: 1FT1, 1FT2, 1K2P, 1K2O).6 
 
 
Figure 1.6.  Reaction pathway of geranylgeranylation (PDB: 1N4P, 1N4Q, 1N4S) 
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1.5.2    Comparing the Isoprenoid Binding Pockets of FTase & GGTase-I 
 
Interestingly, FTase is capable of binding to geranyl pyrophosphate (GPP, 10 carbon 
isoprenoid chain) and GGPP.  In fact, FTase can catalyze reactions with either GPP or FPP, 
although GPP is a much poorer substrate than FPP.  On the other hand, it has been shown that 
GGPP is a competitive inhibitor of FTase.69, 71  When bound to FTase, GGPP hinders proper 
CaaX binding/alignment in such a manner that catalysis cannot occur.  Conversely, FPP can act 
as a substrate for GGTase-I, albeit with 300-fold less affinity than GGPP.  These findings can be 
partially explained by taking a closer look at the enzymes’ active sites.  
The major portion of the enzyme that interacts with the isoprene diphosphate is the β-
subunit.6  As mentioned previously, the β-subunits of FTase and GGTase-I are only ~25% 
homologous; however, the portion of the β-subunits that interact with the isoprene are strikingly 
similar (Figure 1.7A).  Comparing the binding pockets of FTase and GGTase-I shows that FPP 
binds to FTase in an extended conformation, but GGPP binds in such a way that the last isoprene 
unit of GGPP is nearly perpendicular with respect to the rest of the molecule within the active site 
(Figure 1.7B).6 This can be attributed to the fact that W102 β and W106β in FTase-I correspond 
to T49β and F53β, respectively, in GGTase-I.  The differences in the amino acids within the 
active site allow for a larger binding pocket in GGTase-I.  Thus, this could explain why GGPP 
acts as a competitive inhibitor of FTase.  The isoprenoid chain of GGPP can be recognized by and 
bind into the FTase binding pocket; however, due to the longer chain of GGPP, the diphosphate 
head group cannot orientate properly to coordinate with the zinc ion (Figures 1.7C & D).  
Therefore, the geranylgeranyl isoprenoid chain cannot be transferred to the Cys residue of a 





Figure 1.7.  Comparison of FTase & GGTase-I β-subunits within the binding pocket.  Amino 
acid residues that interact with the isoprene unit are shown as sticks; FPP (red) and GGPP (pink).  
(A) Overlay of FTase (blue) and GGTase-I (yellow) reveals several identical amino acids (green).  
(B)  Unique amino acids of the β-subunits within the binding pocket are shown.  (C) Surface view 
of FTase.  A much smaller binding pocket is available due to W102β and W106β.  GGPP does 
not fit properly into the cavity.  (D) Surface view of GGTase-I.  The W102 β and W106β of 
FTase-I correspond to T49β and F53β in GGTase-I allowing for a larger isoprenoid pocket. 






















1.6    GGPP Analogs as Chemical Tools 
 
While the reaction mechanisms of the prenyltransferases have been vastly studied and are 
well understood, there are many unanswered questions pertaining to their in vivo function(s).  
Bioinformatic analysis predicts that there are hundreds of prenylated proteins, but only a small 
percentage of proteins have been experimentally confirmed.  Thus, the true number of prenylated 
proteins, referred to as the prenylome, remains unknown.  Moreover, FTase and GGTase-I have 
been shown to display overlapping substrate specificities with a subset of substrates; however, the 
in vivo extent and the physiological significance of this overlap have been studied on a very 
limited number of substrates. 
  The identification of the elusive “Protein-X targets” can be accomplished via a variety 
of different techniques.  One such method is the use of prenyltransferase inhibitors (PTIs) to 
evaluate the role of individual proteins; however, this approach can be inconvenient due to the 
non-specific nature of PTIs.  It is presumed that FTIs and GGTIs (GGTase-I inhibitors) affect 
farnesylation and geranylgeranylation, respectively, on a global level.  Hence, upon inhibitor 
administration, monitoring the cellular effect(s) of a single protein would be an extremely 
difficult and daunting task when taken into consideration that it is predicted ~2% of all 
mammalian proteins are prenylated (i.e. 6,000-60,000 proteins).   
Fortunately, there are other more attractive approaches that our laboratory has taken 
advantage of in the past.  One such approach is the use of unnatural pyrophosphate analogs.31, 72-76  
These unnatural analogs can be very beneficial when they behave as either selective substrates or 
selective inhibitors of specific CaaX proteins.  For example, if we could design and synthesize a 
GGPP analog that was a selective inhibitor for K-Ras, we could evaluate the role of 
geranylgeranyl-KRas in cells without the interference of other geranylgeranylated proteins.   
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Another approach utilized for elucidating the biological effects of one prenylated protein 
from another is with the use of farnesylated pyrophosphate analogs containing either a 
fluorophore and/or an affinity tag (Figure 1.8).4  Such analogs provide researchers with a means 
to purify farnesylated proteins from cell lysates and/or a method to visualize farnesylated proteins 
in vivo.  While PTIs are a great tool to study global prenylation, selective FPP/GGPP analogs and 
affinity-labeled FPP/GPP analogs are far superior chemical tools to aid in the elucidation of the 
prenylome and “protein-X”.  In the past, these approaches have been largely focused on 
farnesylation; hence, unique GGPP analogs are still largely unexplored. 
 
Figure 1.8.  Examples of farnesylated pyrophosphates containing affinity tags or fluorophores 
utilized in the past.4  
 
Many of the modifications made to the FPP scaffold that our laboratory has investigated 
are shown in Figure 1.9.  These analogs have been extensively screened with various libraries of 
dansylated-CaaX containing peptides and many show activity in our in vitro fluorescence assays 
as either substrates or inhibitors.31, 73, 75-82  Only three of the eight modifications shown have been 
extended to develop analog libraries of GGPP.  With the exception of the 3-substituted analogs, 
the modified GGPP analogs show similar activity/selectivity trends in reference to their FPP 















































































opportunity to develop novel GGPP analogs that could provide insight into protein 
geranylgeranylation.  By developing selective GGPP analogs in combination with an affinity tag 
and/or fluorophore for purification and/or visualization would provide investigators with novel 
chemical tools for monitoring protein geranylgeranylation in vivo. 
Figure 1.9.  Modifications of the farnesyl scaffold explored by our laboratory.  Green: These 
modifications have been evaluated on the geranylgeranyl scaffold.  Blue: These modifications 
have yet to be investigated utilizing a geranylgeranyl scaffold allowing for new opportunity.  
 
 
1.7    In vitro Fluorescence Screening Assay for FTase & GGTase-I Activity 
 
In order to determine the activity of FTase and GGTase-I, a fluorescence-based approach 
was originally developed by Pompliano and coworkers and later modified by Poulter and 
collegues.83, 84  This approach takes advantage of two facts: 1) the minimal recognition sequence 
of FTase and GGTase-I is the tetrapeptide CaaX sequence, and 2) the unique properties of the 
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dansyl fluorophore.  In a simple assay buffer solution, the dansyl group emits at a wavelength of 
550 nm with a 340 nm excitation; however, upon lipidation of a fluorescently labeled peptide, the 
fluorophore undergoes a blue shift to an emission of 505 nm and also leads to a large increase in 
fluorescence (Figure 1.10).  Although it is not quite understood how the increase in hydrophobic 
environment elicits such a response, it has been proven that these assays are robust and 
reproducible.  Due to the added hydrophilic character, prenylation can be confirmed by HPLC.  
With our laboratories optimized conditions, the unprenylated proteins have a retention time of ~1-
2 minutes whereas the prenylated product has a retention time of ~23 minutes.  Therefore, by 
utilizing pentapetides of the form dansyl-GCaaX, we can observe the extent of protein 
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1.8    Protein Prenylation & Other Diseases 
 
 Due to the vastness of protein prenylation, it is not surprising that recent studies have 
brought to light prenylation as a key player in several diseases. While protein prenylation is most 
well-known and investigated for its pivotal role in cancer, it has also been implicated or could be 
a potential target in a variety of other diseases such as neurodegeneration (e.g. Alzheimer’s),85, 86 
atherosclerosis/restenosis,87, 88 angiogenesis,19 retinal degradation,89, 90 premature aging (e.g. 
Hutchinson-Gilford progeria syndrome),91-93 osteoporosis,94 parasitic disease (e.g. malaria),95, 96 
Hepatitis δ virus,97 Costello Syndrome,98, 99 renal disease,100, 101 and asthma.102  It is important to 
remember that protein prenylation is present in all types of cells and a key regulator of a variety 
of cellular functions.  Thus, identifying prenylated proteins and understanding their individual 
cellular roles will aid researchers to determine the best approach to a given disease and perhaps 
even uncover novel therapeutic targets.  The first step is designing selective substrates or 
inhibitors of this cellular pathway to be used as chemical tools to probe the prenylome. 
 
1.9    Significance of Work 
 
 The prenylome is believed to consist of 60-600 thousand proteins; however, only a small 
percentage of these proteins have been confirmed.  Moreover, there is a grey area to protein 
prenylation in which a subset of known proteins can be prenylated by either FTase or GGTase-I.  
This can make therapeutic intervention difficult for diseases reliant on prenylation.  For example, 
FTIs were originally designed for Ras driven tumors; however, K-Ras, the major form of 
oncogenic Ras, can be geranylgeranylated by GGTase-I, rendering FTIs ineffective.  On the other 
hand, Hutchinson-Gilford progeria syndrome and Costello syndrome are genetic disorders caused 
by mutations of the LMNA (lamin A) and H-RAS genes, respectively.  Both lamin A and H-Ras 
are farnesylated proteins; thus, FTIs are being explored as treatment options for these disorders 
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and preliminary findings are promising. While FTIs and GGTIs have the potential to be highly 
effective therapeutic treatments, researchers still lack the ability to determine which diseases FTIs 
and GGTIs would be effective against.  Hence, possessing tools that can identify prenylated 
proteins, unravel their biological significance, and/or determine which prenyltransferase is 
responsible for said prenylation would be of great significance. 
Much work has been focused on the elucidation of farnesylated proteins.  The use of 
unnatural FPP analogs as selective substrates or inhibitors of FTase has been employed in an 
effort to reveal each farnesylated proteins’ biological impact.  The development of selective 
geranylgeranylating substrates or inhibitors would allow researchers to evaluate one or a few 
proteins at a time.  Thus, these analogs should greatly increase the amount of information 
obtained from a single biological assay about a given proteins’ physiological significance.   
 The overall goal of this research is to identify geranylgeranylated proteins and to evaluate 
the enzymatic requirements of FTase and GGTase-I utilizing unnatural GGPP analogs.  Based on 
the crystallographic analysis of FTase and GGTase-I by the Beese laboratory, as well as our 
laboratory’s success with the development of unnatural FPP analogs, we have synthesized a small 
library of unnatural GGPP analogs with frame-modifications.  This library can be classified into 








CHAPTER 2.   SYNTHESIS & BIOCHEMICAL EVALUATION OF ARYL-MODIFIED 
GERANYLGERANYL PYROPHOSPHATE ANALOGS 
 
2.1    Introduction 
 
 In the past, structural studies of FTase by the Beese group have unveiled a hydrophobic 
binding pocket rich with aromatic amino acid residues such as Tyr, Trp, and Phe.7, 56, 57  Such 
findings sparked many researchers, our group included, to explore the possibility of pi-pi stacking 
interactions between these aromatic amino acids and FPP analogs containing aromatic motifs.4, 32, 
82, 103  Many of the previously synthesized aromatic FPP analogs have aryl-modifications at the 
terminal isoprene and have displayed some interesting biochemical results (Figure 2.1).  While 
these aryl-modifications have been greatly explored as FTase substrates and inhibitors, little 
remains known of these modifications in GGTase-I binding ability. 
Previously, our laboratory has concentrated on generating GGPP analogs containing 
substitutions either at the 3 position, the 7 position, or both.74, 80  Although some of these analogs 
have been shown to act as efficient substrates of GGTase-I, others have high nanomolar IC50 
values.  The synthesis of aryl-modified analogs would allow us to investigate greater structural 
diversity in GGPP analogs.  Although some of the aromatic residues (W102, Y361) in FTase 
correspond to non-aromatic resides in GGTase-I (T49, F53, respectively) in order to allow for a 
more spacious binding pocket to accommodate the longer isoprene chain of GGPP,6, 8 structural 
studies of GGTase-I have revealed that it too has a hydrophobic binding pocket abundant with 
aromatic residues (Figure 2.2).  The potential of aryl-containing GGPP analogs to participate in 
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pi-pi stacking interactions with the aromatic amino acid residues of the GGTase-I binding pocket 
prompted us to synthesize and evaluate a small library of aryl-modified GGPP analogs.  
When considering which analogs to evaluate, our goal was to select analogs that best 
mimicked the terminal isoprene unit (Figure 2.3).  In order to do this, we overlaid several 
potential compounds with GGPP in the GGTase-I binding pocket using PyMol (Figure 2.5).  The 
two analogs that best simulate the isoprene unit were 2.6d and 2.6e, which both contain methyl-
substituted benzene rings.  The addition of a methyl substituent on the aromatic ring allows the 
molecule to mimic both terminal CH3 groups of the isoprene unit.  Analogs 2.6a and 2.6b also 
aligned well with GGPP.  While they lack the extra CH3 of 2.6d-e, both of these analogs provide 
the double bond of the terminal isoprene unit.  In comparison, 2.6a-b may provide great insight 
into the need or lack thereof the methyl substitution of the aromatic ring.  Analog 2.6c was 
included to determine if hydrophobic bulk would be sufficient to bind to GGTase-I or, as we 
hypothesize, aromaticity would be more beneficial.   
Due to its unique characteristics such as small size and high electronegativity, fluorine 
has been used to alter physical properties and binding interactions.104  In general, addition of 
fluorine or fluorinated groups results in an increase in lipophilicity of organic molecules, 
especially aromatic compounds.105  Fluorine also has three sets of lone-pair elections that it can 
share with electron-deficient atoms such as acidic hydrogens bound to heteroatoms.  More 
recently, polar C-F bond-protein interactions have been shown to be crucial in stabilizing 
fluorine-containing compounds and their protein targets.  These types of interactions have been 
found between C-F bonds and polar functional groups such as carbonyls (C-F···C=O) and 
guanidinium ion moieties (C-F···C(NH2)(=NH)) of amino acid side chains.
105 Thus, it is not 
surprising that fluorine substituents have been known to enhance binding interactions; therefore, 
compound 2.6f was chosen to evaluate the effects of electronics on the aromatic ring.   
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Recently, our lab has synthesized a potent hIcmt inhibitor designated “TAB” (Figure 
2.4).106  Unfortunately, there is no crystal structure of Icmt; however, it is know that both 
farnesylated and geranylgeranylated proteins bind to hIcmt and are methylated after they are 
proteolytically cleaved by Rce-1.  Thus, it stands to reason that Icmt and the prenyltransferases 
have similar prenyl-binding pockets.  Therefore, we wished to evaluate 2.15 as a potential 























FTase Km ~ 400 nM FTase Ki = 3 nM
mFTase Km = 800 nM mFTase Km = 5.4 µM








Figure 2.2.  Aromatic rich GGTase-I binding site.  Amino acids of the β-subunit that interact 
with GGPP (cyan) are shown in yellow. (A) Interacting amino acids are shown as sticks; (B) 












Figure 2.4.  Comparing protein prenylation with our laboratory’s nanomolar Icmt inhibitor.  Blue 







Figure 2.5.  Overlay of aryl-modified GGPP analogs and GGPP (green) in the GGTase-I binding pocket. 
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2.2    Synthesis of Aryl-Modified Geranylgeranyl Pyrophosphate Analogs 
 
 The synthesis of the aryl-modified GGPP analogs was designed in such a way that all 
compounds could be generated from a common intermediate, 2.3.  Additionally, the availability 
of a wide variety of commercially available Grignard reagents and benzylic/phenylic halides in 
addition to the ease of introduction of the aryl-motifs motivated us to explore this synthetic route.  
To begin the synthesis, THP-protected farnesol (2.1) underwent oxidation in the presence of SeO2 
followed by a NaBH4 reduction to generate alcohol 2.2.
107-109  Next, diethyl chlorophosphate is 
subjected to a displacement reaction in the presence of 2.2 and DIEA to generate diethyl 
phosphate 2.3 in 74% yield.  There were a few advantages of choosing this type of intermediate.  
One advantage to using diethyl phosphate 2.3 is that it can be stored for longer periods of time 
than the corresponding allylic halides which are unstable and easily degrade.  More so, the 
corresponding allylic halides generally undergo Grignard displacement reactions to give a 
mixture of SN2 and SN2’ products usually in fairly equal quantities and isolations of one isomer 
are not facile.110  Thus, with common intermediate 2.3 in hand, a similar method as Snyder & 
Treitler was employed and a variety of Grignard reagents could be utilized in an SN2 
displacement reaction to generate the aryl-modified GGPP analogs 2.4 a-f.111  These analogs were 
first deprotected using PPTS in EtOH to generate alcohols 2.5 a-f and then converted into the 
corresponding pyrophosphates (2.6 a-f) utilizing the method of Davisson et al.112, 113  
 The synthesis of the “TAB-pyrophosphate” 2.15 was accomplished according to the 
procedure of Bergman et al.106  It began with the conversion of 4-bromobut-1-yne (2.7) to alcohol 
2.8 using Negishi’s zirconium-catalyzed asymmetric carbo-alumination (ZACA) reaction.114
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Next, alcohol 2.8 was THP-protected using a standard procedure to generate compound 2.9.  The 
second half of the molecule was generated by subjecting biphenyl-iodide 2.10 to the 1-
(trimethylsilyl)-1-propyne (2.11) anion followed by TMS deprotection with TBAF to afford 
alkyne 2.12.  Alcohol 2.9 was then converted into the corresponding azide in situ by displacement 
of the primary bromide with sodium azide.  Utilizing standard Cu(I) mediated conditions, 
biphenyl alkyne (2.12) was then “clicked” with the freshly generated azide resulting in a 1,4-
disubstituted 1,2,3-triazole (2.13).115-118  These analogs were first deprotected using PPTS in 
EtOH to generate alcohol 2.14.  Halogenations of triazole-containing compounds via standard 
Corey-Kim conditions using NCS has been revealed to be problematic in the past.  Thus, alcohol 
2.14 was first converted in to the mesylate and then converted into the corresponding 





Scheme 2.1.  Synthesis of Aryl-Modified GGPP analogs.  (a) i. DHP, PPTS, DCM; ii. SeO2, t-
BuOOH, salicylic acid, DCM; ii. NaBH4, EtOH (37% - 3 steps); (b) DIEA, (EtO)2POCl, Et2O 
(74%); (c) R-MgX, THF, o/n ; (d) PPTS, EtOH, 70°C; (e) NCS, DMS, DCM, 2.5 hr.; (f) 










Scheme 2.2.  Synthesis of “TAB” pyrophosphate.  (a) Me3Al, Cp2ZrCl2, DCM, 0°C, 18 hr then 
(CH2O)n, 3hr (83%); (b) PPTS, DHP, DCM (79%); (c) i. TMS-propyne, n-BuLi, THF, -78°C; ii. 
K2CO3, MeOH, 12 hr (36% - 2 Steps); (d) NaN3, CuSO4·5H2O, Sodium ascorbate, DMF, 55°C 
(20%); (e) PPTS, EtOH, 70°C (85%); (f) MsCl, DMAP, DCM, 2.5 hrs; (g) (NBu4)3HP2O7, ACN, 




2.3    Biochemical Evaluation of Aryl-Modified Geranylgeranyl Pyrophosphate Analogs 
 
Previously, our laboratory and others have shown that aryl-modified FPP analogs can 
behave as substrates or inhibitors of FTase with various CaaX-peptides.  Thus, we aimed to 
explore these modifications when applied to GGTase-I.  The aryl-modified GGPP analogs 
synthesized (2.6a-f & 2.15) were evaluated for their biochemical activity in an in vitro continuous 
spectrofluorometric assay with GGTase and the co-substrate CaaX-peptide dansyl-GCVLL (the 
CaaX sequence of cdc42).  All biochemical assays were performed in our collaborator Dr. Carol 
Fierke’s laboratory at the University of Michigan by Elia Wright.   
Among the aryl-modified compounds tested, six of the seven compounds synthesized 
displayed substrate activity.  It was not surprising that 2.15 was not a substrate as it was based off 
of an Icmt inhibitor recently synthesized in our laboratory.  As mentioned previously, due to the 
fact that both farnesyl and geranylgeranyl proteins are further processed by Icmt, we 
hypothesized that Icmt and the prenyltransferases have similar prenyl-binding pockets (Figure 
2.4).  Therefore, our original motive for synthesizing this compound was to determine if this 
isoprene-mimic could also inhibit GGTase-I.  Further studies are currently underway to test the 
ability of 2.15 to act as an inhibitor of protein prenylation.  
The remaining six compounds (2.6e-f) all displayed varying degrees of substrate activity.  
From these results (Figures 2.6 & 2.7) it is evident that chain length plays a role in substrate 
ability.  For example, the homobenzyl analog 2.6a is the same overall length as GGPP and 
displays substrate activity comparable to GGPP.  On the other hand, removing one methylene unit 
to afford the benzyl analog 2.6b greatly diminished the substrate ability.  In the case of both 2.6a 
and 2.6b, it appears that our original hypothesis proved true.  By adding a methyl substituent on 
the benzene ring to mimic the terminal isoprene, substrate activity increased (2.6d and 2.6e); 
however, it is important to note that the shorter carbon chain analog (2.6e) still displayed 
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significantly less substrate ability than analogs that have the same overall carbon chain length as 
GGPP (e.g. 2.6d). 
The results of the remaining two analogs (2.6c and 2.6f) were interesting.  We had 
hypothesized that our aromatic compounds would have the added benefit of being able to 
participate in additional favorable interactions with the binding site (such as pi-pi stacking).  
Thus, we believed the aromatic compounds would display a greater degree of activity than a non-
aromatic counter part due to the large number of aromatic residues in the binding pocket of 
GGTase-I.   This did not prove to be true in the case of analog 2.6c.  By comparing analogs 2.6c 
and 2.6b, the only difference is the lack of aromaticity in 2.6c; however, 2.6c displays slightly 
greater substrate activity than its aromatic counterpart 2.6b.  Thus, hydrophobicity may play a 
greater role than aromaticity; however, further studies are needed before a definite conclusion can 
be reached.  
Due to its small size, high electronegativity, and unique chemical reactivity, fluorine is 
becoming more and more common place in medicinal chemistry and drug discovery.  In fact, 
fluorine’s unique nature has been linked to enhancing binding interactions, changing physical 
properties (lipophilicity/solubility), metabolic stability, and selective reactivities.104  Additionally, 
the incorporation of fluorine into our laboratory’s “TAB” compound resulted in a more potent 
Icmt inhibitor.  Assuming the Icmt and GGTase-I binding pockets are similar, we hypothesized 
that a fluorinated aryl-GGPP compound could be beneficial to enzyme activity.  Thus, the last 
analog, 2.6f, was a difluoro compound whose substituent potions were selected based on previous 
data of a “TAB” derivative.   The in vitro analysis revealed that 2.6f displayed substrate activity 
comparable to GGPP (Figure 2.6) and may even be more efficient as a substrate than GGPP 














Figure 2.6.  Bar graphs of substrate activity represented in RFI of aryl-modified GGPP analogs 
2.6a-d versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars 













Figure 2.7.  Bar graphs of substrate activity represented in RFI of aryl-modified GGPP analogs 
2.6e-f and 2.15 versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error 
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*42 ± 6.0% 
*85 ± 11% 
*3.8 ± 0.43% 
*100 ± 5.9% 
OPP
*88 ± 3.9% 
*33 ± 2.7% *24 ± 6.4% 
*80 ± 0.3% 















Figure 2.8.  Monitoring continuous changes in fluorescence of aryl-modified 
 GGPP analogs versus GGPP (+ control) at various concentrations (1 µM, 5µM, 
& 10µM) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.  Experiments 
were performed in triplicate and data points represent the mean.   



























































2.4    Conclusions 
 
The goal of this aim was to focus on the synthesis of a small library of aryl-modified 
GGPP analogs.  While many aromatic derivatives of FPP have been synthesized and investigated 
in the past, these modifications had yet to be extended into the realm of GGTase-I.  Additionally, 
the majority of the FPP analogs previously explored contained either an amine or ether linkage 
between the isoprene chain and the aromatic moiety.   
This aim focused on designing a robust synthetic route which would allow us to quickly 
and efficiently produce a small library of aryl-modified analogs (2.6a-f).  Moreover, this route 
allowed us to produce compounds that contain an all carbon backbone which more effectively 
mimics the natural isoprenoid chain of GGPP.   The synthesis was dependent on the allylic 
diethyl phosphate 2.3 which proved to be more stable than the corresponding allylic halide and 
could be stored over time.  This allowed us to produce larger quantities of the common 
intermediate 2.3 which could rapidly be converted into several aryl-modified GGPP analogs.   
Upon in vitro biochemical evaluation of these analogs, it was discovered that all of these 
analogs displayed substrate activity; however, the length of the carbon chain plays an important 
role.  Having two methylene units between the aromatic ring and the terminal double bond 
(homobenzyl moiety) provides compounds that have substrate ability comparable to GGPP.  By 
decreasing the methylene unit to one (benzyl moiety) the substrate activity was greatly reduced.  
Another important factor that increased substrate activity was the introduction of fluorine 
substituents on the homobenzyl ring (2.6f).  This resulted in an analog that appears to be 
comparable to GGPP.  Unfortunately, the analogs were tested at only three concentrations (1, 5, 
& 10 µM) and many of the reactions did not reach completion at 5 or 10 µM of analog (Figure 
2.8).  In order to determine accurate kcat and Km values, these analogs are currently being retested 
at more concentrations. 
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Moreover, we also synthesized an aromatic analog (2.15) that was based on a nanomolar 
inhibitor of Icmt previously developed in our laboratory.  If the Icmt and GGTase-I isoprenoid 
binding pockets are similar, then 2.15 has the potential of being an inhibitor of GGTase-I.  As 
expected, the in vitro substrate assay revealed that 2.15 did not display substrate activity; further 
testing is currently underway to determine whether or not 2.15 is an inhibitor of GGTase-I. 
We have successfully synthesized a library of aryl-modified GGPP compounds in which 
the ω-isoprene units has been replaced by an aromatic group.  The preliminary biochemical 
evaluation of these compounds revealed several intriguing results.  At a later date, these 
compounds will be screened with an expansive library of dansyl-GCaaX peptides to determine if 









2.5    Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of Aryl-
Modified Geranylgeranyl Pyrophosphate Analogs 
 
General Experimental Procedures:  All reactions were performed with oven-dried or flame-
dried glassware and under dry argon gas.  All commercial reagents and solvents were used 
directly without subsequent purification.  For the organometallic coupling reactions, anhydrous 
THF was freshly distilled from sodium and benzophenone.  All other anhydrous solvents were 
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.  
Reactions were monitored by thin layer chromatography and visualized with one or more of the 
following: UV light, iodine, vanillin solution, potassium permanganate solution, 
dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.  All products were 
purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.  All 
reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded 
with sodium sulfate before column purification.  All NMR spectra were taken either on a 300 
MHz Bruker ARX300 or a 500 MHz Bruker DRX500 spectrometer.  Low-resolution MS (EI/CI) 
were recorded with a Hewlett Packard Engine and low-resolution MS (ESI) were taken on a 




(2.2a):    
To an Erlenmeyer flask charged with t-BuOOH (2.0 eq, 40 mmol, 70% in water) and 60 
mL of CH2Cl2 is added MgSO4.  The solution was then filtered into a round bottom flask 
equipped with a magnetic stir bar.  Next, SeO2 (0.12 eq, 2.4 mmol) and salicylic acid (0.5 eq, 10 
mmol) were added to the reaction mixture.  While the solution stirred, THP-protected farnesol, 
2.1 (1.0 eq, 20 mmol) was added dropwise to the reaction vessel.  The reaction mixture was 
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allowed to stir for 12 hours.  The CH2Cl2 was removed and the resulting residue is resuspended in 
Et2O.  Next, 10% NaOH was added to solution, the organic layer was removed, and the aqueous 
layer was extracted 3 × Et2O (40 mL).  The organic layers are combined, washed with brine, dried 
with MgSO4, filtered, and concentrated.  In an oven-dried round bottom flask, the crude reaction 
product was diluted with 80 mL of ethanol and NaBH4 (1.0 eq, 20 mmol) was added in several 
portions to the reaction vessel.  The reaction was allowed to stir for 1 hour and then diluted with 
200 mL of water.  The aqueous layer was extracted 3 × Et2O (40 mL) and the organic layers were 
combined, washed 2 × H2O, washed with brine, dried with MgSO4, filtered, and concentrated.  
The crude reaction product was purified by column chromatography using 15% Ethyl 
Acetate/Hexanes as the mobile phase to afford 2.2 in 37% yield.  1H NMR (300 MHz, 
Chloroform-d) δ 5.41 – 5.25 (m, 2H), 5.08 (t, J = 6.3 Hz, 1H), 4.59 (t, J = 3.4 Hz, 1H), 4.19 (dd, J 
= 11.9, 6.4 Hz, 1H), 4.06 – 3.91 (m, 3H), 3.85 (ddd, J = 11.1, 7.4, 3.3 Hz, 1H), 3.47 (dt, J = 10.4, 
4.7 Hz, 1H), 2.24 – 1.90 (m, 7H), 1.81 – 1.24 (m, 17H).  13C NMR (75 MHz, CDCl3) δ 140.07 
(s), 134.77 (s), 134.68 (s), 125.62 (s), 124.07 (s), 120.53 (s), 97.54 (s), 68.67 (s), 63.50 (s), 62.11 








Diethyl ((2E,6E,10E) - 2,6,10 - trimethyl -12-((tetrahydro-2H-pyran-2-yl)oxy) dodeca-2,6,10-
trien-1-yl) phosphate (2.3a):   
To a round bottom flask equipped with a magnetic stir bar was added alcohol 2.2  (1.0 eq, 
8.1 mmol) in 10 mL of CH2Cl2.  Next, Et3N (7 eq, 56.7 mmol) was added to the reaction vessel 
and the mixture was cooled to 0°C, where diethyl chlorophosphate (5.5 eq, 44.8 mmol) was 
added dropwise to the reaction. The reaction was allowed to warm to room temperature and 
stirred for 12 hours.  Next, 10% NH4Cl(aq) was added to solution, the organic layer was removed, 
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and the aqueous layer was extracted 3 × Et2O (20 mL).  The organic layers are combined, washed 
with brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified 
by column chromatography using 50% Ethyl Acetate/Hexanes as the mobile phase to afford 
diethyl phosphpate 2.3 in 74% yield.  NMR:  1H NMR (300 MHz, Chloroform-d) δ 5.46 (t, J = 
6.4 Hz, 1H), 5.33 (t, J = 5.6 Hz, 1H), 5.09 (t, J = 6.1 Hz, 1H), 4.67 – 4.54 (m, 1H), 4.36 (d, J = 
6.9 Hz, 2H), 4.21 (dd, J = 11.9, 6.4 Hz, 1H), 4.16 – 3.93 (m, 5H), 3.87 (ddd, J = 11.0, 6.9, 3.7 Hz, 
1H), 3.49 (ddd, J = 11.3, 6.3, 3.5 Hz, 1H), 2.27 – 1.89 (m, 9H), 1.69 – 1.62 (m, 6H), 1.63 – 1.41 
(m, 8H), 1.31 (td, J = 7.1, 1.0 Hz, 6H).  13C NMR (75 MHz, Chloroform-d) δ 140.28, 134.79, 
130.54 (d, J = 6.9 Hz), 129.94, 124.47, 120.76, 97.94, 73.42 (d, J = 5.8 Hz), 63.81, 63.77, 63.73, 
62.44, 39.72, 39.12, 30.87, 26.52, 26.43, 25.65, 19.79, 16.58, 16.35, 16.26, 16.14, 13.74.  31P 
NMR (122 MHz, Chloroform-d) δ -0.25.   
 






To an oven-dried round bottom flask equipped with a magnetic stir bar was added diethyl 
phosphate 2.3 (1.0 eq, 0.5 mmol) dissolved in 2 mL of THF and cooled to 0°C.  Next, 
benzylmagnesium bromide (2 M in THF, 5 eq, 2.5 mmol) was added dropwise to the reaction 
mixture and the reaction was allowed to stir for 12 hours.  The reaction was quenched with 10% 
NH4Cl, the organic layer was removed, and the aqueous layer was extracted 3 × Et2O (5 mL).  
The organic layers are combined, washed with brine, dried with MgSO4, filtered, and 
concentrated. The crude reaction product was purified by column chromatography using 5% 
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Ethyl Acetate/Hexanes as the mobile phase to afford 2.4 a in 76% yield.  NMR:  1H NMR (300 
MHz, Chloroform-d) δ 7.33 – 7.23 (m, 2H), 7.24 – 7.14 (m, 3H), 5.38 (t, J = 6.9 Hz, 1H), 5.13 (q, 
J = 6.6 Hz, 2H), 4.64 (t,1H), 4.26 (dd, J = 11.9, 6.4 Hz, 1H), 4.04 (dd, J = 11.9, 7.4 Hz, 1H), 3.91 
(ddd, J = 11.1, 7.3, 3.3 Hz, 1H), 3.52 (dt, J = 10.5, 4.8 Hz, 1H), 2.81 – 2.65 (m, 2H), 2.33 – 2.22 
(m, 2H), 2.19 – 2.02 (m, 6H), 2.02 – 1.92 (m, 2H), 1.92 – 1.79 (m, 1H), 1.70 (s, 3H), 1.67 (s, 3H), 
1.63 (s, 1H), 1.61 (s, 3H), 1.59 – 1.47 (m, 4H).  13C NMR (75 MHz, Chloroform-d) δ 142.66, 
140.45, 135.36, 134.61, 128.55, 128.38, 125.81, 124.90, 124.12, 120.75, 97.96, 63.83, 62.46, 
41.84, 39.84, 39.80, 34.99, 30.91, 26.80, 26.49, 25.71, 19.83, 16.64, 16.35, 16.22.   
OTHP  
2-(((2E,6E,10E)-3,7,11-trimethyl-12-phenyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran 
(2.4b):   
Yield: 46%. NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.34 – 7.24 (m, 2H), 7.23 – 
7.13 (m, 3H), 5.38 (t, J = 7.3 Hz, 1H), 5.24 (t, J = 6.3 Hz, 1H), 5.13 (t, J = 6.4 Hz, 1H), 4.71 – 
4.57 (m,  1H), 4.25 (dd, J = 11.9, 6.4 Hz, 1H), 4.04 (dd, J = 11.9, 7.4 Hz, 1H), 3.90 (ddd, J = 
11.2, 7.1, 3.8 Hz, 1H), 3.58 – 3.45 (m, 1H), 3.28 (s, 2H), 2.08 (tdd, J = 16.4, 8.7, 5.2 Hz, 8H), 
1.69 (s, 3H), 1.67 – 1.44 (m, 10H). 13C NMR (75 MHz, Chloroform-d) δ 140.46, 135.25, 134.46, 
129.00, 128.34, 126.57, 126.05, 124.29, 120.76, 97.97, 63.84, 62.48, 46.44, 39.83, 30.92, 26.82, 
26.49, 25.71, 19.83, 16.64, 16.19, 15.99. 
OTHP  
2-(((2E,6E,10E)-12-cyclohexyl-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-
pyran (2.4c):  
Yield: 54%. NMR:  1H NMR (300 MHz, Chloroform-d) δ 5.38 – 5.30 (m, 1H), 5.15 – 
4.91 (m, 2H), 4.64 – 4.55 (m, 1H), 4.21 (dd, 1H), 4.00 (dd, J = 11.9, 7.4 Hz, 1H), 3.87 (ddd, J = 
11.2, 7.1, 3.8 Hz, 1H), 3.60 – 3.36 (m, 1H), 2.19 – 1.90 (m, 7H), 1.88 – 1.77 (m, 3H), 1.73 – 1.34 
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(m, 20H), 1.29 – 0.98 (m, 4H), 0.93 – 0.64 (m, 2H).  13C NMR (75 MHz, Chloroform-d) δ 
140.51, 135.41, 133.73, 125.64, 124.11, 120.73, 97.97, 63.84, 62.49, 48.25, 39.98, 39.89, 39.85, 
35.68, 33.48, 30.93, 26.92, 26.77, 26.64, 26.49, 25.72, 19.85, 16.64, 16.19. 
 






To an oven-dried round bottom flask equipped with a magnetic stir bar was added 
magnesium powder (40 eq, 20 mmol) and 6 mL of anhydrous Et2O and an iodide chip was added 
to the round bottom and the mixture was stirred for 5 minutes.  Next, 2-methylbenzyl chloride (10 
eq, 5 mmol) in 2 mL of Et2O was added dropwise to the reaction vessel over a 10 minute period 
and the reaction mixture was stirred for 4 hours.  After the allotted time, the reaction mixture was 
cooled to 0°C where diethyl phosphate 2.3 (1.0 eq, 0.5 mmol) dissolved in 2 mL of THF was 
added dropwise to the mixture and the reaction was allowed to stir for 12 hours.  The reaction 
was quenched with 10% NH4Cl, the organic layer was removed, and the aqueous layer was 
extracted 3 × Et2O (5 mL).  The organic layers are combined, washed with brine, dried with 
MgSO4, filtered, and concentrated. The crude reaction product was purified by column 
chromatography using 5% Ethyl Acetate/Hexanes as the mobile phase to afford 2.4d in 61% 
yield.  NMR:  1H NMR (300 MHz, Chloroform-d) δ 7.20 – 6.99 (m, 4H), 5.44 – 5.32 (m, 1H), 
5.21 – 5.04 (m, 2H), 4.62 (dd, J = 4.3, 2.7 Hz, 1H), 4.24 (dd, J = 11.8, 6.4 Hz, 1H), 4.03 (dd, J = 
11.9, 7.4 Hz, 1H), 3.89 (ddd, J = 11.1, 7.6, 3.3 Hz, 1H), 3.62 – 3.46 (m, 1H), 2.73 – 2.58 (m, 2H), 
2.31 (s, 3H), 2.25 – 2.17 (m, 2H), 2.16 – 1.93 (m, 8H), 1.91 – 1.78 (m, 1H), 1.68 (s, 6H), 1.60 (s, 
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3H), 1.59 – 1.47 (m, 5H).  13C NMR (75 MHz, Chloroform-d) δ 140.89, 140.50, 136.00, 135.40, 
134.96, 130.27, 128.96, 126.08, 126.01, 124.77, 124.17, 120.75, 97.99, 63.86, 62.50, 40.59, 




Yield (45%). NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.20 – 7.11 (m, 1H), 6.99 (t, J 
= 9.2 Hz, 3H), 5.37 (t, J = 6.3 Hz, 1H), 5.23 (t, J = 6.3 Hz, 1H), 5.12 (t, J = 6.2 Hz, 1H), 4.62 (dd, 
J = 4.2, 2.6 Hz, 1H), 4.24 (dd, J = 11.8, 6.4 Hz, 1H), 4.03 (dd, J = 11.9, 7.4 Hz, 1H), 3.89 (ddd, J 
= 11.2, 7.3, 3.7 Hz, 1H), 3.51 (ddd, 1H), 3.23 (s, 2H), 2.32 (s, 3H), 2.20 – 1.98 (m, 7H), 1.85 
(ddd, J = 17.9, 8.1, 5.4 Hz, 2H), 1.68 (s, 3H), 1.63 – 1.46 (m, 11H).  13C NMR (75 MHz, 
Chloroform-d) δ 140.56, 140.42, 137.80, 135.26, 134.52, 129.78, 128.20, 126.78, 126.41, 126.00, 








Yield (65%). NMR:  1H NMR (300 MHz, Chloroform-d) δ 7.08 – 6.95 (m, 2H), 6.89 – 
6.78 (m, 1H), 5.34 (tq, J = 7.6, 6.0, 1.4 Hz, 1H), 5.14 – 4.99 (m, 1H), 4.60 (dd, J = 4.5, 2.6 Hz, 
1H), 4.22 (dd, J = 11.9, 6.4 Hz, 1H), 4.00 (dd, J = 11.9, 7.4 Hz, 1H), 3.87 (ddd, J = 11.1, 7.3, 3.5 
Hz, 1H), 3.49 (ddd, J = 10.6, 5.5, 3.6 Hz, 1H), 2.62 (dd, J = 9.3, 6.6 Hz, 2H), 2.29 – 1.72 (m, 
11H), 1.66 (s, 3H), 1.63 – 1.42 (m, 11H).  19F NMR (282 MHz, Chloroform-d) δ -112.23 (ddd, J 
= 20.7, 11.5, 8.2 Hz), -115.88 – -116.29 (m). 
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In a scintillation vial equipped with a magnetic stir bar, 2.4a (1.0 eq, 0.38 mmol) was 
dissolved in 5.0 mL of absolute EtOH and PPTS (0.1 eq, 0.038 mmol) was added to the vial.  The 
reaction mixture was heated to 75°C and stirred for 12 hours.  Next, the reaction was cooled to 
room temperature where it was poured into a separator funnel containing water and Et2O and the 
aqueous layer was extracted 3 × 5 mL Et2O.  The organic layers were combined and washed with 
water then brine, dried with magnesium sulfate, and concentrated.  The crude reaction product 
was purified by column chromatography using 15% Ethyl Acetate/Hexanes as the mobile phase 
to afford 2.5 a in 65% yield.  NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.33 – 7.24 (m, 2H), 
7.24 – 7.15 (m, 3H), 5.43 (tq, J = 7.0, 5.4, 2.7, 1.3 Hz, 1H), 5.13 (tq, J = 8.1, 6.8, 5.6, 1.4 Hz, 
2H), 4.16 (d, 2H), 2.76 – 2.66 (m, 2H), 2.34 – 2.21 (m, 2H), 2.21 – 1.92 (m, 8H), 1.70 (s, 3H), 
1.67 (s, 3H), 1.61 (s, 3H).13C NMR (75 MHz, Chloroform-d) δ 142.59, 139.89, 135.42, 134.59, 
128.48, 128.32, 125.75, 124.80, 123.93, 123.43, 59.51, 41.77, 39.71, 39.67, 34.91, 26.72, 26.43, 
16.43, 16.29, 16.14. MS (EI) m/z [M++H]; MS (CI) m/z [M++H]. 
OH  
(2E,6E,10E)-3,7,11-trimethyl-12-phenyldodeca-2,6,10-trien-1-ol (2.5b):  
Yield (53%).   NMR: 1H NMR (300 MHz, Chloroform-d) δ 7.28 (ddd, J = 7.7, 6.3, 1.6 
Hz, 2H), 7.24 – 7.13 (m, 3H), 5.47 – 5.36 (m, 1H), 5.29 – 5.21 (m, 2H), 5.17 – 5.09 (m, 2H), 4.16 
(d, J = 6.9 Hz, 2H), 2.27 – 1.86 (m, 9H), 1.69 (s, 77H), 1.62 (s, 3H), 1.54 (s, 3H).  13C NMR (75 
MHz, Chloroform-d) δ 140.65, 139.98, 135.38, 134.50, 129.01, 128.35, 126.54, 126.06, 124.16, 
123.51, 59.59, 46.43, 39.79, 39.74, 26.81, 26.50, 16.51, 16.19, 15.99. MS (EI) m/z 298 [M+]; 280 





(2E,6E,10E)-12-cyclohexyl-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (2.5c):  
Yield (59%).  NMR: 1H NMR (300 MHz, Chloroform-d) δ 5.41 (td, J = 6.6, 6.2, 1.7 Hz, 
1H), 5.10 (t, 1H), 5.03 (t, 1H), 4.15 (d, J = 6.8 Hz, 2H), 2.05 (tt, J = 15.2, 5.8 Hz, 7H), 1.82 (d, J 
= 7.1 Hz, 2H), 1.75 – 1.48 (m, 15H), 1.34 – 1.02 (m, 5H), 0.91 – 0.59 (m, 2H).  13C NMR (75 
MHz, Chloroform-d) δ 139.95, 135.46, 133.69, 125.52, 123.90, 123.41, 59.52, 48.17, 39.88, 
39.68, 37.88, 35.59, 33.40, 26.84, 26.76, 26.67, 26.56, 26.43, 16.42, 16.11.  MS (EI) m/z 304 




(2E,6E,10E)-3,7,11-trimethyl-13-(o-tolyl)trideca-2,6,10-trien-1-ol (2.5d):  
Yield (61%).  NMR:  1H NMR (300 MHz, Chloroform-d) δ 7.19 – 7.04 (m, 4H), 5.41 (tq, 
J = 7.0, 5.5, 2.6, 1.3 Hz, 1H), 5.20 – 5.03 (m, 2H), 4.14 (d, J = 6.9 Hz, 2H), 2.74 – 2.60 (m, 2H), 
2.31 (s, 3H), 2.26 – 2.15 (m, 2H), 2.15 – 1.89 (m, 8H), 1.67 (s, 6H), 1.60 (s, 3H).  13C NMR (75 
MHz, Chloroform-d) δ 140.85, 139.98, 135.97, 135.50, 134.98, 130.25, 128.94, 126.07, 126.00, 
124.72, 124.03, 123.48, 59.58, 40.57, 39.80, 39.76, 32.55, 26.82, 26.51, 19.46, 16.50, 16.39, 
16.22. MS (EI) m/z 308 [M+-H2O]; MS (CI) m/z 309 [(M
++H)-H2O]. 
OH  
 (2E,6E,10E)-3,7,11-trimethyl-12-(m-tolyl)dodeca-2,6,10-trien-1-ol (2.5e):  
Yield (71%).  NMR:  1H NMR (300 MHz, Chloroform-d) δ 7.22 – 7.09 (m, 1H), 6.98 (t, 
J = 8.8 Hz, 3H), 5.47 – 5.38 (m, 1H), 5.29 – 5.20 (m, 1H), 5.18 – 5.08 (m, 1H), 4.14 (d, J = 7.0 
Hz, 2H), 3.25 (d, J = 10.4 Hz, 2H), 2.32 (s, 3H), 2.19 – 1.91 (m, 8H), 1.68 (d, J = 1.3 Hz, 3H), 
1.61 (d, J = 1.4 Hz, 3H), 1.53 (d, J = 1.3 Hz, 3H).  13C NMR (75 MHz, Chloroform-d) δ 140.54, 
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139.89, 137.82, 135.39, 134.55, 129.78, 128.21, 126.78, 126.38, 126.00, 124.11, 123.48, 59.53, 
46.35, 39.79, 39.72, 26.82, 26.49, 21.60, 16.47, 16.18, 15.98. MS (EI) m/z 294 [M+-H2O]; MS 





(2E,6E,10E)-13-(3,4-difluorophenyl)-3,7,11-trimethyltrideca-2,6,10-trien-1-ol (2.5f):   
Yield (26%).  NMR:  1H NMR (300 MHz, Chloroform-d) δ 7.10 – 6.90 (m, 2H), 6.90 – 
6.72 (m, 1H), 5.41 (dt, 1H), 5.22 – 4.84 (m, 2H), 4.15 (d, J = 7.0 Hz, 2H), 2.65 (t, 2H), 2.29 – 
2.17 (m, 2H), 2.14 – 2.01 (m, 6H), 2.00 – 1.91 (m, 2H), 1.68 (s, 3H), 1.63 (s, 3H), 1.58 (s, 3H), 
2.71 – 2.53 (m, 3H).  13C NMR (126 MHz, Chloroform-d) δ 150.46 (dd, J = 181.6, 12.6 Hz), 
148.50 (dd, J = 180.1, 13.0 Hz), 139.95, 139.46 (dd), 135.38, 133.81, 125.53, 124.31 (dd, J = 5.9, 
3.4 Hz), 124.05, 123.49, 117.22 (d, J = 16.6 Hz), 116.92 (d, J = 16.8 Hz), 59.58, 41.47, 39.74, 
39.72, 33.96, 26.73, 26.48, 16.48, 16.25, 16.17.  19F NMR (282 MHz, Chloroform-d) δ -111.86 – 




Representative procedure for the synthesis of pyrophosphates 2.6a-f. 
OPP
 
 (2E,6E,10E)-3,7,11-trimethyl-13-phenyltrideca-2,6,10-trien-1-yl diphosphate (2.6a): 
 To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS 
(2.5 eq, 0.39 mmol) in 0.8 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq, 
0.39 mmol) was added dropwise to the reaction.  Following the addition, the mixture is then 
placed in a 0°C ice bath and stirred for 5 minutes before being recooled back to -30°C.  Next, 
alcohol 2.5a (1 eq, 0.16 mmol) is dissolved in 0.3 mL of CH2Cl2 and added dropwise to the 
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reaction mixture.  The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to 
room temperature.  After the allotted time, brine is added to the reaction mixture and the organic 
layer was extracted.  The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic 
layers were combined, dried with magnesium sulfate, and concentrated.  The crude reaction 
product was used immediately in the following step.  
 To another oven-dried round bottom flask equipped with a magnetic stir bar was added 
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.47 mmol) dissolved in 2.0 mL of 
acetonitrile.  Next, a solution of crude allylic chloride dissolve in 1.4 mL acetonitrile was added 
dropwise to the reaction vessel.  The reaction was stirred for 3 hours at room temperature and 
then the solvent was removed by rotary evaporation at 34°C.  The residue was the dissolve in a 
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20 
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion 
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in 
a flask.  The resulting solution was lyophilized for 3-5 hours.  The resulting residue was then 
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15 
cm) using isopropanol:deionized  H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL 
: 4 g) as the eluent.  In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions 
were collected.  Typically, fractions 12-18 were collected and the organic solvents were removed 
by rotary evaporation at 34°C.  The resulting solution was then lyophilized to afford 
pyrophosphate (2.6a) as a white fluffy solid in 58% yield. 1H NMR (500 MHz, Deuterium Oxide) 
δ 7.02 – 6.91 (m, 3H), 6.92 – 6.81 (m, 2H), 5.35 (s, 1H), 5.11 (s, 2H), 4.40 (s, 2H), 2.42 (s, 2H), 
1.95 (d, J = 45.4 Hz, 10H), 1.80 (s, 3H), 1.62 (s, 6H).  31P NMR (202 MHz, Deuterium Oxide) δ -






 (2E,6E,10E)-3,7,11-trimethyl-12-phenyldodeca-2,6,10-trien-1-yl diphosphate (2.6b): 
 Yield (51%).  1H NMR (500 MHz, Deuterium Oxide) δ 6.99 (s, 2H), 6.92 (s, 3H), 5.51 – 
5.01 (m, 3H), 4.44 (s, 2H), 3.19 (s, 2H), 2.03 (d, J = 41.5 Hz, 8H), 1.68 (s, 3H), 1.58 (s, 3H), 1.55 
(s, 3H).  31P NMR (202 MHz, Deuterium Oxide) δ -10.06, -13.94.  HRMS 457.1554 [M+2H]-, 
calculated 547.1545 (C21H31O7P2). 
OPP  
(2E,6E,10E)-12-cyclohexyl-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate (2.6c): 
 Yield (60%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.41 (s, 1H), 5.14 (s, 1H), 5.08 (s, 
1H), 4.44 (s, 2H), 2.03 (d, J = 53.2 Hz, 8H), 1.83 (d, J = 6.9 Hz, 2H), 1.69 (s, 3H), 1.69 – 1.59 
(m, 6H), 1.60 (s, 3H), 1.55 (s, 3H), 1.29 – 1.04 (m, 5H), 0.81 (d, J = 11.5 Hz, 2H).  31P NMR (202 




(2E,6E,10E)-3,7,11-trimethyl-13-(o-tolyl)trideca-2,6,10-trien-1-yl diphosphate (2.6d): 
 Yield (75%).  1H NMR (500 MHz, Deuterium Oxide) δ 6.80 (s, 4H), 5.36 (s, 1H), 5.01 (s, 
2H), 4.42 (s, 2H), 2.39 (s, 2H), 2.24 – 1.79 (m, 13H), 1.64 (s, 3H), 1.47 (s, 3H), 1.43 (s, 3H).31P 
NMR (202 MHz, Deuterium Oxide) δ -11.24 (d, J = 19.1 Hz), -13.98 (d, J = 17.6 Hz).  HRMS 







(2E,6E,10E)-3,7,11-trimethyl-12-(m-tolyl)dodeca-2,6,10-trien-1-yl diphosphate (2.6e): 
 Yield (87%).   1H NMR (500 MHz, Deuterium Oxide) δ 6.81 (s, 3H), 6.70 (s, 2H), 5.39 
(s, 1H), 5.09 (d, J = 26.3 Hz, 2H), 4.43 (s, 2H), 2.98 (s, 2H), 2.09 (s, 3H), 2.00 (s, 8H), 1.65 (s, 
3H), 1.50 (s, 3H), 1.36 (s, 3H). 31P NMR (202 MHz, Deuterium Oxide) δ -10.17 (d, J = 16.2 Hz), 





(2E,6E,10E)-13-(3,4-difluorophenyl)-3,7,11-trimethyltrideca-2,6,10-trien-1-yl diphosphate (2.6f): 
 Yield (94%).  1H NMR (500 MHz, Deuterium Oxide) δ 6.82 (s, 1H), 6.69 (d, J = 26.5 Hz, 
2H), 5.36 (s, 1H), 4.99 (s, 1H), 4.94 (s, 1H), 4.41 (s, 2H), 2.44 (s, 2H), 2.00 (s, 2H), 1.91 (s, 6H), 
1.78 (s, 2H), 1.63 (s, 3H), 1.47 (s, 6H).  31P NMR (202 MHz, Deuterium Oxide) δ -9.98 (d, J = 
13.0 Hz), -13.75 (d, J = 10.6 Hz).  HRMS 507.1518 [M+2H]-, calculated 507.1513 
(C22H31F2O7P2). 
Br OH  
(E)-5-bromo-3-methylpent-2-en-1-ol (2.8): 
Cp2ZrCl2 (0.25 eq, 3.75mmol) was dissolved in 15 mL dichloromethane and the solution 
was cooled to 0°C, where a Me3Al solution (2.0 M in heptanes, 2.5eq, 37.5mmol) was added 
dropwise.  After stirring the reaction mixture at 0°C for 30 minutes, 4-bromo-1-butyne (1.0 eq, 15 
mmol) was diluted in 7.5 mL of dichloromethane and added to the reaction mixture dropwise.  
The reaction mixture was allowed to slowly warm to room temperature and stirred an additional 
12 hours.  Next, the reaction mixture was cooled to 0°C, where (CH2O)n (5 eq, 75 mmol) was 
added in several portions.  The reaction continued to stir for 3 hours after which it was slowly 
poured into an ice-cold 10% HCl(aq) solution.  The solution was then filtered over a pad of Celite 
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545, extracted with 3 × 50 mL dichloromethane, washed with brine, dried with magnesium 
sulfated, filtered, and concentrated.   Column chromatography (30% Ethyl acetate in Hexanes) 
afforded 2.8 in 85% yield. 
Br OTHP  
(E)-2-((5-bromo-3-methylpent-2-en-1-yl)oxy)tetrahydro-2H-pyran (2.9): 
(E)-5-bromo-3-methylpent-2-en-1-ol (1 eq, 31.32 mmol) was dissolved in 100 mL of 
dichloromethane where PPTS (0.1 eq, 3.13 mmol) and 2,3-dihydropyran (3.0 eq, 94 mmol) were 
added to the reaction vessel.  The reaction was allowed to stir for 1 hour at room temperature and 
was then concentrated down and loaded directly onto a silica flash column ( % Ethyl acetate in 
Hexanes) to afford 2.9 in 79% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.46 – 5.38 (m, 1H), 
4.60 (t, J = 3.5 Hz, 1H), 4.21 (dd, J = 12.2, 6.3 Hz, 1H), 4.02 (dd, J = 12.2, 7.3 Hz, 1H), 3.91 – 
3.79 (m, 1H), 3.43 (t, J = 7.5 Hz, 2H), 2.56 (t, J = 7.4 Hz, 2H), 1.89 – 1.71 (m, 1H), 1.67 (s, 3H), 
1.64 (d, J = 1.0 Hz, 1H), 1.61 – 1.43 (m, 5H).  13C NMR (75 MHz, Chloroform-d) δ 136.82 (s), 
124.04 (s), 98.09 (s), 77.65 (s), 77.23 (s), 76.80 (s), 63.56 (s), 62.58 (s), 42.83 (s), 30.99 (d, J = 
19.6 Hz), 25.66 (s), 19.81 (s), 16.23 (s).   
 
4-(but-3-yn-1-yl)-1,1'-biphenyl (2.12):  
An oven-dried round bottom flask equipped with a magnetic stir bar was charged with 1-
(trimethylsilyl)propyne (2.5 eq, 7.5 mmol) dissolved in 9.5 mL of anhydrous THF and cooled to -
78°C.  Next, n-BuLi (2.5 eq, 7.5 mmol) was slowly added to the mixture and the reaction was 
allowed to stir 1.5 hours.  After the allotted time, 2.10a (1.0 eq, 3 mmol) in 15 mL of THF was 
added dropwise to the reaction vessel at -78°C.  The reaction was allowed to stir for an additional 
12 hours after which time the reaction was quenched by the addition of 10% NH4Cl.  The organic 
layer was removed, and the aqueous layer was extracted 3 × Et2O (5 mL).  The organic layers 
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were combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude 
reaction product was then dissolved in a saturated K2CO3/MeOH solution and stirred for an 
additional 4 hours.  Next, the reaction was poured into a separator funnel containing water and 
Et2O and the aqueous layer was extracted 3 × 15 mL Et2O.  The organic layers were combined 
and washed with water then brine, dried with magnesium sulfate, and concentrated.  The crude 
reaction product was purified by column chromatography using 2.5% Ethyl Acetate/Hexanes as 
the mobile phase to afford 2.12 in 36% yield.  NMR:  1H NMR (300 MHz, Chloroform-d) δ 7.62 
– 7.49 (m, 4H), 7.42 (t, J = 7.8 Hz, 2H), 7.37 – 7.26 (m, 3H), 2.88 (t, J = 7.5 Hz, 2H), 2.52 (td, J 
= 7.5, 2.6 Hz, 2H), 1.99 (t, J = 2.6 Hz, 1H). 13C NMR (75 MHz, Chloroform-d) δ 139.70, 139.53, 






To a scintillation vial equipped with a magnetic stir bar was added bromide 2.9 (1.0 eq, 
0.85 mmol) and 4.5 mL of DMF.  Next, NaN3 (3 eq, 2.55 mmol), sodium ascorbate (0.5 eq,.43 
mmol), and CuSO4·H2O (0.25 eq, 0.21 mmol) are added sequentially to the vial.  Alkyne 2.12 
(1.2 eq, 1.02 mmol) was then dissolved in 2.3 mL of DMF and added to the vial.  The reaction 
was heated to 70°C and allowed to stir for 36 hours. The reaction was then quenched with 10% 
NH4Cl and the aqueous layer was extracted 3 × EtOAC (10 mL).  The organic layers were 
combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction 
product was purified by column chromatography using 60% Ethyl Acetate/Hexanes as the mobile 
phase to afford 2.13 in 20% yield.  1H NMR (300 MHz, Chloroform-d) δ 7.60 – 7.20 (m, 9H), 
7.11 (s, 1H), 5.33 (s, 1H), 4.53 (t, J = 3.6 Hz, 1H), 4.39 (t, J = 7.4 Hz, 2H), 4.23 – 3.91 (m, 2H), 
3.83 (s, 1H), 3.50 (s, 1), 3.03 (q, J = 3.3 Hz, 4H), 2.55 (t, J = 7.4 Hz, 2H), 1.68 (s, 5H), 1.51 (tq, J 
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= 7.3, 4.3, 2.9 Hz, 4H). 13C NMR (75 MHz, Chloroform-d) δ 147.27, 141.04, 140.46, 139.12, 
135.13, 129.02, 128.86, 127.21, 127.08, 124.46, 120.95, 98.10, 63.42, 62.50, 48.63, 40.26, 35.35, 





In a scintillation vial equipped with a magnetic stir bar, 2.13 (1.0 eq, 0.17 mmol) was 
dissolved in 5.0 mL of absolute EtOH and PPTS (0.1 eq, 0.02 mmol) was added to the vial.  The 
reaction mixture was heated to 75°C and stirred for 12 hours.  Next, the reaction was cooled to 
room temperature where it was poured into a separator funnel containing water and EtOAc and 
the aqueous layer was extracted 3 × 5 mL EtOAc.  The organic layers were combined and washed 
with water then brine, dried with magnesium sulfate, and concentrated.  The crude reaction 
product was purified by column chromatography using 5% MeOH/ CH2Cl2 as the mobile phase to 
afford 2.14 in 85% yield.  1H NMR (300 MHz, Chloroform-d) δ 7.65 – 6.97 (m, 9H), 5.46 – 5.21 
(m, 1H), 4.38 (t, J = 7.2 Hz, 2H), 4.07 (d, J = 6.7 Hz, 2H), 3.03 (h, J = 1.9 Hz, 4H), 2.53 (t, J = 
7.2 Hz, 2H), 1.67 (s, 3H).  13C NMR (75 MHz, Chloroform-d) δ 147.41, 147.38, 141.09, 140.50, 
140.47, 139.19, 134.52, 129.13, 128.96, 127.32, 127.27, 127.14, 127.09, 121.08, 59.21, 48.66, 






 To an oven-dried round bottom flask equipped with a magnetic stir bar was added 
methanesulfonyl chloride (1.3 eq, 0.09 mmol), DMAP (1.5 eq, 0.10 mmol) and 0.4 mL of 
dichloromethane.  The mixture was cooled to 0°C and a solution of alcohol 2.14 in 0.2 mL of 
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dichloromethane was added dropwise to the reaction vessel and allowed to stir for 2.5 hours.  
Hexanes were then added to the reaction vessel and the solution was filtered and concentrated.  
Next, Et2O was added to the crude product and was again filtered and concentrated.  The crude 
allylic chloride was then converted to the pyrophosphate following the same method described 
for 2.6a-f.  Yield (89%).  1H NMR (500 MHz, Deuterium Oxide) δ 7.93 – 6.96 (m, 10H), 5.27 (s, 
1H), 4.34 (s, 2H), 4.20 (s, 2H), 2.80 (s, 4H), 2.35 (s, 2H), 1.53 (s,3H).  31P NMR (202 MHz, 
Deuterium Oxide) δ -9.89 (d, J = 14.0 Hz), -13.85 (d, J = 18.0 Hz).  HRMS 506.1252 [M+2H]-, 
calculated 506.1246 (C22H26N3O7P2). 
 
General procedure for in vitro biochemical substrate screening:   
All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s 
laboratory at the University of Michigan by Elia Wright.  Preliminary evaluation of all 
pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansyl-
GCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO (N-2-
hydroxyethylpiperazine-N’-2-hydroxypropanesulfonic acid) pH 7.8, 5 mM 
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).  
Protein prenylation was determined by monitoring the dansylated peptide using a continuous 
spectrofluorometic assay and all assays were performed in triplicate.  Upon prenylation of the 
peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group 
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader.  Peptide in assay buffer was 




CHAPTER 3.   SYNTHESIS & BIOCHEMICAL EVALUATION OF SATURATED 
GERANYLGERANYL PYROPHOSPHATE ANALOGS 
 
3.1    Introduction 
 
It is known that the first isoprene is critical for substrate activity.  Addition of one methylene 
unit between the double bond of the first isoprene and the pyrophosphate moiety of FPP converts 
the native substrate of FTase into an inhibitor.80  It is still unclear whether or not the other 
isoprene units are required for substrate activity.  In the past, there have been several inhibitors of 
GGTase-I that contain long saturated hydrocarbon chains with some of these inhibitors displaying 
submicromolar IC50’s.
119  Some of these inhibitors are bisubstrate inhibitors that contain 
components that mimic both the peptide substrate (Figure 3.1, blue) and the isoprenoid chain 
(Figure 3.1, red).  Such compounds led us to question whether or not the β, γ, and ω isoprene 
units are essential for enzyme activity (Figure 3.2).  To address the query, we synthesized a 
variety of pyrophosphate analogs in which one or more of the isoprene units were removed.   
In order to determine if the α-isoprene is sufficient to produce substrate activity, the first set 
of analogs synthesized contained compounds in which the β, γ, and ω isoprene units were 
removed from GGPP and replaced with aliphatic chains (Figure 3.3).  Next, analogs that contain 
only the α- and β-subunits were synthesized.  This means that the ω-isoprene is missing in the 
case of FPP or that both the γ and ω-isoprene units are missing in GGPP.  These analogs vary in 
length between that of FPP and GGPP and will determine if the first two isoprene units are 
sufficient for substrate activity. 
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Next, the ω-isoprene unit was re-installed to obtain compounds that lack the β and γ isoprene 
units.  These compounds will examine the importance of the central isoprene units and whether or 
not they are required for substrate activity.  Finally, we synthesized (2E,6E)-10,11,14,15-
tetrahydrogeranylgeranyl pyrophosphate and (2E,6E,10E)-14,15-dihydrogeranylgeranyl 
pyrophosphate (Figure 3.3).  The dihydro-GGPP analog lacks the ω double bond but retains the 
methylene unit at the 15 position (Figure 3.2).  The tetrahydro-GGPP analog lacks both the γ and 
ω double bonds but retains the methylene units at the 11 and 15 positions (Figure 3.2).  When 
compared to the saturated GGPP analogs and GGPP itself, these analogs will aid in determining 


























3.2    Synthesis of Saturated Geranylgeranyl Pyrophosphate Analogs 
 
The synthesis of the saturated GGPP analogs began with the compounds containing only 
the α-isoprene unit.  The synthesis of these three analogs was simple and straight forward 
(Scheme 3.1).  Briefly, commercially available alkynes 3.1 were subjected to Negishi’s ZACA 
reaction and quenched with paraformaldehyde to afford alcohols 3.2a-c in 50-58% yields.114  
Next, these alcohols underwent Corey-Kim chlorination with NCS followed by 
pyrophosphorylation according to the procedure of Davisson et al. to produce the pyrophosphates 
3.3a-c  in moderate to good yields.112, 113  
Next, we focused on the synthesis of analogs that contain only the α- and β-subunits 
(Scheme 3.2).  To synthesize these compounds, commercially available alkynes 3.4 underwent 
Negishi’s ZACA reaction followed by and iodine quench to provided vinyl iodides 3.5a-d.  
Previously synthesized bromide 2.8 can then be converted into the organoborane and coupled to 
vinyl iodides 3.5a-d via a Suzuki coupling reaction to yield alcohols 3.6a-d.120 Following a THP 
deprotection with PPTS/EtOH and standard chlorination/pyrophosphorylation procedures,112, 113 
diphosphates 3.7a-d were obtained in moderate to good yields. 
We then turned our attention to the synthesis of analogs where the ω-isoprene unit was 
reinstalled to obtain compounds that lack the β- and γ-isoprene units (Scheme 3.3).  In general, 
commercially available diol 3.7 was subjected to mono-iodination.  With halo-alcohols 3.7 and 
3.10 in hand, Swern oxidations afforded aldehydes 3.8 and 3.11, which then underwent Wittig 
reactions to install the ω-isoprene of 3.9 and 3.12.  With these two alkenyl iodides in hand, we 
turned our attention to synthesizing vinyl iodide 3.14.  This was accomplished by first generating 
the Schwartz’s reagent in situ following a method developed by Huang & Negishi.121  Following 
the addition of TBDMS-protected but-2-yn-1-ol, hydrozirconation-iodinolysis proceeds to yield 
vinyl iodide 3.14.  Alkyl iodides 3.9 and 3.12 were then converted into their corresponding 
59 
 
organoboranes and coupled to vinyl iodide 3.14 via Suzuki coupling to yield vinyl alcohols 
3.15a-b.  Utilizing standard chlorination/pyrophosphorylation procedures, diphosphates 3.16a-d 
were afforded. 
The synthesis of tetrahydro-GGPP began with the synthesis of diethyl phosphate 3.18, 
which was accomplished in a similar manner as 2.3 (Scheme 3.4).111  The remainder of this 
synthesis followed the methodology used to synthesize the aryl-modified analogs of Chapter 2.  
First, Grignard reagent 3.17 was generated from the corresponding bromide followed by the slow 
addition of diethyl phosphate 3.18 to the reaction lead to a SN2 displacement of the phosphate 
group.  Next, standard THP-deprotection yielded alcohol 3.20.  Again, standard chlorination and 
pyrophosphorylation procedures were utilized to generate diphosphate 3.21. 
The final compound of this series, dihydro-GGPP (3.26), was accomplished using a 
Cu(I)-mediated Grignard displacement of an allylic THP-ether.110, 122  Briefly, alcohol 3.22 was 
protected as the THP-ether and then deacetylated using standard protocols.  After Grignard 
reagent 3.24 was generated from the corresponding bromide, it was slowly added to a cooled 
solution of THP-ether 3.23 and Cu(I)Br to yield alcohol 3.25.  It is crucial to keep this reaction at 
-10°C to avoid degradation of the organocuprate intermediate.  Following standard 











Scheme 3.1.  Synthesis of α-containing pyrophosphates.  (a) i. Me3Al, Cp2ZrCl2, DCM 0°C, 18 




Scheme 3.2.  Synthesis of α & β-containing pyrophosphates.  (a) i. Me3Al, Cp2ZrCl2, DCM, 0°C, 
18 hr, then I2, 3 hr, (b) i. t-BuLi, Et2O, -78°C, ii. β-MeO-9-BBN, THF, -78°C warming to RT o/n, 
iii. K3PO4, PdCl2(dppf), DMF, 85°C, 18 hr; (c) PPTS, MeOH, 60°C (Yields given for 2 steps); (d) 




Scheme 3.3.  Synthesis of α & ω-containing pyrophosphates.  (a) PPh3, Imidazole, I2, DCM, 0°C; 
(b) (COCl)2, DMSO, Et3N, DCM, -78°C (28%); (c)  i-PrPh3I, n-BuLi, THF, -78°C; (d) i. 
Cp2ZrCl2, DIBAL, THF, 0°C, 0.5 hr; ii. 3.13, warm to rt, 1.5 hr; iii. I2, THF, -78°C, 0.5 hr;  (e) i. 
DIEA, TBDMSCl, DCM (95%); ii. DIBAL, Cp2ZrCl2, THF, 0°C (40%); (f)  i. t-BuLi, Et2O, -
78°C, ii. β-MeO-9-BBN, THF, -78°C warming to RT o/n; iii. K3PO4, PdCl2(dppf), DMF, 85°C, 









Scheme 3.4.  Synthesis of tetrahydro-GGPP.  (a)  R-MgX, THF, o/n (15%); (b) PPTS, EtOH, 




Scheme 3.5.  Synthesis of dihydro-GGPP.  (a) i. DHP, PPTS, DCM; (b) saturated K2CO3/MeOH, 
(74% - 2 steps); (c) 3.24, Cu(I)Br, THF, -10°C, 48 hr (17%); (d) NCS, DMS, DCM, 2.5 hr; (e) 








3.3    Biochemical Evaluation of Saturated Geranylgeranyl Pyrophosphate Analogs 
 
In the past, little has been done to investigate the isoprene requirements of GGTase-I.  
While it is known that the α-isoprene is required for substrate activity, it is unclear if the 
remaining three isoprenes are essential for enzyme recognition and activity.  Therefore, our goal 
was to synthesize a library of compounds that was lacking the β, γ, or ω isoprene units or lacking 
a combination of isoprene units.  These analogs were designed to range in length between FPP 
(12 carbons long) and GGPP (16 carbons long).  The saturated GGPP analogs synthesized (3.3a-
c, 3.7a-d, 3.16a-b, 3.21, & 3.24) were evaluated for their biochemical activity in an in vitro 
continuous spectrofluorometric assay with GGTase and the co-substrate CaaX-peptide dansyl-
GCVLL.  All biochemical assays were performed in our collaborator Dr. Carol Fierke’s 
laboratory at the University of Michigan by Elia Wright.   
 It appears that all of the saturated compounds synthesized display some degree of 
substrate activity.  The first set of compounds containing only the α-isoprene unit (3.3a-c) 
revealed that GGTase-I can recognize and utilize these compounds as substrates (Figure 3.4); 
however, it is evident that the length of the aliphatic carbon chain plays a definite role in the level 
of enzyme activity.  When the carbon chain length is 14 carbons (3.3a) we notice that the 
substrate activity is greatly diminished when compared to GGPP; however, when the carbon 
chain length is increased to 16 carbons (3.3c), the same length as GGPP, we see an increase in 
substrate activity although it is still much less than GGPP.  
In order to determine if any substrate activity could be regained, we synthesized 
compounds that contained both the α- and β-isoprene units (3.7a-d).  Indeed, replacing the β-
subunit of 3.3a (14 carbons long) to generate 3.7b resulted in a moderate increase of substrate 
activity (Figure 3.5); however the same modification to 3.3c (16 carbons long) to generate 3.7d 
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only led to a minimal increase in substrate activity.  Although decreasing the length of the carbon 
chain to 13 carbons seemed to hinder substrate activity, increasing the carbon chain from 14 to 16 
carbons did not appear to greatly affect the substrate activity. 
 The next two analogs tested contained only the α- and ω-isoprene units (3.16a-b; Figure 
3.6).  These compounds were synthesized for two main reasons: (1) could we increase substrate 
activity when compared to compounds containing only α-isoprene units and (2) are the two 
central isoprene units necessary for substrate activity.  In fact, replacing the ω-subunit of 3.3c to 
generate 3.16b resulted in an increase in activity.  Similar to the α-isoprenoid analogs, we noticed 
that by decreasing the length of the carbon chain from 16 carbons (3.16b; the length of GGPP) to 
15 carbons (3.16a) resulted in a significant decrease of substrate activity. 
 The final two compounds analyzed lacked the γ and/or ω isoprene double bonds but 
retained the methylene units (3.21 & 3.26).  Interestingly, when both the γ and ω double bond are 
saturated the substrate activity greatly decreases (Figure 3.7).  When compared to other saturated 
molecules of the same length (e.g. 3.3a and 3.7d), analog 3.21 is a poorer substrate.  One possible 
explanation for this observation is that the compound has a chiral carbon at position 7 and was 
synthesized as a mixture of isomers.  Thus, it is possible that only one isomer is active.  A more 
likely explanation is molecular geometry.  With the double bonds in place, the geometry of the 
molecule is planar; however, by removing the double bonds the molecular geometry changes 
from planar to tetrahedral.  This change in geometry could lead to unfavorable interaction with 
the active site of the enzyme and ultimately reduce substrate ability.  Analog 3.26 also displayed 













Figure 3.4.  Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.3a-c 
versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent 












Figure 3.5.  Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.7a-d 
versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent 









*100 ± 0.73% 
†22 ± 1.7% 
*59 ± 1.6% 




*100 ± 0.73% 
*8.2 ± 7.1% *23 ± 0.62% 
*56 ± 2.0% 














Figure 3.6.  Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.16a-
b versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I. Error bars represent 












Figure 3.7.  Bar graphs of substrate activity represented in RFI of saturated GGPP analogs 3.21 
& 3.26 versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.  Error bars 





*100 ± 0.73% 
*16 ± 1.1% 
*88 ± 1.6% 
(Same length as GGPP) 
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Figure 3.8. Monitoring continuous changes in fluorescence of saturated 
GGPP analogs versus GGPP (+ control) at various concentrations (1 µM, 
5µM, & 10µM) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.  








































































3.4    Conclusions 
 
The goal of this chapter was to focus on the synthesis of a small library of saturated 
GGPP analogs in order to determine the isoprene requirements of the enzyme GGTase-I.  While 
various types of FPP and GGPP analogs have been synthesized in the past (Figure 1.9), it was 
unknown if all of the isoprene units were required for enzyme recognition and activity.   
This aim was centered on designing synthetic routes that would enable us to rapidly 
develop our small library of compounds.  Although our laboratory has employed Negishi 
couplings in the past to generate FPP analogs, this reaction is highly sensitive to moisture and air.  
Therefore, we wished to develop alternative synthetic routes that utilized less sensitive coupling 
procedures such as Suzuki couplings.   
Considering the number of commercially available alkynes, Negishi’s ZACA reaction 
was an appealing method for the facile generation of various isoprenoid units.  Through the 
utilization of the ZACA reaction, we were able to synthesize the α-containing analogs 3.3a-c and 
the vinyl iodides 3.5a-d which underwent Suzuki couplings to produce the α/β-containing 
analogs 3.7a-d.  In order to synthesize the α/ω- containing analogs, an alternative approach was 
needed.  Thus, by utilizing Swern and Wittig reactions we could generate the alkyl halides 3.9 
and 3.12 which were converted to organoboranes and subjected to Suzuki coupling to afford 
3.16a-b. 
The synthesis of the of the tetrahydro-GGPP analog 3.21 was accomplished using similar 
chemistry as discussed in Chapter 1; however, a different approach was needed to yield the 
dihydro-GGPP analog 3.24 due to an increase in SN2’ product resulting from a decrease in the 
steric bulk of the Grignard reagent. Instead, a Cu(I)-mediated THP-ether displacement by a 
Grignard reagent was utilized.  
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Upon in vitro biochemical testing, it was revealed that all analogs displayed some degree 
of substrate activity.  Generally, if we increase the number of carbons in the chain it results in 
greater substrate activity.  Interestingly, it became evident that the α-isoprene unit is sufficient to 
warrant enzyme recognition and catalysis; however, increasing the carbon length from 14 to 16 
greatly added to the analogs substrate ability.  Replacing the β-isoprene unit seems to have the 
greatest effect on analogs that are shorter than GGPP (less than 16 carbons).  For instance, 
replacing the β-isoprene of 3.3a (14 carbons long) to generate 3.7b had a much greater effect on 
substrate ability than the same modification of 3.3c (16 carbons long) to generate 3.7d. 
When replacing the terminal isoprene to generate α/ ω-containing analogs it appears that 
chain length is essential.  Having just one carbon unit short of the length of GGPP is detrimental 
to the analog’s substrate ability (3.16a); however, with the proper chain length (3.16b), the data 
suggest that this modification is the most advantageous resulting in an analog comparable to 
GGPP.  By examining the data in Figure 3.8, it appears that analog 3.16b is turned over more 
quickly than GGPP.  That is to say, analog 3.16b reaches its fluorescence maximum more quickly 
than GGPP.  Many of the other compounds seem to turn over more slowly than GGPP or have a 
lower affinity for the enzyme.  Unfortunately, the analogs were tested at only three concentrations 
(1, 5, & 10 µM) and many of the reactions did not reach completion at 10 µM of analog.  In order 
to determine accurate kcat and Km values, these analogs are currently being retested at more 
concentrations.  
We have successfully synthesized a library of saturated GGPP compounds in which one 
or more of the isoprene units has been removed from the molecule.  The preliminary biochemical 
evaluation revealed several intriguing results.  At a later date, these compounds will be screened 
with an expansive library of dansyl-GCaaX peptides to determine if these analogs globally or 
selectively geranylgeranylate proteins.  In addition, these compounds ranged in length between 
70 
 
GGPP and FPP; therefore, we will also be testing these compounds with FTase to determine their 
ability to be recognized and utilized by one enzyme over another.   
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3.5    Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of Saturated 
Geranylgeranyl Pyrophosphate Analogs 
 
General Experimental Procedures:  All reactions were performed with oven-dried or flame-
dried glassware and under dry argon gas.  All commercial reagents and solvents were used 
directly without subsequent purification.  For the organmetallic coupling reactions, anhydrous 
THF was freshly distilled from sodium and benzophenone.  All other anhydrous solvents were 
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.  
Reactions were monitored by thin layer chromatography and visualized with one or more of the 
following: UV light, iodine, vanillin solution, potassium permanganate solution, 
dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.  All products were 
purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.  All 
reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded 
with sodium sulfated before column purification.  NOTE: *Dry glassware is critical for the 
organometallic reactions in this publication.  This was accomplished by taking oven-dried 
glassware (dried for at least 24 hr and then cooled under argon) and flame drying the round 
bottom flask under vacuum.  The flask was then purged with argon and cooled to room 
temperature.  This process was repeated 3 times to produce a completely water free 
environment.*  **Deoxygenated solvents are extremely crucial for successful organometallic 
reactions in this publication.  In order to achieve completely deoxygenated solutions, the solvent 
was placed in a flame-dried round bottom and under vacuum was sonicated for 30 seconds and 
then purged with argon for 30 seconds.  This process was repeated 3 times to yield completely 
deoxygenated solvents.**  All NMR spectra were taken either on a 300 MHz Bruker ARX300 or 
a 500 MHz Bruker DRX500 spectrometer.  Low-resolution MS (EI/CI) were recorded with a 
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Hewlett Packard Engine and low-resolution MS (ESI) were taken on a Thermoquest LCQ.  All 
high-resolution mass spectra were recorded on a FinniganMAT XL95. 
 
Representative procedure for the synthesis of vinyl alcohols 3.2a-c: 
OH  
(E)-3-methyltetradec-2-en-1-ol (3.2a): 
Cp2ZrCl2 (0.25 eq, 0.38 mmol) was dissolved in dichloromethane (1.5 mL) and the 
solution was cooled to 0°C, where AlMe3 solution (2.0 M in heptanes, 2.5eq, 4.5 mmol, 2.25 mL) 
was added dropwise.  After stirring the reaction mixture at 0°C for 30 minutes, 1-tridecyne (1.0 
eq, 1.5 mmol) was diluted in dichloromethane (1.0 mL) and added to the reaction mixture 
dropwise.  The reaction mixture was allowed to slowly warm to room temperature and stirred an 
additional 12 hours.  Next, the reaction mixture was cooled to 0°C, where (CH2O)n (5 eq, 4.5 
mmol, 135 mg) was added in several portions.  The reaction continued to stir for 3 hours after 
which it was slowly poured into an ice-cold 10% HCl(aq) solution.  The solution was then filtered 
over a pad of Celite 545, extracted with 3 × 10 mL dichloromethane, washed with brine, dried 
with magnesium sulfated, filtered, and concentrated.  Column chromatography (10% Ethyl 
acetate in Hexanes) afforded 3.2 in 50% yield. 1H NMR (300 MHz, CDCl3) δ 5.41 – 5.30 (m, 
1H), 4.11 (d, J = 6.9 Hz, 2H), 2.01 – 1.91 (m, 2H), 1.62 (s, 3H), 1.23 (s, 18H), 0.84 (t, J = 6.6 Hz, 
3H); 13C NMR (75 MHz, Chloroform-d) δ 140.31, 123.26, 59.53, 39.76, 32.12, 29.88, 29.84, 









Yield (58%); 1H NMR (300 MHz, Chloroform-d) δ 5.49 – 5.24 (m, 1H), 4.13 (d, J = 7.0 
Hz, 2H), 1.98 (t, J = 7.5 Hz, 2H), 1.64 (d, J = 1.3 Hz, 3H), 1.24 (d, J = 4.1 Hz, 20H), 0.86 (t, J = 
6.3 Hz, 3H). 13C NMR (75 MHz, Chloroform-d) δ 140.52, 123.25, 59.64, 39.79, 32.15, 29.94, 
29.91, 29.87, 29.84, 29.77, 29.59, 29.55, 27.91, 22.92, 16.40, 14.36.  MS (EI) m/z 222 [M+-H2O].; 
MS (CI) m/z 241 [M++H]. 
OH  
(E)-3-methylhexadec-2-en-1-ol (3.2c): 
Yield (56%);  1H NMR (300 MHz, Chloroform-d) δ 5.38 (ddt, J = 7.0, 5.6, 1.5 Hz, 1H), 
4.13 (d, J = 7.0 Hz, 2H), 1.98 (t, J = 7.5 Hz, 2H), 1.64 (d, J = 1.3 Hz, 3H), 1.24 (d, J = 3.8 Hz, 
22H), 0.85 (t, J = 6.3 Hz, 3H). 13C NMR (75 MHz, Chloroform-d) δ 140.53, 123.24, 59.65, 39.79, 
32.15, 29.94, 29.91, 29.88, 29.84, 29.77, 29.59, 29.55, 27.91, 22.92, 16.40, 14.36.  MS (EI) m/z 
236 [M+-H2O].; MS (CI) m/z 253 [M
+-H]. 
 
Representative procedure for the synthesis of vinyl iodides 3.5a-d: 
I  
(E)-1-iodo-2-methyloct-1-ene (3.5a):   
Cp2ZrCl2 (0.25 eq, 0.75 mmol) was dissolved in dichloromethane (3 mL) and the solution 
was cooled to 0°C, where a Me3Al solution (2.0 M in heptanes, 2.5eq, 9 mmol) was added 
dropwise.  After stirring the reaction mixture at 0°C for 30 minutes, 1-octyne (1.0 eq, 3 mmol) 
was diluted in dichloromethane (1.5 mL) and added to the reaction mixture dropwise.  The 
reaction mixture was allowed to slowly warm to room temperature and stirred an additional 12 
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hours.  Next, the reaction mixture was cooled to 0°C, where I2 (2.5 eq, 7.5 mmol) was added in 
several portions.  The reaction continued to stir for 3 hours after which it was slowly poured into 
an ice-cold 10% HCl(aq) solution.  The solution was then filtered over a pad of Celite 545, 
extracted with 3 × 20 mL dichloromethane, washed with saturated Na2S2O3  × 2, washed with 
brine, dried with magnesium sulfated, filtered, and concentrated to afford 3.5 a in 55% yield. 
NMR:  1H NMR (300 MHz, Chloroform-d) δ 5.97 – 5.56 (m, 1H), 2.17 (t, J = 7.5 Hz, 2H), 1.80 
(s, 3H), 1.53 – 1.07 (m, 8H), 0.86 (t, J = 6.1 Hz, 3H). 13C NMR (75 MHz, Chloroform-d) δ 




Yield (63%); 1H NMR (300 MHz, Chloroform-d) δ 5.83 (s, 1H), 2.17 (t, J = 7.5 Hz, 2H), 
1.80 (s, 3H), 1.24 (s, 10H), 0.86 (dt, 3H).  13C NMR (75 MHz, Chloroform-d) δ 104.96, 74.52, 




Yield (75%); 1H NMR (300 MHz, CDCl3) δ 5.85 – 5.81 (m, 1H), 2.22 – 2.11 (m, 2H), 
1.80 (d, J = 1.0 Hz, 3H), 1.24 (s, 12H), 0.86 (t, J = 6.6 Hz, 3H).  13C NMR (75 MHz, Chloroform-
d) δ 148.50, 74.54, 39.82, 32.08, 29.58, 29.45, 29.27, 27.92, 24.03, 22.89, 14.34.   
I  
(E)-1-iodo-2-methylundec-1-ene (3.5d): 
Yield (81%); 1H NMR (300 MHz, CDCl3) δ 5.95 – 5.63 (m, 1H), 2.23 – 2.10 (m, 2H), 
1.80 (s, 3H), 1.24 (s, 14H), 0.86 (t, J = 6.6 Hz, 3H).  13C NMR (75 MHz, CDCl3) δ 148.54, 74.53, 
39.82, 32.10, 29.74, 29.62, 29.53, 29.27, 27.93, 24.04, 22.90, 14.35.   
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 Representative Procedure for the Synthesis of Suzuki Couplings: 
OTHP  
2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran:  
An oven-dried round-bottom flask containing powdered molecular sieves was charged 
with (E)-2-((5-bromo-3-methylpent-2-en-1-yl)oxy)tetrahydro-2H-pyran (stored over sieves; 2.0 
eq, 4 mmol) which was dissolved in 13 mL of anhydrous Et2O and cooled to -78°C.  Next, t-BuLi 
(1.7M in pentane; 3.0 eq, 6.0 mmol, 3.53 mL) was slowly added to the reaction flask and stirred 
for 1 hour at -78°C.  Afterward, β-MeO-9-BBN (1.0M in Hexanes; 3.8 eq, 7.6 mmol) was slowly 
added to the reaction vessel and the mixture was stirred for 16 hours slowly warming to room 
temperature.   
In a scintillation vial, (E)-1-iodo-2-methyldec-1-ene (1.0 eq, 2.0 mmol) and Pd(dppf)Cl2 
(0.15 eq, 0.3 mmol) are dissolved in 7 mL of DMF.  Next, K3PO4 (3 M in H2O, 3.0 eq, 6.0 mmol, 
3mL) is added to the vial and after deoxygenating the solvent, the vinyl-iodide solution is added 
to the round-bottom flask containing the newly formed organoborane. The reaction mixture is 
allowed to stir for an additional 16 hours at 85°C after which it is poured into a separatory funnel 
containing water and Et2O and the aqueous layer was extracted 3 × 30 mL Et2O.  The organic 
layers were combined and washed with water then brine, dried with magnesium sulfate, and 
concentrated.  The crude reaction product was purified by column chromatography using 5% 
Diethyl ether/Hexanes as the mobile phase to afford THP-protected alcohol in 70% yield.  1H 
NMR (300 MHz, CDCl3) δ 5.32 (t, J = 7.0 Hz, 1H), 5.05 (t, J = 6.7 Hz, 1H), 4.58 (t, J = 3.2 Hz, 
1H), 4.19 (dd, J = 12.0, 6.4 Hz, 1H), 3.98 (dd, J = 12.0, 7.4 Hz, 1H), 3.85 (td, J = 8.7, 6.5, 2.6 Hz, 
1H), 3.61 – 3.39 (m, 1H), 2.03 (dd, J = 11.6, 6.0 Hz, 3H), 1.95 – 1.66 (m, 3H), 1.63 (s, 3H), 1.59 
– 1.25 (m, 10H), 1.22 (s, 12H), 0.98 – 0.71 (m, 3H).  13C NMR (75 MHz, CDCl3) δ 140.34, 
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135.70, 123.74, 120.74, 97.82, 63.73, 62.35, 39.84, 39.82, 32.08, 30.87, 29.79, 29.74, 29.53, 
29.46, 28.13, 26.40, 25.68, 22.86, 19.77, 16.54, 16.04, 14.27.   
OTHP  
2-(((2E,6E)-3,7-dimethylpentadeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran: 
Yield (47%);  1H NMR (300 MHz, CDCl3) δ 5.39 – 5.27 (m, 1H), 5.05 (dd, J = 7.1, 6.1 
Hz, 1H), 4.59 (t, J = 3.4 Hz, 1H), 4.20 (dd, J = 11.9, 6.4 Hz, 1H), 3.99 (dd, J = 11.9, 7.3 Hz, 1H), 
3.86 (ddd, J = 11.1, 7.2, 3.6 Hz, 1H), 3.47 (dt, J = 10.7, 5.3 Hz, 1H), 2.05 (d, J = 11.0 Hz, 3H), 
1.90 (d, J = 7.9 Hz, 2H), 1.86 – 1.66 (m, 2H), 1.64 (s, 3H), 1.52 (dd, J = 10.0, 5.6 Hz, 7H), 1.39 – 
1.11 (m, 11H), 0.88 – 0.78 (m, 5H). 13C NMR (75 MHz, Chloroform-d) δ 140.47, 135.79, 123.76, 
120.71, 97.90, 63.79, 62.43, 39.87, 34.89, 32.10, 30.89, 29.72, 29.52, 29.48, 28.16, 26.42, 25.69, 
22.87, 19.80, 16.58, 16.09, 14.31.   
OTHP  
2-(((2E,6E)-3,7-dimethyltetradeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran: 
Yield (35%);  1H NMR (300 MHz, CDCl3) δ 5.32 (dd, J = 10.1, 3.7 Hz, 1H), 5.06 (dd, J 
= 6.6, 5.8 Hz, 1H), 4.59 (t, J = 3.4 Hz, 1H), 4.27 – 3.40 (m, 4H), 2.14 – 1.66 (m, 7H), 1.64 (s, 
3H), 1.61 – 1.14 (m, 18H), 0.85 (dd, J = 7.7, 5.7 Hz, 4H). 13C NMR (75 MHz, CDCl3) δ 140.44 
(s), 135.78 (s), 123.76 (s), 120.73 (s), 97.90 (s), 63.79 (s), 62.42 (s), 39.86 (s), 32.07 (s), 30.90 
(s), 29.44 (s), 28.16 (s), 26.42 (s), 25.70 (s), 22.87 (s), 19.81 (s), 16.58 (s), 16.08 (s), 14.30 (s).   
OTHP  
2-(((2E,6E)-3,7-dimethyltrideca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran: 
Yield (23 % based on NMR).  Compound co-eluted with an impurity after column 
chromatography (5% Diethyl ether/Hexanes).  Impure compound was taken on and deprotected in 
the next step.    
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Representative procedure for the synthesis of alcohols 3.6a-d: 
 
(2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-ol (3.6d):   
In a scintillation vial, 2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl)oxy)tetrahydro-
2H-pyran (1.0 eq, 1.4 mmol) was dissolved in 7.5 mL of absolute EtOH and PPTS (0.1 eq, 0.14 
mmol) was added to the vial.  The reaction mixture was heated to 60°C and stirred for 12 hours.  
Next, the reaction was cooled to room temperature where it was poured into a separator funnel 
containing water and Et2O and the aqueous layer was extracted 3 × 10 mL Et2O.  The organic 
layers were combined and washed with water then brine, dried with magnesium sulfate, and 
concentrated.  The crude reaction product was purified by column chromatography using 10% 
Ethyl Acetate/Hexanes as the mobile phase to afford 3.6d in 76% yield (mg).  NMR:  1H NMR 
(300 MHz, CDCl3) δ 5.38 (t, J = 6.9 Hz, 1H), 5.06 (t, J = 6.7 Hz, 1H), 4.11 (d, J = 6.8 Hz, 2H), 
2.13 – 1.97 (m, 3H), 1.92 (t, J = 7.5 Hz, 2H), 1.64 (s, 3H), 1.55 (s, 3H), 1.43 – 1.05 (m, 15H), 
0.98 – 0.66 (m, 3H).  13C NMR (75 MHz, CDCl3) δ 139.85, 135.91, 123.66, 123.52, 59.50, 39.86, 
39.77, 32.10, 29.81, 29.77, 29.55, 29.48, 28.17, 26.46, 22.89, 16.43, 16.06, 14.30.  MS (EI) m/z 
266 [M+-].; MS (CI) m/z 265 [M+-H]. 
OH  
(2E,6E)-3,7-dimethylpentadeca-2,6-dien-1-ol (3.6c):   
Yield (56%):  NMR:  1H NMR (300 MHz, CDCl3) δ 5.42 (td, J = 6.9, 1.2 Hz, 1H), 5.08 
(dt, J = 6.7, 3.4 Hz, 1H), 4.15 (d, J = 6.9 Hz, 2H), 2.17 – 1.99 (m, 4H), 1.95 (t, J = 7.4 Hz, 2H), 
1.68 (s, 3H), 1.58 (s, 3H), 1.42 (s, 1H), 1.40 – 1.29 (m, 2H), 1.26 (s, 10H), 0.88 (t, J = 6.7 Hz, 
3H).  13C NMR (75 MHz, CDCl3) δ 140.06 (s), 135.98 (s), 123.56 (d, J = 14.2 Hz), 77.65 (s), 
77.23 (s), 76.81 (s), 59.60 (s), 39.84 (d, J = 7.4 Hz), 32.12 (s), 29.87 – 29.37 (m), 28.19 (s), 26.46 
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(s), 22.89 (s), 16.48 (s), 16.11 (s), 14.34 (s).  MS (EI) m/z 236 [M+-H2O].; MS (CI) m/z  235 
[(M++H)-H2O]. 
 
(2E,6E)-3,7-dimethyltetradeca-2,6-dien-1-ol (3.6b):   
Yield (66%);  NMR:  1H NMR (300 MHz, CDCl3) δ 5.38 (td, J = 6.9, 1.2 Hz, 1H), 5.11 – 
5.00 (m, 1H), 4.11 (d, J = 6.9 Hz, 2H), 2.14 – 1.96 (m, 4H), 1.92 (t, J = 7.4 Hz, 2H), 1.64 (s, 3H), 
1.55 (s, 3H), 1.48 – 1.11 (m, 12H), 0.85 (dd, J = 8.4, 5.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
139.90 (s), 135.92 (s), 123.66 (s), 123.50 (s), 59.53 (s), 39.86 (s), 39.77 (s), 32.07 (s), 29.43 (s), 
29.43 (s), 28.17 (s), 26.45 (s), 22.87 (s), 16.44 (s), 16.07 (s), 14.30 (s).  MS (EI) m/z 238 [M+].; 
MS (CI) m/z 237 [M+-H]. 
 
(2E,6E)-3,7-dimethyltrideca-2,6-dien-1-ol (3.6a):  
Yield (52%; 12% from coupling step).  1H NMR (300 MHz, Chloroform-d) δ 5.42 (td, J 
= 7.5, 6.9, 1.2 Hz, 0H), 5.09 (t, J = 6.5 Hz, 0H), 4.15 (dd, J = 7.1, 2.9 Hz, 1H), 2.07 (ddt, J = 
13.7, 9.1, 4.2 Hz, 1H), 1.95 (t, J = 7.5 Hz, 0H), 1.68 (s, 1H), 1.58 (s, 1H), 1.43 – 1.16 (m, 2H), 
0.88 (t, J = 6.7 Hz, 1H). 13C NMR (75 MHz, Chloroform-d) δ 140.08, 135.98, 123.67, 123.50, 
59.63, 39.89, 39.80, 32.01, 29.17, 28.15, 26.47, 22.88, 16.48, 16.12, 14.34.  MS (EI) m/z 224 [M+-




10-iododecan-1-ol:   
To an oven dried round bottom flask cooled under Argon is added decane-1,10-diol (1.3 
eq, 39 mmol) dissolved in 50 mL of anhydrous dichloromethane.  The reaction flask is cooled to 
0°C where PPh3 (1.0 eq, 30 mmol) followed by imidazole (1.5 eq, 45mmol) are added to the 
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reaction vessel.  After stirring at 0°C for 10 minutes, iodine (1.0 eq, 30 mmol) is added to the 
reaction portion wise; after complete addition, the reaction is stirred for 3.5 hours at room 
temperature.  The reaction was then quenched with 10% NH4Cl(aq) and the aqueous layer was 
extracted 3 × 100 mL of hexanes. The organic layers were combined, dried with sodium sulfate, 
and concentrated.  The crude reaction product was purified column chromatography by dry-
loading with sodium sulfate and using 30% Ethyl Acetate/Hexanes as the mobile phase to afford 
title compound in 45% yield.  1H NMR (300 MHz, CDCl3) δ 3.61 (t, J = 6.2 Hz, 2H), 3.16 (t, J = 
7.0 Hz, 2H), 1.85 – 1.71 (m, 2H), 1.52 (dd, J = 13.7, 6.8 Hz, 2H), 1.42 – 1.11 (m, 14H). 13C NMR 
(75 MHz, CDCl3) δ 77.65 (s), 77.23 (s), 76.81 (s), 63.25 (s), 33.73 (s), 32.97 (s), 30.69 (s), 29.81 
– 29.40 (m), 28.71 (s), 25.92 (s), 7.62 (s).   
O
I  
10-iododecanal (3.8):   
An oven dried multi-neck round bottom flask is equipped with an oven dried addition 
funnel and cooled under Argon.  The flask is charged with (COCl)2 (1.2 eq, 16 mmol) dissolved 
in 16 mL of dichloromethane and cooled to -78°C.  Next, DMSO (2.4 eq, 32 mmol) is dissolved 
in 2.2 mL of dichloromethane, added to the addition funnel, and slowly added to the reaction 
vessel over a 20 minute period at -78°C.  The reaction is allowed to stir at this temperature for 30 
minutes after which 11-iodoundecan-1-ol (1.0 eq, 13.34 mmol) diluted with 26 mL of 
dichloromethane is added slowly to the reaction mixture.  The reaction is allowed to stir for an 
additional 1.5 hours at -78°C followed by the addition of Et3N (5.0 eq, 66.7 mmol).  After 
allowing the reaction to come to room temperature, it is quenched by adding 10% NH4Cl(aq) and 
the aqueous layer was extracted 3 × 75 mL of DCM. The organic layers were combined, washed 
with brine, dried with magnesium sulfate, filtered, and concentrated.  The crude reaction product 
was purified column chromatography using 5% Ethyl Acetate/Hexanes as the mobile phase to 
afford 3.8 in 81% yield.  1H NMR (300 MHz, CDCl3) δ 9.67 (t, J = 1.5 Hz, 1H), 3.09 (t, J = 7.0 
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Hz, 2H), 2.33 (td, J = 7.3, 1.7 Hz, 2H), 1.71 (dd, J = 14.4, 7.1 Hz, 2H), 1.59 – 1.47 (m, 2H), 1.21 
(s, 10H).  13C NMR (75 MHz, Chloroform-d) δ 202.74, 43.88, 33.49, 30.44, 29.24, 29.19, 29.09, 
28.45, 22.03, 7.43.   
BrO  
11-bromoundecanal (3.11):   
Yield (75%); 1H NMR (300 MHz, CDCl3) δ 9.74 (d, J = 1.5 Hz, 1H), 3.38 (t, J = 6.8 Hz, 
2H), 2.40 (t, J = 7.3 Hz, 2H), 1.81 (dd, J = 14.3, 7.2 Hz, 2H), 1.68 – 1.53 (m, 2H), 1.38 (d, J = 6.9 
Hz, 2H), 1.26 (s, 12H).  13C NMR (75 MHz, CDCl3) δ 203.16 (s), 77.65 (s), 77.23 (s), 76.80 (s), 
44.12 (s), 34.28 (s), 33.01 (s), 29.46 (t, J = 8.0 Hz), 28.93 (s), 28.35 (s), 22.26 (s).   
 
Representative procedure of the Wittig reaction: 
I  
12-iodo-2-methyldodec-2-ene (3.9):   
An oven dried round bottom flask is charged with isopropyl triphenylphosphine iodide 
(1.5eq, mmol) and THF.  The flask is cooled to 0°C where n-BuLi (2.5 M in Hexanes, 1.5 eq, 
mmol) is added dropwise to give a red solution.  The reaction mixture is stirred for 30 minutes at 
0°C, after which 10-iododecanal (1.0 eq, mmol) dissolved in mL of THF is added dropwise to the 
reaction.  The reaction is allowed to stir for an additional 4 hours at room temperature.  Upon 
completion of the reaction, the reaction mixture is quenched by adding 10% NH4Cl(aq) and the 
aqueous layer was extracted 3 ×  mL of Et2O. The organic layers were combined, washed with 
brine, dried with magnesium sulfate, filtered, and concentrated.  The crude reaction product was 
purified with column chromatography by dry-loading with sodium sulfate and using hexanes as 
the mobile phase to afford 3.9 in 58% yield.  1H NMR (300 MHz, CDCl3) δ 5.13 – 5.04 (m, 1H), 
3.15 (t, J = 7.1 Hz, 2H), 1.92 (t, J = 6.5 Hz, 2H), 1.78 (dd, J = 14.5, 7.1 Hz, 2H), 1.66 (d, J = 0.9 
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Hz, 3H), 1.57 (s, 3H), 1.42 – 1.31 (m, 2H), 1.26 (s, 11H).  13C NMR (75 MHz, CDCl3) δ 131.19, 
125.03, 33.74, 30.69, 30.05, 29.66, 29.59, 29.46, 28.73, 28.20, 25.92, 17.85, 7.35.   
Br
 
13-bromo-2-methyltridec-2-ene (3.10):   
Yield (63%);  1H NMR (300 MHz, CDCl3) δ 5.14 – 5.04 (m, 1H), 3.39 (t, J = 6.9 Hz, 
2H), 1.92 (t, J = 6.6 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.66 (d, J = 0.9 Hz, 3H), 1.58 (s, 3H), 1.53 (s, 
1H), 1.46 – 1.34 (m, 2H), 1.25 (s, 14H).  13C NMR (75 MHz, Chloroform-d) δ 131.37, 125.13, 
34.32, 33.06, 30.11, 29.75, 29.66, 29.54, 29.00, 28.40, 28.26, 25.96, 17.89.   
OTBS
 
(but-2-yn-1-yloxy)(tert-butyl)dimethylsilane:   
To a round bottom flask is added but-2-yn-1-ol (1.0 eq, 12 mmol) dissolved in DCM.  
Next, DIEA (1.3 eq, 15.6 mmol) followed by TBDMSCl (1.3 eq, 15.6 mmol) is added to the 
reaction vessel and stirred for 6 hours at room temperature.  Upon completion of the reaction, the 
reaction mixture is quenched by adding 10% NH4Cl(aq) and the aqueous layer was extracted 3 ×  
50 mL of Et2O. The organic layers were combined, washed with brine, dried with magnesium 
sulfate, filtered, and concentrated.  The crude reaction product was purified column 
chromatography using 2% ethyl acetate/hexanes as the mobile phase to afford the title compound 
in 95% yield.  1H NMR (300 MHz, CDCl3) δ 4.23 (q, J = 2.3 Hz, 1H), 1.79 (t, J = 2.4 Hz, 1H), 
0.87 (s, 5H), 0.07 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 81.02, 77.92, 52.14, 26.05, 18.54, 3.77, 







(E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (3.14):   
To an oven dried round bottom flask, which was also flame dried under vacuum and 
cooled with Argon three times, is added Cp2ZrCl2 (1.5 eq, 17 mmol) in anhydrous THF(39 mL) 
and cooled to 0°C.  DIBAL (1.0 M in Toluene, 1.5 eq, 17 mmol) is then slowly added to afford a 
milky yellow solution which is stirred 30 minutes at 0°C.  Next, (but-2-yn-1-yloxy)(tert-butyl) 
dimethylsilane dissolved in THF (6 mL) is slowly added and the reaction mixture is allowed to 
war to room temperature where it is stirred until a homogeneous solution results (~1 hour).  
Finally, the reaction is cooled to -78°C and I2 dissolved in THF (17 mL) is added slowly and the 
mixture is allowed to stir for an additional 30 minutes at -78°C. The reaction mixture is quenched 
by pouring into a beaker containing 10% HCl(aq) and the aqueous layer was extracted 3 ×  50 mL 
of Et2O. The organic layers were combined, washed with saturated Na2S2O3, saturated NaHCO3, 
and brine. The organic layer is dried with magnesium sulfate, filtered, and concentrated.  The 
crude reaction product was purified column chromatography using 2% ethyl acetate/hexanes as 
the mobile phase to afford 3.14 in 40% yield.  1H NMR (300 MHz, Chloroform-d) δ 6.26 (td, J = 
6.3, 1.5 Hz, 1H), 4.09 (d, J = 6.5 Hz, 3H), 2.38 (d, J = 1.4 Hz, 4H), 0.86 (s, 12H), 0.04 (s, 7H).  




(E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane  and 12-iodo-2-methyldodec-2-
ene were coupled using the same procedure as 2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-
yl)oxy)tetrahydro-2H-pyran.  The crude reaction product was purified by column 
chromatography using 5% ethyl acetate/hexanes as the mobile phase to afford the title compound 
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in 86% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.27 (t, J = 6.4 Hz, 1H), 5.14 – 5.03 (m, 1H), 
4.17 (d, J = 6.3 Hz, 2H), 1.94 (q, J = 8.0 Hz, 5H), 1.66 (s, 4H), 1.57 (s, 10H), 1.24 (s, 15H), 0.88 
(s, 15H), 0.05 (s, 8H). 13C NMR (75 MHz, Chloroform-d) δ 137.52, 131.29, 125.16, 124.33, 
60.56, 39.77, 30.13, 29.85, 29.82, 29.78, 29.57, 28.28, 27.90, 26.25, 26.20, 25.95, 17.88, 16.47, -
4.81.   
OTBS  
(E)-tert-butyl((3,15-dimethylhexadeca-2,14-dien-1-yl)oxy)dimethylsilane: 
13-bromo-2-methyltridec-2-ene and 12-iodo-2-methyldodec-2-ene were coupled using 
the same procedure as 2-(((2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran.  
The crude reaction product was purified by column chromatography using 5% ethyl 
acetate/hexanes as the mobile phase to afford the title compound in 66% yield.  1H NMR (300 
MHz, CDCl3) δ 5.29 (tq, J = 6.4, 5.1, 1.3 Hz, 1H), 5.11 (tq, J = 7.3, 5.8, 2.9, 1.5 Hz, 1H), 4.19 
(dd, J = 6.4, 0.9 Hz, 2H), 1.96 (q, J = 8.2 Hz, 4H), 1.69 (d, J = 1.4 Hz, 3H), 1.60 (dd, J = 2.8, 1.3 
Hz, 6H), 1.27 (d, J = 2.7 Hz, 16H), 0.91 (s, 9H), 0.07 (s, 6H).13C NMR (75 MHz, CDCl3) δ 
137.51, 131.27, 125.16, 124.34, 60.55, 39.77, 30.14, 29.88, 29.82, 29.78, 29.59, 29.56, 28.28, 
27.90, 26.24, 25.94, 18.65, 17.87, 16.46, -4.82.   
 
Representative procedure for TBDMS deprotection: 
OH
 
(E)-3,14-dimethylpentadeca-2,13-dien-1-ol (3.15a):  
In a scintillation vial equipped with a magnetic stirrer was added (E)-tert-butyl((3,14-
dimethylpentadeca-2,13-dien-1-yl)oxy)dimethylsilane (1.0 eq, 1.32 mmol) in THF (2 mL) and 
cooled to 0°C.  Next, TBAF (1.5 eq, 1.97 mmol) was added to the vial and the reaction mixture 
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was allowed to stir for 2 hours coming to room temperature.  The reaction mixture was quenched 
by adding 10% NH4Cl(aq) and the aqueous layer was extracted 3 ×  mL of Et2O. The organic 
layers were combined, washed with brine, dried with magnesium sulfate, filtered, and 
concentrated.  The crude reaction product was purified by column chromatography using hexanes 
as the mobile phase to afford 3.15 in 26% yield.  1H NMR (300 MHz, CDCl3) δ 5.37 (t, J = 7.0 
Hz, 1H), 5.09 (t, J = 7.4 Hz, 1H), 4.12 (d, J = 7.0 Hz, 2H), 2.04 – 1.85 (m, 4H), 1.64 (d, J = 7.0 
Hz, 6H), 1.57 (s, 3H), 1.24 (s, 14H).  13C NMR (75 MHz, Chloroform-d) δ 140.39, 131.30, 
125.13, 123.25, 59.57, 39.76, 30.10, 29.79, 29.79, 29.74, 29.55, 29.52, 28.25, 27.89, 25.92, 17.85, 
16.36.  MS (EI) m/z 234 [M+-H2O]. 
OH  
(E)-3,15-dimethylhexadeca-2,14-dien-1-ol (3.15b):   
Yield (64%);  1H NMR (300 MHz, CDCl3) δ 5.45 – 5.29 (m, 1H), 5.14 – 4.99 (m, 1H), 
4.12 (d, J = 7.1 Hz, 2H), 2.02 – 1.86 (m, 4H), 1.66 (s, 3H), 1.63 (s, 3H), 1.57 (s, 3H), 1.23 (s, 
16H).  13C NMR (75 MHz, Chloroform-d) δ 140.38, 131.29, 125.14, 123.26, 59.57, 39.77, 30.11, 
29.86, 29.82, 29.80, 29.75, 29.56, 29.52, 28.25, 27.90, 25.93, 17.85, 16.36. MS (EI) m/z 248 [M+-
H2O]. 
 
(2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-dien-1-yl diethyl phosphate 
(3.18):   
 To an Erlenmeyer flask charged with t-BuOOH (2.0 eq, 49 mmol, 70% in water) and 65 
mL of CH2Cl2 is added MgSO4.  The solution was then filtered into a round bottom flask 
equipped with a magnetic stir bar.  Next, SeO2 (0.12 eq, 2.94 mmol) and salicylic acid (0.1 eq, 2.5 
mmol) were added to the reaction mixture.  While the solution stirred, THP-protected geraniol 
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(1.0 eq, 24.5 mmol) dissolved in 10 mL of CH2Cl2 was added dropwise to the reaction vessel.  
The reaction mixture was allowed to stir for 12 hours.  The CH2Cl2 was removed and the 
resulting residue was resuspended in Et2O.  Next, 10% NaOH was added to solution, the organic 
layer was removed, and the aqueous layer was extracted 3 × Et2O (40 mL).  The organic layers 
are combined, washed with brine, dried with MgSO4, filtered, and concentrated. In an oven-dried 
round bottom flask, the crude reaction product was diluted with 80 mL of ethanol and NaBH4 (1.0 
eq, 24.5 mmol) was added in several portions to the reaction vessel.  The reaction was allowed to 
stir for 1 hour and then diluted with 200 mL of water.  The aqueous layer was extracted 3 × Et2O 
(40 mL) and the organic layers were combined, washed with brine, dried with MgSO4, filtered, 
and concentrated. The crude reaction product was purified by column chromatography using 20% 
Ethyl Acetate/Hexanes as the mobile phase to afford (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-
pyran-2-yl)oxy)octa-2,6-dien-1-ol in 27% yield. 
 To a separate round bottom flask equipped with a magnetic stir bar was added (2E,6E)-
2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-dien-1-ol (1.0 eq, 5.15 mmol) in 10 mL 
of dichloromethane.  Next, pyridine (2.5 eq, 12.9 mmol) was added to the reaction vessel and the 
mixture was cooled to 0°C, where diethyl chlorophosphate (1.5 eq, 7.7 mmol) was added 
dropwise to the reaction. The reaction was allowed to warm to room temperature and stirred for 
12 hours.  Next, 10% NaOH was added to solution, the organic layer was removed, and the 
aqueous layer was extracted 3 × EtOAc (20 mL).  The organic layers are combined, washed with 
brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified by 
column chromatography using 80% Ethyl Acetate/Hexanes as the mobile phase to afford diethyl 
phosphpate 3.18 in 76% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.44 (t, J = 6.8 Hz, 1H), 
5.31 (t, J = 6.7 Hz, 1H), 4.68 – 4.50 (m, 1H), 4.34 (d, J = 7.0 Hz, 2H), 4.18 (dd, 1H), 4.05 (dp, 
4H), 3.98 (dd, J = 7.4 Hz, 1H), 3.89 – 3.77 (m, 1H), 3.55 – 3.37 (m, 1H), 2.13 (q, J = 7.7, 7.3 Hz, 
2H), 2.02 (dd, J = 9.4, 6.2 Hz, 2H), 1.86 – 1.66 (m, 1H), 1.63 (s, 6H), 1.59 – 1.40 (m, 5H), 1.34 – 
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1.22 (m, 6H).  13C NMR (75 MHz, Chloroform-d) δ 139.67, 130.87, 129.52, 121.12, 98.06, 73.31 
(d, J = 5.5 Hz), 63.79 (d, J = 5.6 Hz). 63.78, 62.47, 39.02, 30.85, 26.15, 25.63, 19.78, 16.58, 
16.35, 16.26, 13.74.  31P NMR (202 MHz, Chloroform-d) δ -0.32. 
 
(2E,6E)-3,7,11,15-tetramethylhexadeca-2,6-dien-1-ol (3.20): 
 To an oven-dried round bottom flask equipped with a magnetic stir bar was added 
magnesium powder (18 eq, 20 mmol) and 6 mL of anhydrous Et2O and an iodide chip was added 
to the round bottom and the mixture was stirred for 5 minutes.  Next, 1-bromo-3,7-
dimethyloctane (4.5 eq, 4.5 mmol) in 2 mL of Et2O was added dropwise to the reaction vessel 
over a 10 minute period and the reaction mixture was stirred for 4 hours.  After the allotted time, 
the reaction mixture was cooled to 0°C where diethyl phosphate 3.18 (1.0 eq, 1.0 mmol) 
dissolved in 6 mL of THF was added dropwise to the mixture and the reaction was allowed to stir 
for 12 hours.  The reaction was quenched with 10% NH4Cl, the organic layer was removed, and 
the aqueous layer was extracted 3 × Et2O (5 mL).  The organic layers are combined, washed with 
brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was purified by 
column chromatography using 3% Ethyl Acetate/Hexanes as the mobile phase to afford 3.19 in 
15% yield. 
 In a scintillation vial equipped with a magnetic stir bar, 3.19 (1.0 eq, 0.155 mmol) was 
dissolved in 5.0 mL of absolute EtOH and PPTS (0.1 eq, 0.016 mmol) was added to the vial.  The 
reaction mixture was heated to 75°C and stirred for 12 hours.  Next, the reaction was cooled to 
room temperature where it was poured into a separator funnel containing water and Et2O and the 
aqueous layer was extracted 3 × 5 mL Et2O.  The organic layers were combined and washed with 
water then brine, dried with magnesium sulfate, and concentrated.  The crude reaction product 
was purified by column chromatography using 10% Ethyl Acetate/Hexanes as the mobile phase 
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to afford 3.20 in 70% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.39 (t, J = 7.4 Hz, 1H), 5.07 
(t, J = 6.2 Hz, 1H), 4.12 (d, J = 6.9 Hz, 2H), 2.17 – 1.97 (m, 4H), 1.91 (t, J = 7.3 Hz, 2H), 1.65 (s, 
3H), 1.56 (s, 3H), 1.55 – 1.42 (m, 2H), 1.29 – 0.98 (m, 10H), 0.84 (d, J = 6.5 Hz, 6H), 0.81 (d, J 
= 5.5 Hz, 3H).  13C NMR (75 MHz, Chloroform-d) δ 140.00, 135.96, 123.71, 123.49, 59.56, 
40.17, 39.79, 39.54, 37.48, 36.85, 32.86, 28.17, 26.48, 25.58, 25.01, 22.92, 22.83, 19.91, 16.47, 
16.10. MS (EI) m/z 294 [M+] and 276 [M+-H2O]; MS (CI) 293 [M-H]
+ and 295 [M+H]+. 
 
(2E,6E,10E)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl acetate (3.22): 
Compound 3.21 was synthesized using the same method as compound 2.2 with the 
exception that acetyl-protected farnesol was utilized instead of THP-protected farnesol.  Yield 
(28%).  1H NMR (300 MHz, Chloroform-d) δ 5.37 – 5.16 (m, 2H), 5.13 – 4.85 (m, 1H), 4.50 (d, J 
= 7.1 Hz, 2H), 3.89 (s, 2H), 2.10 – 1.72 (m, 13H), 1.62 (s, 3H), 1.57 (s, 3H), 1.52 (s, 3H).  13C 
NMR (75 MHz, Chloroform-d) δ 171.30, 142.24, 135.17, 134.82, 125.75, 123.89, 118.34, 68.77, 




To a round bottom flask equipped with a magnetic stir bar was added 3.21 (1.0 eq, 5.62 
mmol) and 30 mL of dichloromethane.  Next, 3,4-dihydro-2H-pyran (2.0 eq, 11.24 mmol) 
followed by pyridinium p-toluenesulfonate (0.15 eq, 0.84 mmol) was added to the reaction flask 
and the reaction was allowed to stir for 12 hours.  Saturated NaHCO3(aq) was added to the reaction 
flask and organic layer was isolated.  The aqueous layer was further extracted 3 × DCM (25 mL) 
and the organic layers were combined, washed with brine, dried with MgSO4, filtered, and 
concentrated.  In a round bottom flask, the crude product was redissolved in a saturated solution 
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of K2CO3 in MeOH (30 mL) and stirred for 12 hours.  After the allotted time, water (150 mL) and 
Et2O (30 mL) were added to the reaction mixture and the organic layer was isolated.  The 
aqueous layer was further extracted 3 × Et2O (25 mL) and the organic layers were combined, 
washed with brine, dried with MgSO4, filtered, and concentrated.  The crude reaction product was 
purified by column chromatography using 15% Ethyl Acetate/Hexanes as the mobile phase to 
afford 3.22 in 74% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.40 (t, J = 6.9 Hz, 2H), 5.10 (t, J 
= 6.4 Hz, 1H), 4.64 – 4.56 (m, 1H), 4.14 (d, J = 6.9 Hz, 2H), 4.08 (d, J = 11.6 Hz, 1H), 3.94 – 
3.78 (m, 2H), 3.59 – 3.40 (m, 1H), 2.07 (dp, J = 27.1, 7.4 Hz, 8H), 1.92 – 1.78 (m, 1H), 1.66 (s, 
3H), 1.64 (s, 3H), 1.59 (s, 3H), 1.65 – 1.46 (m, 6H).  13C NMR (75 MHz, Chloroform-d) δ 
139.55, 135.11, 131.90, 127.98, 124.16, 123.59, 97.48, 73.07, 62.28, 59.46, 39.61, 39.34, 30.77, 
26.37, 26.36, 25.61, 19.63, 16.39, 16.09, 14.19. 
 
(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-ol (3.25): 
To an oven-dried round bottom flask equipped with a magnetic stir bar was added 
magnesium powder (14.5 eq, 14.5 mmol) and 5 mL of anhydrous THF and an iodide chip was 
added to the round bottom and the mixture was stirred for 5 minutes.  Next, 1-bromo-3-
methylbutane (10 eq, 10mmol) in 3 mL of Et2O was added dropwise to the reaction vessel over a 
10 minute period and the reaction mixture was stirred for 4 hours to produce Grignard 3.24.   
In a separate oven-dried round bottom flask was added THP-ether 3.23 (1.0 eq, 1mmol) 
and dissolved in 5 mL of anhydrous THF and the solution was cooled to -35°C.  Next, Cu(I)Br 
(1.5 eq, 1.5 mmol) was added in one portion followed by the dropwise addition of the newly 
formed Grignard reagent.  The reaction was stirred for 1 hour at -35°C and allowed to warm to -
10°C where it was stirred for 48 hours.  The reaction mixture is quenched with 10% NH4Cl(aq) and 
the aqueous layer was extracted 3 ×  15 mL of Et2O. The organic layers were combined, washed 
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with brine, dried with magnesium sulfate, filtered, and concentrated.  The crude reaction product 
was purified column chromatography using 15% ethyl acetate/hexanes as the mobile phase to 
afford 3.25 in 17% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.39 (t, J = 6.9 Hz, 1H), 5.07 (q, 
J = 6.8, 6.3 Hz, 2H), 4.12 (d, J = 6.9 Hz, 2H), 1.98 (ddt, J = 31.0, 15.2, 6.8 Hz, 10H), 1.65 (s, 
3H), 1.58 (s, 3H), 1.55 (s, 3H), 1.55 – 1.40 (m, 1H), 1.42 – 1.27 (m, 3H), 1.16 – 1.01 (m, 2H), 
0.84 (d, J = 6.6 Hz, 6H).  13C NMR (75 MHz, Chloroform-d) δ 40.10, 39.92, 39.75, 38.79, 28.09, 
26.77, 26.51, 25.94, 22.85, 16.47, 16.20, 16.08.  MS (EI) m/z 274 [M+-H2O]; MS (CI) m/z 293 
[M-H]+. 
 
Representative procedure for the synthesis of pyrophosphates: 
 
(E)-3-methyltetradec-2-en-1-yl diphosphate (3.3a): 
To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS 
(2.5 eq, 0.44 mmol) in 1 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq, 0.44 
mmol) was added dropwise to the reaction.  Following the addition, the mixture is then placed in 
a 0°C ice bath and stirred for 5 minutes before being re-cooled back to -30°C.  Next, alcohol 3.2a 
(1 eq, 0.22 mmol) is dissolved in CH2Cl2 (0.44 mL) and added dropwise to the reaction mixture.  
The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room 
temperature.  After the allotted time, brine is added to the reaction mixture and the organic layer 
was extracted.  The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic layers 
were combined, dried with magnesium sulfate, and concentrated.  The crude reaction product was 
used immediately in the following step.  
 To another oven-dried round bottom flask equipped with a magnetic stir bar was added 
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.66 mmol) dissolved in 3 mL of 
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acetonitrile.  Next, a solution of crude allylic chloride dissolve in 2 mL of acetonitrile was added 
dropwise to the reaction vessel.  The reaction was stirred for 3 hours at room temperature and 
then the solvent was removed by rotary evaporation at 34°C.  The residue was the dissolve in a 
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20 
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion 
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in 
a flask.  The resulting solution was lyophilized for 3-5 hours.  The resulting residue was then 
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15 
cm) using isopropanol:deionized  H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL 
: 4 g) as the eluent.  In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions 
were collected.  Typically, fractions 12-18 were collected and the organic solvents were removed 
by rotary evaporation at 34°C.  The resulting solution was then lyophilized to afford 
pyrophosphate (3.3a) as a white fluffy solid in 57% yield. 1H NMR (500 MHz, Chloroform-d) δ 
5.44 – 5.23 (m, 1H), 4.34 (s, 2H), 1.92 (s, 2H), 1.62 (d, J = 24.3 Hz, 3H), 1.20 (s, 18H), 0.98 – 
0.70 (m, 3H).  31P NMR (202 MHz, Deuterium Oxide) δ -9.96 (d, J = 15.9 Hz), -13.61 (d, J = 
22.1 Hz).  HRMS 385.1548 [M+2H]-, calculated 385.1545 (C15H31O7P2). 
 
(E)-3-methylpentadec-2-en-1-yl diphosphate (3.3b): 
Yield (64%).  1H NMR (300 MHz, Deuterium Oxide) δ 5.43 (t, 1H), 4.44 (s, 2H), 2.03 (s, 
2H), 1.68 (s, 3H), 1.25 (s, 20H), 0.83 (t, J = 5.8 Hz, 3H).  31P NMR (122 MHz, Chloroform-d) δ -







(E)-3-methylhexadec-2-en-1-yl diphosphate (3.3c): 
Yield (83%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.37 (s, 1H), 4.39 (s, 2H), 2.04 – 
1.93 (m, 2H), 1.65 (s, 3H), 1.25 (d, J = 7.4 Hz, 22H), 0.91 (t, J = 7.4 Hz, 3H).  31P NMR (202 
MHz, Deuterium Oxide) δ -9.99 (d, J = 19.2 Hz), -13.70 (d, J = 20.9 Hz).  HRMS 413.1852 
[M+2H]-, calculated 413.1858 (C17H35O7P2). 
 
(2E,6E)-3,7-dimethyltrideca-2,6-dien-1-yl diphosphate (3.6a): 
Yield (91%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (t, J = 6.9 Hz, 1H), 5.10 (d, 
J = 6.4 Hz, 1H), 4.40 (d, J = 7.3 Hz, 2H), 2.16 – 2.02 (m, 2H), 2.03 – 1.94 (m, 2H), 1.89 (t, J = 
7.8 Hz, 2H), 1.66 (s, 3H), 1.54 (s, 3H), 1.21 (s, 8H), 0.82 (t, J = 6.4 Hz, 3H).  31P NMR (202 
MHz, Deuterium Oxide) δ -10.01, -13.74 (d, J = 15.5 Hz).  HRMS 383.1391 [M+2H]-, calculated 
383.1389 (C15H29O7P2). 
 
(2E,6E)-3,7-dimethyltetradeca-2,6-dien-1-yl diphosphate (3.6b): 
Yield (49%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.52 – 5.32 (m, 1H), 5.08 (d, J = 
7.1 Hz, 1H), 4.41 (s, 2H), 2.05 (s, 2H), 2.02 – 1.94 (m, 2H), 1.91 (d, J = 8.0 Hz, 2H), 1.68 (d, J = 
16.2 Hz, 3H), 1.60 – 1.49 (m, 3H), 1.24 (s, 10H), 0.84 (d, J = 6.9 Hz, 3H).  31P NMR (202 MHz, 
Deuterium Oxide) δ -11.27 (d, J = 14.8 Hz), -13.98 (d, J = 15.3 Hz).  HRMS 397.1547 [M+2H]-, 






(2E,6E)-3,7-dimethylpentadeca-2,6-dien-1-yl diphosphate (3.6c): 
Yield (58%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (d, J = 5.9 Hz, 1H), 5.23 – 
4.99 (m, 1H), 4.67 – 4.36 (m, 2H), 2.09 – 2.01 (m, 2H), 2.00 – 1.94 (m, 2H), 1.94 – 1.83 (m, 2H), 
1.65 (s, 3H), 1.54 (s, 3H), 1.24 (s, 12H), 0.84 (t, J = 6.4 Hz, 3H).  31P NMR (202 MHz, 
Deuterium Oxide) δ -12.53 (d, J = 19.6 Hz), -16.19 (d, J = 17.9 Hz).  HRMS 411.1698 [M+2H]-, 
calculated 411.1702 (C17H33O7P2). 
 
(2E,6E)-3,7-dimethylhexadeca-2,6-dien-1-yl diphosphate (3.6d): 
Yield (70%).  1H NMR (300 MHz, Deuterium Oxide) δ 5.39 (s, 1H), 5.09 (s, 1H), 4.43 (s, 
2H), 1.93 (t, J = 19.3 Hz, 6H), 1.70 (d, J = 10.3 Hz, 3H), 1.56 (d, J = 7.1 Hz, 3H), 1.26 (d, J = 8.2 
Hz, 14H), 0.88 (t, J = 5.9 Hz, 3H).  31P NMR (122 MHz, Chloroform-d) δ -15.06, -16.83.  HRMS 
425.1860 [M+2H]-, calculated 425.1858 (C18H35O7P2). 
 
(E)-3,14-dimethylpentadeca-2,13-dien-1-yl diphosphate (3.16a): 
Yield (86%).  1H NMR (500 MHz, Chloroform-d) δ 5.37 (s, 1H), 5.03 (s, 1H), 4.41 (s, 
2H), 1.90 (s, 4H), 1.69 – 1.45 (m, 9H), 1.24 (s, 14H). 31P NMR (202 MHz, Deuterium Oxide) δ -








(E)-3,15-dimethylhexadeca-2,14-dien-1-yl diphosphate (3.16 b): 
Yield (69%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (s, 1H), 5.06 (s, 1H), 4.42 (s, 
2H), 1.96 (d, J = 37.9 Hz, 4H), 1.67 (s, 3H), 1.61 (s, 3H), 1.53 (s, 3H), 1.27 (s, 16H).  31P NMR 
(202 MHz, Deuterium Oxide) δ -14.26 (d, J = 18.7 Hz), -16.53 (d, J = 17.6 Hz).  HRMS 
425.1859 [M+2H]-, calculated 425.1858 (C18H35O7P2). 
 
(2E,6E)-3,7,11,15-tetramethylhexadeca-2,6-dien-1-yl diphosphate (3.21): 
Yield (52%).  1H NMR (500 MHz, Chloroform-d) δ 5.40 (s, 1H), 5.10 (s, 1H), 4.41 (s, 
2H), 2.06 (s, 2H), 1.98 (s, 2H), 1.91 (s, 2H), 1.68 (s, 3H), 1.57 (s, 3H), 1.25 (s, 10H), 0.85 (s, 3H), 
0.84 (s, 6H).  31P NMR (202 MHz, Deuterium Oxide δ -9.88 (d J = 16.2 Hz), -13.59 (d, J = 18.3 
Hz).  HRMS 453.2174 [M+2H]-, calculated 453.2171 (C20H39O7P2). 
 
(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-yl diphosphate (3.24): 
Yield (28%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.42 (s, 1H), 5.05 (s, 2H), 4.43 (s, 
2H), 2.13 – 1.76 (m, 10H), 1.68 (s, 3H), 1.65 – 1.39 (m, 7H), 1.32 (s, 3H), 1.14 – 1.01 (m, 2H), 
0.82 (s, 6H).  31P NMR (202 MHz, Deuterium Oxide) δ -10.16, -14.05.  HRMS 451.2022 
[M+2H]-, calculated 451.2014 (C20H39O7P2). 
 
General procedure for in vitro biochemical substrate screening:   
All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s 
laboratory at the University of Michigan by Elia Wright.  Preliminary evaluation of all 
pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansyl-
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GCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO pH 7.8, 5 mM 
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).  
Protein prenylation was determined by monitoring the dansylated peptide using a continuous 
spectrofluorometic assay and all assays were performed in triplicate.  Upon prenylation of the 
peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group 
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader.  Peptide in assay buffer was 







CHAPTER 4.   SYNTHESIS & BIOCHEMICAL EVALUATION OF FRAME-SHIFTED 
GERANYLGERANYL PYROPHOSPHATE ANALOGS 
 
4.1    Introduction 
 
Isoprenoids are found in almost all life forms and are the largest and most structurally 
diverse class of natural products.123, 124  As such, they are responsible for a multitude of 
biochemical functions including their use as hormones (e.g. steroids, gibberellins, and abscisic 
acid) and roles in cell membrane structure (e.g. cholesterol), electron transfer (e.g. quinones), and 
photosynthesis (e.g. carotenoids).125  As precursors to a myriad of lipid moieties, isoprenoids are 
important biosynthetic intermediates that lead to the production of sterols, triterpenes (e.g. 
squalene), carotenoids, and hopanoids.125  Isoprenoids can also serve as lipid anchors for proteins 
and carbohydrates.4, 126  Perhaps the most interesting and complex group of isoprenoid 
biosynthetic products is the vast set of cyclic terpene natural products such as monoterpenes, 
sesquiterpenes, and diterpenes.124, 127  Due to the extensive diversity of isoprenoid natural 
products, it is not surprising that many promising and effective pharmaceuticals such as Taxol 
(cancer), artemisinin (malaria), vinblastine (cancer), and prostratin (HIV) have been 
discovered.125  Not only are cyclic isoprenoids of importance to the pharmaceutical industry, but 
they are also of great interest in the materials, chemical, and fuel industries.128  Therefore, there is 
significant interest in generating novel isoprenoid diphosphate analogs to use as chemical tools to 
further explore these multifarious processes. 
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Our lab has a long-standing interest in the design and synthesis of novel FPP and GGPP 
analogs as chemical tools to explore the enzyme specificity and requirements of FTase.  Recently, 
Dr. Andrew Placzek developed a method for the preparation of a small library of frame-shifted 
FPP analogs (Figure 4.1).75  These analogs were designed to increase and/or decrease the carbon 
spacers of the FPP backbone in order to examine the relevance of the length and flexibility of the 
isoprenoid chain and how this pertains to FTase activity.  Preliminary evaluation revealed that 
four of the eight FPP frame-shifted analogs are substrates of FTase (2,2,1,1-OPP; 1,2,1-OPP; 
1,3,1-OPP, 3,1,1-OPP; Figure 4.1, Blue solid box). The numbering scheme refers to the number 
of carbon spacers between the double bonds or between the first isoprene double bond and the 
pyrophosphate group.  While three of these compounds have an overall comparable length to that 
of FPP, the surprising result was the ability of 2,2,1,1-OPP (an analog that is only one CH2 unit 
shorter than GGPP) to act as a substrate of FTase.  Moreover, it appears that conformationally 
restricting the last isoprene unit leads to very poor or non-substrates.  With this information in 
hand, we decided to construct 1,2,2,1-OPP (4.21).  This analog is of same overall length as 
2,2,1,1-OPP and also incorporates the conformationally restrictive 1E,4E-pentadiene structural 
motif; thus, it would be interesting to see how these features translate into biochemical activity in 
FTase and GGTase-I binding. Additionally, in the case of 3,1,1-OPP and 2,2,1,1-OPP, it appeared 
that deletion of a methylene group from between the α and β isoprenoids led to good substrates 
with comparable kcat/KM to FPP; however, the kcat and KM values were ~10-fold lower than FPP.  
Of the four analogs that did not behave as substrates, a preliminary inhibitory potency 
assay revealed that one analog, homofarnesyl diphosphate (2,2,2-OPP), was an inhibitor of FTase 
with an IC50 below 1 µM (Figure 4.1, Purple dashed box).  This inhibitory activity is believed to 
be attributed to the lower nucleophilicity at the now non-allylic C1 (the C attached to the –OPP).  
To see if this holds true in GGTase-I binding as well, we synthesized a nonallylic GGPP analog, 
homogeranylgeranyl pyrophosphate (2,2,2,2-OPP; 4.32).   
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With the preliminary data in hand, our goal was to expand upon this theme and develop 
novel frame-shifted analogs in an effort to explore the enzyme specificity and requirements of 
GGTase-I versus FTase.  The target compounds were 3,3,1-OPP; 2,3,1-OPP; 1,2,2,1-OPP; 
2,2,2,2-OPP; 3,2,1-OPP; 4,2,1-OPP; 5,2,1-OPP; and 6,2,1-OPP (Figure 4.2).  Unlike the 
previously synthesized frame-shifted analogs, these analogs are much more flexible and vary 
greatly in length between FPP and GGPP.  Additionally, 6,2,1-OPP is essentially the same as 
GGPP with the exception that the third (γ) isoprene unit has been removed. We believe that 








Figure 4.1.  Frame-shifted analog numbering scheme & previously synthesized FPP analogs. (A) 
General numbering scheme.  (B) Previously synthesized frame-shifted FPP analogs by Andrew 
Plazcek.  Green box indicated substrates; red box indicates inhibitor.  Green circle indicates 
methylene unit added; Red square represents methylene unit removed; Blue solid box represents 












Figure 4.2.  Newly synthesized frame-shifted analogs.  Green circle indicates methylene unit 
added; Red square represents methylene unit removed; Blue solid box represents substrates; 












4.2    Synthesis of Frame-Shifted Geranylgeranyl Pyrophosphate Analogs 
 
The synthesis began with the preparation of 3,3,1-OPP (Scheme 4.1).  To begin, 4-
pentyn-1-ol (4.1) was transformed into the corresponding iodide (4.2) which underwent Negishi’s 
ZACA reaction and quenched with paraformaldehyde to afford iodo-alcohol 4.3.114  Similarly, 5-
hexyn-1-ol (4.5) underwent a ZACA reaction and was quenched with iodide to yield the vinyl-
iodide 4.6.  To install the last isoprene unit, 4.6 was subjected to Swern oxidation conditions 
followed by a Wittig reaction to generate vinyl-iodide 4.8.  Following THP-protection of alcohol 
4.3, alkyl iodide 4.4 could be converted into the organoborane and then coupled with vinyl-iodide 
4.8 under Suzuki cross-coupling conditions to afford 3,3,1-OTHP (4.9), which was then 
deprotected to yield 4.10.120  Pyrophosphorylation was accomplished in a similar manner as 
described by Davisson et al. to produce 4.11 (3,3,1-OPP).112, 113 
To synthesize 2,3,1-OH (Scheme 4.2), we first needed to synthesize bishomogeranyl 
iodide, 4.14. This could be accomplished by employing a method described by Kuwajima & Doi 
and later used in our laboratory.129, 130  Briefly, LDA was added to an equimolar amount of ethyl 
acetate in the presence of Cu(I)I at -110°C.  The solution was then allowed to slowly warm to -
30°C at which point geranyl bromide (4.12) was added to the reaction to give ester 4.13 in 34% 
yield.  The ester was then subjected to DIBAL reduction followed by iodination to afford 
bishomogeranyl iodide 4.15.  Utilizing Suzuki coupling, vinyl-iodide 3.14 and alkyl-iodide 4.15 
were coupled. Following deprotection of the TBS-group with TBAF, 4.16 (2,3,1-OH)  was 
produced in 38% yield.  Subsequent chlorination and pyrophosphorylation resulted in compound 
4.17. 
The strategy for the synthesis of 1,2,2,1-OH was based on the displacement of allylic 
diethyl phosphates with Grignard reagents utilized by Snyder and colleagues (Scheme 4.3).111  
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Displacement of the phosphate group by Grignard 4.18 followed by THP-deportation produced 
4.20 (1,2,2,1-OH).  Subsequent chlorination and pyrophosphorylation resulted in compound 4.21. 
In the synthesis of 3,2,1-OH (Scheme 4.4), iodide 4.25 was obtained by first converting 
the THP ether of farnesol to epoxide 4.22 via a bromohydrin intermediate.  Epoxide 4.22 was 
then converted to aldehyde 4.23 using periodic acid which was later reduced to alcohol 4.24 via a 
borohydride reduction.  Following iodination, iodide 4.22 was obtained and subjected to THP-
deprotection to afford iodo-alcohol 4.26.  Employing a method originally developed by Derguini-
Boumechal & Linstrumelle, vinyl-Grignard 4.18 can be used to substitute the alkyl iodide of 4.26 
when done in the presence of Cu(I)I  to produced 3,2,1,-OH (4.27).75, 131  Subsequent chlorination 
and pyrophosphorylation resulted in compound 4.28. 
One compound targeted for synthesis was a GGPP analog containing a nonallylic 
diphosphate (4.32).  Previously, homofarnesyl pyrophosphate (2,2,2-OPP) was synthesized in our 
lab as part of an FTase screen.  The significant decrease in nucleophilicity at C1 of the 
homoallylic diphosphate lead to the hypothesis that 2,2,2-OPP would behave as a non-substrate. 
In fact, homofarnesyl pyrophosphate displayed inhibitory activity with an IC50 below 1µM.  Thus, 
we hypothesis that homogeranylgeranyl pyrophospahte will behave in a similar manner as the 
farnesyl derivative.  In order to synthesized homogeranylgeranyl pyrophospahte (2,2,2,2-OPP, 
4.32), we utilized a synthetic route similar to the one our laboratory used to synthesized 
geranylgeraniol (Scheme 4.5).  Briefly, farnesyl chloride (4.29) is subjected to the TMS-propynyl 
anion, displacing the chloride.  Following TMS-deprotection with TBAF, alkyne 4.30 can 
undergo a ZACA reaction which is subsequently quenched with oxirane to produce 
homogeranylgeraniol (3.31).132, 133  Attempts to chlorinate alcohol 4.31 via NCS lead to poor 
yields which may be contributed to the less reactive homoallylic position.  To avoid this problem, 
the alcohol was first converted into the mesylate and subsequently pyrophosphorylated to yield 
compound 4.32.112, 113 
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With the above alcohols in hand, we turned to synthesizing the remaining three alcohols 
(Scheme 4.6).  Commercially available bromo-alkylesters (4.33) were easily converted into the 
corresponding iodoalkenes (4.34a-c) with a series of Finkelstein, DIBAL reduction, and Wittig 
reactions. In order to complete the unique transformation of 4.34 to 4.37, we employed a strategy 
utilized previously in our laboratory which was first developed by Wenkert and colleagues and 
later used by Kocienski and colleagues.75, 134-136  In order to transform the carbon-oxygen bonds 
into carbon-carbon bonds, this method relies upon the nickel-catalyzed ring opening of 
dihydrofurans (or dihydropyrans) with Grignard reagents to produces stereo-defined trisubstituted 
alkenes.  First, iodides 4.34a-c underwent alkylation with 5-lithio-2,3-dihydrofuran (4.36) using a 
modified procedure of Placzek and coworkers.75  We found that increasing the equivalents of 4.36 
from 0.95 to 3.0 equivalents resulted in higher yields when applied to our compounds.  The newly 
prepared alkylated dihydrofuran was immediately reacted with MeMgBr in the presence of 
NiCl2(PPh3)2 to produce alcohols 4.37a-c.  The corresponding iodides (4.48a-c) were converted 
into their organoborane derivatives.  Suzuki cross-coupling of these organoboranes with vinyl 
iodide 3.14 followed by TBS-deprotection with TBAF afforded alcohols 4.39a-c.  Subsequent 









Scheme 4.1.  Synthesis of 3,3,1-OPP. (a) I2, PPh3, Imidazole, DCM, 0°C, 4 hr; (b) Me3Al, 
Cp2ZrCl2, DCM, 0°C, 18 hr then (CH2O)n, 3 hr (52%; 2 steps); (c) PPTS, DHP, DCM (86%); (d) 
Me3Al, Cp2ZrCl2, DMC 0°C, 18 hr then I2, 3 hr (25%); (e) (COCl)2, DMSO, DCM, -78C, 1hr 
then Et3N (67%); (f) i-PrPPh3I, n-BuLi, THF, -78°C, 4 hr (65%); (g) i. t-BuLi, Et2O, -78°C, ii. β-
MeO-9-BBN, THF, -78°C warming to RT o/n, iii. K3PO4, PdCl2(dppf), DMF, 18 hr; (h) PPTS, 
MeOH, 60°C (25%-2 Steps); (i) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (j) (NBu4)3HP2O7, ACN, 2.5 




Scheme 4.2.  Synthesis of 2,3,1-OPP. (a) Ethyl Acetate, Cu(I)I, LDA, THF, -110°C (34%)  (b) 
DIBAL, THF, 0°C; (c) I2, PPh3, Imidazole, DCM, 0°C (68% - 2 Steps); (d) i. t-BuLi, Et2O, -
78°C, ii. β-MeO-9-BBN, THF, -78°C warming to RT o/n, iii. K3PO4, PdCl2(dppf), DMF, 85°C, 
18 hr; (e) TBAF, THF, 0°C (56% - 2 Steps); (f) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (g) 






Scheme 4.3.  Synthesis of 1,2,2,1-OPP. (a) 4.18, THF, o/n (52%); (b) PPTS, EtOH, 70°C. (71%); 





Scheme 4.4.  Synthesis of 3,2,1-OPP. (a) i. NBS, THF:H2O (2:1); ii. K2CO3, MeOH (46% - 2 
Steps); (b) i.H5IO6, THF, Et2O; (c) NaBH4, EtOH; (d) PPh3, I2, imidazole, DCM (55%-3 steps); 
(e) PPTS, EtOH, 65°C (68%); (f) 4.18, Cu(I)I, THF, -30°C (29%); (g) NCS, DMS, DCM, 0°C to 






Scheme 4.5.  Synthesis of 2,2,2,2-OPP. (a) i. TMS-propyne, n-BuLi, THF, -78°C; ii. TBAF, 
THF, 0°C (73%); (b) i. Cp2ZrCl2, Me3Al, DCM, 0°C to r.t., 16 hr; ii. n-BuLi, 0.5 hr, -78°C; iii. 
oxirane, 4 hr, -78°C to r.t. (18%); (c) MsCl, DMAP, DCM, 0°C to rt, 2.5 hr; (d) (NBu4)3HP2O7, 
ACN, 2.5 hr (71% - 2 steps). 
 
 
Scheme 4.6.  Synthesis of 4,2,1-OPP. 5,2,1-OPP, & 6,2,1-OPP. (a) i. KI, Acetone, Reflux; ii. 
DIBAL, DCM, -78°C; iii. i-PrPPh3I, n-BuLi, THF, 0°C; (b) t-BuLi, Et2O, -78°C; (c) i. 4.35, THF, 
-78°C to r.t., 16 hr; ii. NiCl2(PPh3)2, MeMgBr, PhH, 75°C; (d) Imidazole, PPh3, I2, 0°C; (e) i. t-
BuLi, Et2O, -78°C; ii. β-MeO-9-BBN, THF, -78°C to r.t., 16 hr; iii. 3.14, K3PO4, PdCl2(dppf), 
DMF, 85°C, 16 hr; (f) TBAF, THF, 0°C; (g) NCS, DMS, DCM, 0°C to rt, 2.5 hr; (h) 




4.3    Biochemical Evaluation of Frame-Modified Geranylgeranyl Pyrophosphate Analogs 
 
Previously, Dr. Andrew Placzek of our laboratory synthesized a small library of frame-
shifted FPP analogs.  Upon evaluation of these analogs, it was revealed that four behaved as 
substrates while one was shown to be an inhibitor of FTase.  Based on these results, our goal was 
to synthesize a small library of similar compounds ranging in length between FPP and GGPP. 
These frame-shifted analogs (4.11, 4.17, 4.21, 4.28, 4.32, 4.40a-c) were evaluated for their 
biochemical activity in an in vitro continuous spectrofluorometric assay with GGTase and the co-
substrate CaaX-peptide dansyl-GCVLL.  All biochemical assays were performed in our 
collaborator Dr. Carol Fierke’s laboratory at the University of Michigan by Elia Wright.   
Upon in vitro evaluation, it was evident that seven of the eight frame-shifted analogs 
(4.11, 4.17, 4.21, 4.28, 4.40a-c) were substrates of GGTase-I.   While the data in Figure 4.3 may 
not appear to indicate that 4.11 and 4.17 are substrates, an endpoint assay monitored 1 µM 
analog, 5 µM peptide, and 50 nM GGTase-I for 3 hours and revealed these analogs do get turned 
over by the enzyme, albeit very slowly (Figure 4.5); however, further investigation of these 
analogs as potential inhibitors should be considered.   
Once again, the chain length of our analogs plays a crucial role in determining substrate 
activity; however, by comparing analogs of 13 carbons in chain length (4.17 and 4.28), an 
additional feature seems to hinder substrate activity (Figure 4.3 & 4.4).  Compounds 4.17 and 
4.28 differ only in the position of the β-isoprene unit; by adding an extra methylene group 
between the α- and β-isoprene units, substrate activity is decreased.  This trend is also apparent 
when comparing analogs of 14 carbons in chain length (4.11 and 4.40a; Figures 4.3-4.5).  One 
possible reason for this observation could be that extending the β-isoprene into the binding pocket 
of GGTase could result in unfavorable interactions between the analog and the enzyme and/or 
peptide substrate; however, further structural studies are needed.  Hence, the β-isoprene unit is 
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not required for substrate recognition and activation as demonstrated in Chapter 3; however, if it 
is present, its location/orientation in the molecule appears to be crucial. 
When comparing compounds of 15 carbons in length (4.21 and 4.40b), it becomes 
apparent that chain length plays a much larger role in determining substrate activity rather than 
flexibility (Figures 4.3-4.5).  The only difference between these two analogs is that 4.40b lacks 
the γ-isoprene unit of 4.21; however, both analogs have very similar substrate abilities.  Thus, the 
lack of flexibility in the ω-isoprene of 4.21 seems not to be an important factor.  The similarity 
between these two compounds also indicates that the γ-isoprene has no added benefit to the 
substrate activity.  Addtionally, chain length of molecules containing the ω-isoprene is critical for 
substrate activity.   
By examining the length of analogs 4.28 and 4.40a-b (Figure 4.4), it appears that 
increasing the length of the carbon chain from 13 to 15 carbons has minimal effects on substrate 
activity.  Thus, having three isoprene units attenuates the effects of increased chain length when 
the number of carbons is less than GGPP; however, when the carbon length is increased to that of 
GGPP (4.40c), we notice a significant jump in substrate ability.  In fact, analog 4.40c exhibited 
substrate activity comparable to GGPP.  Analog 4.40c also reveals that the γ-isoprene unit of 
GGPP is not needed for enzyme recognition. 
Not surprisingly, our homo-GGPP analog (4.32) displayed no substrate activity.  This 
analog was originally synthesized to determine if it would act as an inhibitor of GGTase-I.  
Reactions with 1 µM or 5 µM analog with 10 µM GGPP displayed no increase in fluorescence 
(Figure 4.6).  A preliminary inhibitor assay (Figure 4.6) suggests that analog 4.32 is an inhibitor 














Figure 4.3.  Bar graphs of substrate activity represented in RFI of 4.11, 4.17, 4.21, 4.32, & 
1,2,2,1-OPP versus GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I..  Error 












Figure 4.4.  Bar graphs of substrate activity represented in RFI of 4.28 & 4.40a-c versus GGPP 
(+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.  Error bars represent mean ± SD (n 
= 3).  *Values shown are for 10 µM analog at 1.5 hours. 
*-0.3 ± 0.60% 
*100 ± 5.4% 
*21 ± 1.1% *31 ± 2.6% 
*34 ± 1.5% 
*114 ± 2.1% 






























































































































































































*15 ± 1.7% 
*100 ± 5.4% 
*6.1 ± 0.94% 
*43 ± 1.8% 


















Figure 4.5.  Monitoring continuous changes in fluorescence of frame-shifted GGPP analogs versus GGPP (+ control) at various 
concentrations (1 µM, 5µM, & 10µM) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.  Experiments were performed in triplicate and data 

































































Figure 4.6.  Preliminary inhibitor assay results for 4.32 with 50 nM GGTase-I.  Raw fluorescence 
was not subtracted from background.  Reactions with inhibitor were not above background 








4.4    Conclusions 
 
The goal of this chapter was to focus on the synthesis of a small library of frame-shifted 
GGPP analogs in order to determine the isoprene requirements of the enzyme GGTase-I.  
Previously, our lab synthesized a library of frame-shifted FPP analogs that displayed interesting 
result in vivo.  Therefore, our laboratory aimed to expand this library to include analogs in length 
between FPP and GGPP.  
This aim was centered on designing synthetic routes that would enable us to generate our 
small library of eight compounds to use as chemical tools to probe the tolerance of the GGTase-I 
binding pocket.  Unfortunately, no one synthetic route could be utilized for all frame-shifted 
compounds.  The synthesis of 4.11 was dependent upon the availability of the alkynyl-alcohols 
4.1 and 4.5 (Scheme 4.1).  This route could not be utilized for the other analogs for multiple 
reasons.  First, various attempts to oxidize iodo-alcohols shorter than 4.6 resulted in low yields or 
unstable aldehydes.  Second, longer alkynyl-alcohols of 4.5 needed in the synthesis of 4.40a-c 
were not commercially available.  Therefore, in order to synthesize 4.17 we utilized a method 
originally developed by Kuwajima & Doi and was later used in our laboratory to generate 
bishomogeraniol.129  The synthesis of 4.21 was accomplished in a similar manner as employed in 
Chapter 2 to generate the aryl-modified analogs.   To generate 4.28, we employed a method 
developed by Derguini-Boumechal & Linstrumell to substitute an alkyl iodide with a vinyl-
Grignard reagent.131  This method was later used by Andrew Placzek in the synthesis of the 
frame-shifted FPP analogs.75  Homogeranylgeraniol could easily be synthesized utilizing the 
ZACA reaction.  By simply substituting oxirane for paraformaldehyde we could generate a 
homoallylic alcohol which was then converted into 4.32.  The remaining analogs 4.40a-c were 
synthesized using a modified method as employed by Andrew Placzek to generate the frame-
shifted FPP analogs.75  This method was originally developed by Wenkert and colleagues and was 
112 
 
used to synthesize the intermediates (4.37a-c).134  The original method called for 0.95 equivalents 
of dihydrofuran 4.35; however, this produced very low yields (< 20%).  By increasing the 
equivalents to 3 resulted in much higher yielding transformations.  
 The biochemical evaluation of these compounds revealed several interesting trends.  The 
first observation was that by increasing or decreasing the number of carbons between the α- and 
β-isoprenes by one methylene result in a significant decrease in substrate activity.  These analogs 
could be selective substrates; thus, while these analogs are poor co-substrates with Dansyl-
GCVLL, they could potentially be great co-substrates with other CaaX sequences.  Alternatively, 
these modifications could hinder product release from the enzyme, which is dependent on the 
movement of the isoprene chain into an exit groove; however, further structural analyses are 
needed.  The second observation is that the length of the carbon chain appears to be more 
important than flexibility (4.21 vs 4.39b).  Moreover, when the analog has three or more isoprene 
units and two carbons between the α- and β-isoprene units, increasing the carbon chain length 
from 13 to15 carbons has a minimal effect; however, increasing the length to 16 carbons (4.39c) 
has a substantial effect on enzyme activity.  Additionally, the γ-isoprene appears to be irrelevant; 
by removing this isoprene unit we generated an analog that displays substrate activity comparable 
to GGPP.  The preliminary data suggests the homoallylic analog (4.32) is an inhibitor of GGTase-
I.  Further analysis is underway to determine the IC50 value of this analog. 
We have successfully generated a small library of frame-shifted GGPP analogs designed 
to probe the GGPP binding pocket of GGTase-I.  Data shown in Figure 4.5 indicates our frame-
shifted molecules are either turned over more slowly than GGPP or display a lower affinity for 
the enzyme than GGPP.  Unfortunately, the analogs were tested at only three concentrations (1, 5, 
& 10 µM) and none of the reactions reached completion at 5 or 10 µM of analog in the time they 
were monitored.  In order to determine accurate kcat and Km values, these analogs are currently 
being retested at more concentrations and longer reaction times. Our preliminary results are very 
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promising and we anticipate doing more extensive in vitro screening with a large library of 
dansyl-GCaaX sequences to determine the selectivity of our analogs.  Additionally, we also 
expect to test the analogs that demonstrated poor or no substrate activity as inhibitors.  These 
compounds range in length between GGPP and FPP; therefore, at a later date, we will also be 
testing these compounds with FTase to determine their ability to be recognized and utilized by 
one enzyme over another.  
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4.5    Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of Frame-
Shifted Geranylgeranyl Pyrophosphate Analogs 
 
General Experimental Procedures:  All reactions were performed with oven-dried or flame-
dried glassware and under dry argon gas.  All commercial reagents and solvents were used 
directly without subsequent purification.  For the organmetallic coupling reactions, anhydrous 
THF was freshly distilled from sodium and benzophenone.  All other anhydrous solvents were 
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.  
Reactions were monitored by thin layer chromatography and visualized with one or more of the 
following: UV light, iodine, vanillin solution, potassium permanganate solution, 
dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.  All products were 
purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.  All 
reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded 
with sodium sulfated before column purification.  NOTE: *Dry glassware is critical for the 
organometallic reactions in this publication.  This was accomplished by taking oven-dried 
glassware (dried for at least 24 hr and then cooled under argon) and flame drying the round 
bottom flask under vacuum.  The flask was then purged with argon and cooled to room 
temperature.  This process was repeated 3 times to produce a completely water free 
environment.*  **Deoxygenated solvents are extremely crucial for successful organometallic 
reactions in this publication.  In order to achieve completely deoxygenated solutions, the solvent 
was placed in a flame-dried round bottom and under vacuum was sonicated for 30 seconds and 
then purged with argon for 30 seconds.  This process was repeated 3 times to yield completely 
deoxygenated solvents.**  All NMR spectra were taken either on a 300 MHz Bruker ARX300 or 
a 500 MHz Bruker DRX500 spectrometer.  Low-resolution MS (EI/CI) were recorded with a 
115 
 
Hewlett Packard Engine and low-resolution MS (ESI) were taken on a Thermoquest LCQ.  All 
high-resolution mass spectra were recorded on a FinniganMAT XL95. 
 
(E)-6-iodo-3-methylhex-2-en-1-ol (4.3):  
To a round bottom flask was added pent-4-yn-1-ol (1 eq, 8 mmol), PPh3 (1.3 eq, 10.4 
mmol) and imidazole (1.7 eq, 13.6 mmol) dissolved in dichloromethane (10 mL).  Next, the 
solution was cooled to 0°C with and ice-bath and I2 (1.3 eq, 10.4 mmol) was added to the reaction 
flask.  The reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room temperature 
and stirred for an additional 1.5 hr.  Upon completion of the reaction, 10% Na2S2O3 was added to 
the flask and stirred for 20 minutes.  The organic layer was isolated and the aqueous layer was 
extracted 1 × DCM (10 mL).  Due to the volatility of 5-iodopent-1-yne, it was used in the next 
step with purification and was not concentrated.   
Cp2ZrCl2 (0.25 eq, 2.0 mmol) was dissolved in dichloromethane (8.0 mL) and the 
solution was cooled to 0°C, where AlMe3 solution (2.0 M in heptanes, 2.5 eq, 24 mmol, 12.0 mL) 
was added dropwise.  After stirring the reaction mixture at 0°C for 30 minutes, 5-iodopent-1-yne 
(1.0 eq, 8.0 mmol) was diluted in dichloromethane (20 mL) and added to the reaction mixture 
dropwise.  The reaction mixture was allowed to slowly warm to room temperature and stirred an 
additional 12 hours.  Next, the reaction mixture was cooled to 0°C, where (CH2O)n (5 eq, 40.0 
mmol) was added in several portions.  The reaction continued to stir for 3 hours after which it 
was slowly poured into an ice-cold 10% HCl(aq) solution.  The solution was then filtered over a 
pad of Celite 545, extracted with 3 × 30 mL dichloromethane, washed with brine, dried with 
magnesium sulfated, filtered, and concentrated.  Column chromatography (30% Ethyl acetate in 
Hexanes) afforded 4.3a in 52% yield over 2-steps.  1H NMR: (300 MHz, CDCl3) δ 5.44 (ddd, J = 
8.1, 5.7, 1.3 Hz, 1H), 4.13 (d, J = 6.8 Hz, 2H), 3.14 (t, J = 6.9 Hz, 2H), 2.11 (t, J = 7.3 Hz, 2H), 
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1.98 – 1.87 (m, 2H), 1.65 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 137.81 (s), 124.84 (s), 59.50 (s), 
40.12 (s), 31.48 (s), 16.41 (s), 6.51 (s).   
 
(E)-2-((6-iodo-3-methylhex-2-en-1-yl)oxy)tetrahydro-2H-pyran (4.4):  
A round bottom flask was charged with (E)-6-iodo-3-methylhex-2-en-1-ol (1.0 eq, 4.13 
mmol) dissolved in DCM (10 mL).  Next, 3,4-dihydro-2H-pyran (3.0 eq, 12.40 mmol) and 
pyridinium p-toluenesulfonate (0.1 eq, 0.413 eq) were added to the reaction flask.  The reaction 
was stirred at room temperature for 1 hour and then concentrated.  The residue was loaded 
directly onto a silica column and column chromatography (7.5% Ethyl acetate in Hexanes) 
afforded 4.4a in 86% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.32 (t, J = 6.3 Hz, 1H), 4.53 
(s, 1H), 4.04 (ddd, J = 64.9, 11.9, 6.9 Hz, 2H), 3.79 (dd, J = 12.8, 5.6 Hz, 1H), 3.68 – 3.32 (m, 
1H), 3.08 (t, J = 6.9 Hz, 2H), 2.05 (t, J = 7.3 Hz, 2H), 1.86 (p, J = 7.0 Hz, 2H), 1.81 – 1.69 (m, 
1H), 1.59 (s, 3H), 1.54 – 1.37 (m, 5H). 13C NMR (75 MHz, Chloroform-d) δ 137.95, 122.02, 
97.85, 63.52, 62.28, 40.02, 31.33, 30.70, 25.50, 19.62, 16.37, 6.45.   
 
(E)-6-iodo-5-methylhex-5-en-1-ol (4.6):  
Cp2ZrCl2 (0.25 eq, 4.0 mmol) was dissolved in dichloromethane (16.0 mL) and the 
solution was cooled to 0°C, where AlMe3 solution (2.0 M in heptanes, 2.5 eq, 48 mmol, 24.0 mL) 
was added dropwise.  After stirring the reaction mixture at 0°C for 30 minutes, 5-hexyn-1-ol (1.0 
eq, 16.0 mmol) was diluted in dichloromethane (8 mL) and added to the reaction mixture 
dropwise.  The reaction mixture was allowed to slowly warm to room temperature and stirred an 
additional 12 hours.  Next, the reaction mixture was cooled to 0°C, where I2 (3.5 eq, 56.0 mmol) 
was added in several portions.  The reaction continued to stir for 3 hours after which it was 
slowly poured into an ice-cold 10% HCl(aq) solution.  The solution was then filtered over a pad of 
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Celite 545, extracted with 3 × 50 mL dichloromethane, washed with brine, dried with magnesium 
sulfated, filtered, and concentrated.  Column chromatography (15% Ethyl acetate in Hexanes) 
afforded 4.6 in 25% yield.  1H NMR (300 MHz, CDCl3) δ 5.86 (dd, J = 2.2, 1.1 Hz, 1H), 3.63 
(dd, J = 7.2, 5.0 Hz, 2H), 2.24 – 2.17 (m, 2H), 1.81 (d, J = 1.0 Hz, 3H), 1.54 – 1.47 (m, 5H). 13C 
NMR (75 MHz, Chloroform-d) δ 148.00, 75.01, 62.83, 39.46, 32.23, 24.06, 23.96.   
 
(E)-6-iodo-5-methylhex-5-enal (4.7): 
An oven-dried multi-neck round bottom flask and addition funnel are assembled while 
hot and cooled down under argon.  The flask is then charged with (COCl)2 (1.2 eq, 4.84mmol) 
dissolved in 5 mL of anhydrous DCM. The flask is then cooled down to -78°C and DMSO (2.4 
eq, 9.67 mmol) diluted in 2 mL of anhydrous DCM is added dropwise to the reaction mixture 
over the course of 20 minutes via the addition funnel and stirred for an additional 30 minutes at -
78°C.  Next, (E)-6-iodo-5-methylhex-5-en-1-ol (1.0 eq, 4.03 mmol) is dissolved in 8 mL of 
anhydrous DCM and slowly added to the reaction mixture via the addition funnel.  Upon 
complete addition of the alcohol, the reaction is stirred for an additional 1.5 hr at -78°C.  Finally, 
Et3N (5.0 eq, 20.15 mmol) is added to the reaction; the mixture is removed from the cooling bath 
and is allowed to stir until it warms to room temperature.  The reaction is then quenched by the 
addition of 10% NH4Cl and extracted 3 × 50 mL DCM.  The organic layers were combined 
washed brine, dried with magnesium sulfate, and concentrated.  The crude reaction product was 
purified by column chromatography (30% Et2O/Hexanes) to afford 4.7 in 67% yield.  
1H NMR 
(300 MHz, Chloroform-d) δ 9.69 (q, J = 1.2 Hz, 1H), 5.84 (t, 1H), 2.36 (tt, J = 7.2, 1.2 Hz, 2H), 
2.17 (t, J = 7.5 Hz, 2H), 1.75 (t, J = 1.1 Hz, 3H), 1.74 – 1.67 (m, 2H). 13C NMR (75 MHz, 





To an oven-dried round bottom flask is added (i-Pr)Ph3PI (1.3 eq, 3.51 mmol) dissolved 
in 17.5 mL of anhydrous THF.  The mixture is cooled to 0°C where n-BuLi (2.5 M in hexanes, 
1.3 eq, 3.51 mmol) is added dropwise.  The resulting orange solution is stirred for 1 hr at 0°C.  
Next, E)-1-iodo-2,7-dimethylocta-1,6-diene (1.0 eq, 2.7 mmol) is diluted in 1.2 mL of anhydrous 
THF and added dropwise to the reaction mixture, which is allowed to stir for 4 hours coming to 
room temperature.  Upon completion of the reaction, saturated NH4Cl(aq) is added to the reaction 
vessel and stirred for 15 minutes.  Following extraction with 3 × 50 mL hexanes, the organic 
layers were combined, washed with brine, dried with magnesium sulfate, and concentrated.  The 
crude reaction product was purified by column chromatography (100% Hexanes) to afford 4.8 in 
65% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.84 (dd, J = 2.2, 1.1 Hz, 1H), 5.06 (t, J = 7.2 
Hz, 1H), 2.18 (t, 2H), 1.93 (q, J = 7.3 Hz, 2H), 1.80 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 0.9 Hz, 3H), 
1.57 (s, 3H), 1.50 – 1.39 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 148.21 (s), 132.13 (s), 124.11 
(s), 74.75 (s), 39.28 (s), 28.01 (s), 27.50 (s), 25.94 (s), 24.01 (s), 17.95 (s).   
 
2-(((2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-yl)oxy)tetrahydro-2H-pyran (4.9):    
An oven-dried round-bottom flask containing powdered molecular sieves was charged 
with (E)-2-((6-iodo-3-methylhex-2-en-1-yl)oxy)tetrahydro-2H-pyran (stored over sieves; 2.11 eq, 
3.55 mmol) which was dissolved in 3.5 mL of anhydrous Et2O and cooled to -78°C.  Next, t-BuLi 
(1.7 M in pentane; 4.22 eq, 7.1 mmol) was slowly added to the reaction flask and stirred for 1 
hour at -78°C.  Afterward, β-MeO-9-BBN (1.0M in Hexanes; 4  eq, 6.72mmol) was slowly added 
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to the reaction vessel and the mixture was stirred for 16 hours slowly warming to room 
temperature.   
In a scintillation vial, (E)-1-iodo-2,7-dimethylocta-1,6-diene (1.0 eq, 1.68 mmol) and 
Pd(dppf)Cl2 (0.1 eq, 0.17 mmol) are dissolved in 8 mL of DMF.  Next, K3PO4 (3.0 eq, 5.0 mmol) 
is added to the vial and after deoxygenating the solvent, the vinyl-iodide solution is added to the 
round-bottom flask containing the newly formed organoborane. The reaction mixture is allowed 
to stir for an additional 16 hours at 85°C after which it is poured into a separatory funnel 
containing water and Et2O and the aqueous layer was extracted 3 × 50 mL Et2O.  The organic 
layers were combined and washed with water then brine, dried with magnesium sulfate, and 
concentrated.  The crude reaction product was purified by column chromatography (5% 
Et2O/Hexanes) to afford 4.9 in 38% yield. 
 1H NMR (300 MHz, Chloroform-d) δ 5.32 (t, J = 7.0 
Hz, 1H), 5.08 (t, J = 7.1 Hz, 2H), 4.60 (t, J = 3.5 Hz, 1H), 4.10 (ddd, J = 62.6, 11.9, 6.8 Hz, 2H), 
3.86 (td, J = 7.6, 3.8 Hz, 1H), 3.47 (dd, J = 11.0, 5.1 Hz, 1H), 2.06 – 1.85 (m, 8H), 1.66 (s, 3H), 
1.63 (s, 3H), 1.56 (s, 3H), 1.54 (s, 3H), 1.53 – 1.28 (m, 10H). 
 
(2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-ol (4.10): 
In a scintillation vial, 2-(((2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-
yl)oxy)tetrahydro-2H-pyran (1.0 eq, 0.63 mmol) was dissolved in 5.0 mL of absolute EtOH and 
PPTS (0.1 eq, 0.07 mmol) was added to the vial.  The reaction mixture was heated to 60°C and 
stirred for 12 hours.  Next, the reaction was cooled to room temperature where it was poured into 
a separator funnel containing water and Et2O and the aqueous layer was extracted 3 × 5 mL Et2O.  
The organic layers were combined and washed with water then brine, dried with magnesium 
sulfate, and concentrated.  The crude reaction product was purified by column chromatography 
using 10% Ethyl Acetate/Hexanes as the mobile phase to afford 4.10 in 67% yield.  1H NMR 
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(300 MHz, Chloroform-d) δ 5.38 (dd, J = 7.9, 6.2 Hz, 1H), 5.13 – 5.01 (m, 2H), 4.12 (d, J = 6.8 
Hz, 2H), 1.95 (ddd, J = 13.1, 9.4, 6.0 Hz, 8H), 1.66 (s, 3H), 1.64 (s, 3H), 1.57 (s, 3H), 1.55 (s, 
3H), 1.41 (ddt, J = 15.0, 12.8, 7.5 Hz, 4H). 13C NMR (75 MHz, Chloroform-d) δ 140.25, 135.63, 
131.53, 124.89, 124.37, 123.42, 59.60, 39.53, 39.34, 28.38, 28.09, 27.84, 27.71, 25.94, 17.89, 
16.39, 16.15.  MS (EI) m/z 250; MS (CI) m/z 249. 
 
(E)-ethyl 5,9-dimethyldeca-4,8-dienoate (4.13):   
A round bottom flask charged with Cu(I)I (4.0 eq, 12 mmol) and placed in a drying oven 
for 1.5 hr, after which it is cooled to room temperature under argon.  Anhydrous EtOAc (2.05 eq, 
24.6 mmol, 2.42 mL) and anhydrous THF (90 mL) are added to the round bottom flask, which is 
then cooled to -107°C utilizing an isooctane/N2(liq) bath.  To this mixture is added LDA (2.0 M in 
heptanes/THF/ethyl benzene, 2.05 eq, 24.6 mmol) dropwise.  The reaction is allowed to slowly 
warm to -30°C over 2 hr, at which point geranyl bromide (1.0 eq, 12 mmol) is dissolved in 15 mL 
of THF and added slowly to the reaction mixture.  Upon complete addition of geranyl bromide, 
the reaction is stirred an additional 1 hr at  -30°C, allowed to warm to 0°C and quenched with 
saturated NH4Cl (80 mL).  The aqueous layer was extracted with 30 mL Et2O × 3, the organic 
layers were pooled together, washed with brine, dried with MgSO4, filtered and concentrated.  
Purification by flash chromatography using 3% EtOAc/Hexanes as the eluent afforded the title 
compound in 34% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.13 – 5.01 (m, 2H), 4.10 (q, J = 
7.1 Hz, 2H), 2.29 (d, J = 3.1 Hz, 4H), 2.10 – 1.88 (m, 4H), 1.65 (s, 3H), 1.59 (s, 3H), 1.57 (s, 
3H), 1.23 (t, J = 7.2 Hz, 3H).  13C NMR (75 MHz, Chloroform-d) δ 191.48, 136.71, 131.54, 








To an oven-dried round bottom flask is added (E)-ethyl 5,9-dimethyldeca-4,8-dienoate 
(1.0 eq, 4.034 mmol) dissolved in 15 mL of toluene which is then cooled to -78°C.  DIBAL (1.0 
M in toluene, 4.0 eq) was added dropwise to the reaction mixture and allowed to stir for 4 hours.  
The reaction mixtures was then slowly poured into an ice-cold 10% HCl(aq) solution and then 
filtered over a pad of Celite 545.  The aqueous layer was extracted with 30 mL Et2O × 3, the 
organic layers were pooled together, washed with brine, dried with MgSO4, filtered and 
concentrated.  Purification by flash chromatography using 15% EtOAc/Hexanes as the eluent 
afforded the title compound in 38% yield (Yield given is for 2-steps from geranyl bromide).  1H 
NMR (300 MHz, Chloroform-d) δ 5.09 (t, J = 7.6 Hz, 1H), 5.03 (t, J = 7.0 Hz, 1H), 3.56 (t, J = 
6.6 Hz, 2H), 2.36 (s, 1H), 2.08 – 1.87 (m, 6H), 1.63 (s, 3H), 1.61 – 1.49 (m, 8H). 13C NMR (75 
MHz, Chloroform-d) δ 135.76, 131.46, 124.38, 123.92, 62.57, 39.84, 32.82, 26.77, 25.79, 24.36, 
17.77, 16.05.   
 
(Z)-10-iodo-2,6-dimethyldeca-2,6-diene (4.15): 
To a round bottom flask was added (E)-5,9-dimethyldeca-4,8-dien-1-ol (1 eq, 4.6 mmol), 
PPh3 (1.3 eq, 6.0 mmol) and imidazole (1.7 eq, 7.8 mmol) dissolved in dichloromethane (15 mL).  
Next, the solution was cooled to 0°C with and ice-bath and I2 (1.3 eq, 6.0 mmol) was added to the 
reaction flask.  The reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room 
temperature and stirred for an additional 1.5 hr.  Upon completion of the reaction, 10% Na2S2O3 
was added to the flask and stirred for 20 minutes.  The organic layer was isolated and the aqueous 
layer was extracted 3 × DCM (10 mL).  The organic layers were pooled together, washed with 
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brine, dried with MgSO4, filtered and concentrated.  Purification by flash chromatography using 
hexanes as the eluent afforded the title compound in 68% yield.  1H NMR (300 MHz, 
Chloroform-d) δ 5.04 (td, J = 7.4, 6.7, 3.9 Hz, 2H), 3.16 (t, J = 6.9 Hz, 2H), 2.14 – 1.92 (m, 6H), 
1.84 (p, J = 7.0 Hz, 2H), 1.66 (s, 3H), 1.61 (s, 3H), 1.58 (s, 3H).  13C NMR (75 MHz, 
Chloroform-d) δ 136.94, 131.64, 124.38, 122.46, 39.91, 33.81, 28.79, 26.77, 25.94, 17.92, 16.42, 
7.06.   
 
(2E,7E)-3,8,12-trimethyltrideca-2,7,11-trien-1-ol (4.16): 
An oven-dried round-bottom flask containing powdered molecular sieves was charged 
with (Z)-10-iodo-2,6-dimethyldeca-2,6-diene (stored over sieves; 2.0 eq) which was dissolved in 
4.6 mL of anhydrous Et2O and cooled to -78°C.  Next, t-BuLi (1.7M in pentane; 3.0 eq, 2.06 
mmol) was slowly added to the reaction flask and stirred for 1 hour at -78°C.  Afterward, β-MeO-
9-BBN (1.0M in Hexanes; 3.8 eq, 2.6 mmol) was slowly added to the reaction vessel and the 
mixture was stirred for 16 hours slowly warming to room temperature.   
In a scintillation vial, (E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (1.0 eq, 
0.69 mmol) and Pd(dppf)Cl2 (0.15 eq, 0.10 mmol) are dissolved in 6.6 mL of DMF.  Next, K3PO4 
(3.0 eq, 2.06 mmol) is added to the vial and after deoxygenating the solvent, the vinyl-iodide 
solution is added to the round-bottom flask containing the newly formed organoborane. The 
reaction mixture is allowed to stir for an additional 16 hours at 85°C after which it is poured into 
a separatory funnel containing water and Et2O and the aqueous layer was extracted 3 × 50 mL 
Et2O.  The organic layers were combined and washed with water then brine, dried with 
magnesium sulfate, and concentrated.  The crude reaction product was run through a silica 
column (3% EtOAc/Hexanes) to remove most of the impurities and any oxidizing species.  
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In a scintillation vial, the semi-crude product was dissolved in 5.0 mL of THF, cooled to 
0°C, and TBAF (1.0 M in THF, 2.0 eq, 1.15 mmol) was added to the vial. The reaction was 
allowed to stir for 4 hours and then quenched with 10% NH4Cl(aq).  Next, the organic layer was 
removed, and the aqueous layer was extracted 3 × Et2O (10 mL).  The organic layers are 
combined, washed with brine, dried with MgSO4, filtered, and concentrated.  The crude reaction 
product was purified by column chromatography using 15% Ethyl Acetate/Hexanes as the mobile 
phase to afford 4.16 in 56% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.35 (t, J = 7.0 Hz, 1H), 
5.07 (q, J = 7.3 Hz, 2H), 4.09 (d, J = 6.9 Hz, 2H), 1.95 (h, J = 7.0 Hz, 8H), 1.64 (s, 3H), 1.62 (s, 
3H), 1.56 (s, 3H), 1.55 (s, 3H), 1.42 (p, J = 7.5 Hz, 2H).  13C NMR (75 MHz, Chloroform-d) δ 
140.15, 135.40, 131.47, 124.53, 124.46, 123.43, 59.55, 39.92, 39.28, 28.03, 27.67, 26.87, 25.89, 
17.87, 16.37, 16.19.  MS (EI) m/z 236; MS (CI) m/z 235. 
 
2-(((2E,6E,10E)-3,7,11,14-tetramethylpentadeca-2,6,10,13-tetraen-1-yl)oxy)tetrahydro-2H-pyran 
(4.19):   
In an oven-dried round bottom flask is added 2.3 (1.0 eq, 0.5 mmol) dissolved in 2.5 mL 
of anhydrous THF.  The mixture is cooled to 0°C where 2-methyl-1-propenylmagnesium bromide 
(0.5 M in THF, 10 eq, 5 mmol) is added dropwise.  The mixture is allowed to stir for 12 hours 
and quenched by the addition of 10% NH4Cl(aq) solution.  The mixture was then poured into a 
separator funnel and the aqueous layer was extracted 3 × 10 mL Et2O.  The organic layers were 
combined and washed with water then brine, dried with magnesium sulfate, and concentrated.  
The crude reaction product was purified by column chromatography using 3% Ethyl 
Acetate/Hexanes as the mobile phase to afford 4.19 in 52% yield.  1H NMR (300 MHz, 
Chloroform-d) δ 5.40 – 5.30 (m, 1H), 5.19 – 4.97 (m, 3H), 4.60 (dd, J = 4.3, 2.7 Hz, 1H), 4.21 
(dd, J = 11.9, 6.4 Hz, 1H), 4.00 (dd, J = 11.9, 7.4 Hz, 1H), 3.95 – 3.79 (m, 1H), 3.59 – 3.44 (m, 
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1H), 2.61 (d, J = 7.5 Hz, 2H), 2.22 – 1.88 (m, 8H), 1.69 (d, J = 1.5 Hz, 3H), 1.66 (d, J = 1.3 Hz, 
4H), 1.61 – 1.46 (m, 14H).  13C NMR (75 MHz, Chloroform-d) δ 140.49, 135.42, 134.74, 132.57, 
124.22, 124.10, 122.86, 120.73, 97.96, 63.84, 62.47, 39.91, 39.85, 38.43, 30.92, 26.87, 26.50, 
26.01, 25.71, 19.83, 17.86, 16.64, 16.36, 16.23.   
 
(2E,6E,10E)-3,7,11,14-tetramethylpentadeca-2,6,10,13-tetraen-1-ol (4.20): 
In a scintillation vial, 1,2,2,1-OTHP (1.0 eq, 0.258 mmol) was dissolved in 5.0 mL of 
absolute EtOH and PPTS (0.1 eq, 0.026 mmol) was added to the vial.  The reaction mixture was 
heated to 75°C and stirred for 12 hours.  Next, the reaction was cooled to room temperature 
where it was poured into a separator funnel containing water and Et2O and the aqueous layer was 
extracted 3 × 5 mL Et2O.  The organic layers were combined and washed with water then brine, 
dried with magnesium sulfate, and concentrated.  The crude reaction product was purified by 
column chromatography using 10% Ethyl Acetate/Hexanes as the mobile phase to afford 4.20 in 
71% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.48 – 5.36 (m, 1H), 5.22 – 5.04 (m, 3H), 4.12 
(d, J = 7.0 Hz, 2H), 2.61 (d, J = 7.4 Hz, 2H), 2.19 – 1.86 (m, 9H), 1.68 (s, 3H), 1.65 (s, 3H), 1.59 
(s, 3H), 1.57 (s, 3H), 1.54 (s, 3H).  13C NMR (75 MHz, Chloroform-d) δ 139.94, 135.53, 134.76, 
132.58, 124.17, 123.97, 123.49, 122.84, 59.55, 39.88, 39.74, 38.40, 26.84, 26.49, 25.99, 17.84, 





A suspension of THP-protected farnesol (1.0 eq, 5.55 mmol) in 50 mL THF/H2O (2:1) 
was added to a round bottom flask and cooled to 0°C.  THF was carefully added dropwise to the 
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mixture to discharge the turbidity.  Next, NBS (1.1 eq, 6.1 mmol) was added and the reaction 
mixture was allowed to warm to room temperature.  After 3 hr of stirring, the THF is evaporated 
and the aqueous layer is extracted 3 × 20 mL hexanes.  The organic layers were pooled, washed 
with brine, dried with MgSO4, and concentrated.  The bromo-hydrin was taken on cured in the 
following step by dissolving it in MeOH (70 mL) and adding K2CO3 (2.0 eq, 11.1 mmol) to the 
mixture.  The reaction was allowed to stir for 1 hr then the MeOH was removed.  Water (50 mL) 
and Et2O (20 mL) were added to the concentrated solution.  The Et2O layer was collected and the 
aqueous layer was further extracted with 20 mL Et2O × 2, the organic layers were pooled 
together, washed with brine, dried with MgSO4, filtered and concentrated.  Purification by flash 
chromatography using 10% EtOAc/Hexanes as the eluent afforded the title compound in 46% 
yield.  1H NMR (300 MHz, Chloroform-d) δ 5.31 (t, J = 6.3 Hz, 1H), 5.11 (t, J = 6.2 Hz, 1H), 
4.58 (t, J = 3.4 Hz, 1H), 4.08 (ddd, J = 66.2, 11.9, 6.9 Hz, 2H), 3.85 (ddd, J = 11.1, 7.3, 3.4 Hz, 
1H), 3.46 (dt, J = 10.5, 4.8 Hz, 1H), 2.65 (t, J = 6.2 Hz, 1H), 2.03 (dq, J = 13.6, 7.1, 5.8 Hz, 6H), 
1.95 – 1.39 (m,14H), 1.25 (s, 3H), 1.21 (s, 3H).  13C NMR (75 MHz, CDCl3) δ 140.24 (s), 134.49 
(s), 124.69 (s), 120.81 (s), 97.97 (s), 64.34 (s), 63.80 (s), 62.44 (s), 58.50 (s), 39.70 (s), 36.46 (s), 
30.87 (s), 27.59 (s), 26.43 (s), 25.66 (s), 25.07 (s), 19.79 (s), 18.92 (s), 16.60 (s), 16.18 (s).   
 
 4E,8E)-4,8-dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dien-1-ol (4.25): 
To an oven-dried round bottom flask is added H5IO6 (1.2 eq, 3.05 mmol) in 2.5 mL of 
THF and cooled to 0°C where 4.22 (1.0 eq, 2.54 mmol) in 13 mL of Et2O was added rapidly to 
the reaction flask.  The reaction was allowed to stir for 30 minutes and quenched by the addition 
of 40mL of saturated Na2S2O3(aq). The Et2O layer was collected and the aqueous layer was further 
extracted with 20 mL Et2O × 3, the organic layers were pooled together, washed with brine, dried 
with MgSO4, filtered, concentrated, and taken on crude.  
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To an oven-dried round bottom flask was added 4.23 (1.0 eq, 2.54 mmol) in 30 mL of 
absolute EtOH and cooled to 0°C.  Next, NaBH4 (2.0 eq, 5.1 mmol) was added to the reaction 
vessel in several portions and the reaction was allowed to stir for 1 hour.  The reaction was then 
quenched by the addition of 50 mL of water and extracted with 20 mL Et2O × 3, the organic 
layers were pooled together, washed with brine, dried with MgSO4, filtered, concentrated, and 
again taken on crude.  
To a round bottom flask was added alcohol 4.24 (1.0 eq, 2.54 mmol), PPh3 (1.3 eq, 3.3 
mmol) and imidazole (1.7 eq, 4.23 mmol) dissolved in dichloromethane (10 mL).  Next, the 
solution was cooled to 0°C with and ice-bath and I2 (1.3 eq, 3.3 mmol) was added to the reaction 
flask.  The reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room temperature 
and stirred for an additional 1.5 hr.  Upon completion of the reaction, 10% Na2S2O3 was added to 
the flask and stirred for 20 minutes.  The organic layer was isolated and the aqueous layer was 
extracted 3 × DCM (10 mL).  The organic layers were pooled together, washed with brine, dried 
with MgSO4, filtered and concentrated.  Purification by flash chromatography using 5% 
EtOAc/hexanes as the eluent afforded the title compound in 55% yield over 3 steps.  1H NMR 
(300 MHz, Chloroform-d) δ 5.37 – 5.29 (m, 1H), 5.13 (t, J = 6.2 Hz, 1H), 4.59 (t, J = 3.5 Hz, 
1H), 4.10 (ddd, J = 66.0, 11.9, 6.9 Hz, 2H), 3.91 – 3.79 (m, 1H), 3.58 – 3.39 (m, 1H), 3.10 (t, J = 
6.9 Hz, 2H), 2.16 – 1.67 (m, 10H), 1.64 (s, 3H), 1.60 – 1.43 (m, 7H).  13C NMR (75 MHz, 
CDCl3) δ 140.15 (s), 133.28 (s), 125.61 (s), 120.92 (s), 97.98 (s), 63.81 (s), 62.46 (s), 40.15 (s), 
39.66 (s), 31.67 (s), 30.89 (s), 26.36 (s), 25.67 (s), 19.80 (s), 16.57 (s), 16.01 (s), 6.91 (s). 
 
(2E,6E)-10-iodo-3,7-dimethyldeca-2,6-dien-1-ol (4.26): 
In a scintillation vial, 2-(((2E,6E)-10-iodo-3,7-dimethyldeca-2,6-dien-1-
yl)oxy)tetrahydro-2H-pyran (1.0 eq, 0.88 mmol) was dissolved in 5.0 mL of absolute EtOH and 
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PPTS (0.1 eq, 0.09 mmol) was added to the vial.  The reaction mixture was heated to 75°C and 
stirred for 12 hours.  Next, the reaction was cooled to room temperature where it was poured into 
a separator funnel containing water and Et2O and the aqueous layer was extracted 3 × 5 mL Et2O.  
The organic layers were combined and washed with water then brine, dried with magnesium 
sulfate, and concentrated.  The crude reaction product was purified by column chromatography 
using 10% Ethyl Acetate/Hexanes as the mobile phase to afford 4.26 in 68% yield.  1H NMR 
(300 MHz, Chloroform-d) δ 5.37 (t, J = 6.9 Hz, 1H), 5.13 (t, J = 6.7 Hz, 1H), 4.11 (d, J = 7.0 Hz, 
2H), 3.10 (t, J = 6.9 Hz, 2H), 2.04 (dd, J = 13.7, 6.2 Hz, 6H), 1.92 – 1.77 (m, 2H), 1.63 (s, 3H), 
1.55 (s, 3H).  13C NMR (75 MHz, Chloroform-d) δ 139.49, 133.32, 125.51, 123.71, 59.49, 40.06, 
39.55, 31.57, 26.33, 16.40, 15.98, 6.95.   
 
(2E,6E)-3,7,12-trimethyltrideca-2,6,11-trien-1-ol (4.27): 
To an oven-dried round bottom flask is added (2E,6E)-10-iodo-3,7-dimethyldeca-2,6-
dien-1-ol (1.0 eq, 0.6 mmol) and dissolved in 2.2 mL of anhydrous THF.  Next, Cu(I)I (0.5 eq, 
0.3 mmol) is added to the flask and the mixture is cooled to  -40°C, where 2-methyl-1-
propenylmagnesium bromide (0.5 M in THF, 5.0 eq, 3.0 mmol, 6 mL) is slowly added dropwise 
to the reaction.  The reaction is rapidly warmed to 0°C and stirred for 9 hr. Warming to room 
temperature, the reaction is allowed to stir for an additional 9 hr then slowly poured into beaker 
containing 30 mL of 10% NH4Cl(aq) and 10 mL of Et2O.  The organic layer was isolated and the 
aqueous layer was extracted 3 × Et2O (10 mL).  The organic layers were pooled together, washed 
with brine, dried with MgSO4, filtered and concentrated.  Purification by flash chromatography 
using 25% EtOAc/hexanes as the eluent afforded the title compound in 29% yield.  1H NMR (300 
MHz, Chloroform-d) δ 5.44 – 5.33 (m, 1H), 5.22 – 4.94 (m, 2H), 4.12 (d, J = 6.9 Hz, 2H), 2.15 – 
1.97 (m, 4H), 1.91 (dt, J = 13.7, 7.3 Hz, 4H), 1.66 (d, J = 2.8 Hz, 6H), 1.56 (s, 6H), 1.38 (p, J = 
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7.6 Hz, 2H).  13C NMR (75 MHz, Chloroform-d) δ 139.96, 135.71, 131.58, 124.86, 123.89, 
123.53, 59.60, 39.77, 39.47, 28.33, 27.81, 26.46, 25.94, 17.89, 16.47, 16.12.  MS (EI) m/z 236. 
 
(5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-1-yne (4.30): 
An oven-dried round bottom flask is cooled under argon and charged with TMS-propyne 
(1.3 eq, 6.5 mmol) and 8 mL of anhydrous THF then cooled to -78°C.  Next, n-BuLi (2.5 M in 
hexanes, 1.3 eq, 6.5 mmol) is added dropwise.  The reaction mixture is allowed to stir for 1.5 hr, 
after which farnesyl chloride (1.0 eq, 5 mmol) is dissolved in THF (2 mL) and added slowly to 
the reaction mixture at -78°C.  The reaction is allowed to stir 16 hr and is then quenched by the 
addition of 10% NH4Cl(aq).  The organic layer was isolated and the aqueous layer was extracted 3 
× Et2O (25 mL).  The organic layers were pooled together, washed with brine, dried with MgSO4, 
filtered and concentrated.  The crude TMS-protected alkyne was used directly in the next step 
without purification.  
In a round bottom flask was added trimethyl((5E,9E)-6,10,14-trimethylpentadeca-5,9,13-
trien-1-yn-1-yl)silane (1.0 eq, 5 mmol) and 20 mL of THF and cooled to 0°C.  Next, TBAF (1.0 
M in THF, 1.5 eq, 7.5 mmol) is added to the reaction flask and allowed to stir for 2 hours.  Upon 
completion of the reaction, 30 mL of 10% NH4Cl(aq) and 15 mL Et2O are added and the organic 
layer was isolated.  The aqueous layer was further extracted 3 × Et2O (20 mL).  The organic 
layers were pooled together, washed with brine, dried with MgSO4, filtered and concentrated.  
The crude reaction product was purified by column chromatography using 1% Ethyl 
Acetate/Hexanes as the mobile phase to afford 4.30 in 73% yield (yield given is for 2 steps).  1H 
NMR (300 MHz, Chloroform-d) δ 5.15 (t, J = 7.0 Hz, 1H), 5.08 (q, J = 6.4 Hz, 2H), 2.26 – 2.12 
(m, 4H), 2.12 – 1.93 (m, 8H), 1.92 (d, J = 2.4 Hz, 1H), 1.66 (s, 3H), 1.61 (s, 3H), 1.58 (s, 6H).  
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13C NMR (75 MHz, Chloroform-d) δ 136.90, 135.20, 131.44, 124.57, 124.26, 122.65, 84.71, 
68.30, 39.92, 39.83, 27.39, 26.95, 26.70, 25.91, 19.12, 17.88, 16.32, 16.21.   
 
(3E,7E,11E)-4,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-ol (4.31): 
Cp2ZrCl2 (0.25 eq, 0.81 mmol) was dissolved in dichloromethane (3.5 mL) and the 
solution was cooled to 0°C, where Me3Al solution (2.0 M in heptanes, 2.5 eq, 8.1 mmol) was 
added dropwise.  After stirring the reaction mixture at 0°C for 30 minutes, (5E,9E)-6,10,14-
trimethylpentadeca-5,9,13-trien-1-yne (1.0 eq, 3.22 mmol) was diluted in dichloromethane (1.6 
mL) and added to the reaction mixture dropwise.  The reaction mixture was allowed to slowly 
warm to room temperature and stirred an additional 12 hours. Next, the reaction mixture was 
cooled to -78°C and n-BuLi (2.5 M in hexanes, 1.5 eq, 4.8 mmol) was added dropwise and the 
reaction was stirred for 1 hr.  After 1 hr, ethylene oxide (1.4 M in toluene, 3.0 eq, 9.7 mmol) was 
slowly added dropwise to the reaction at -78°C.  The reaction continued to stir for 5 hours, slowly 
warming to room temperature.  The reaction mixture was then slowly poured into an ice-cold 
10% HCl(aq) solution.  The solution was then filtered over a pad of Celite 545, extracted with 3 × 
50 mL dichloromethane, washed with brine, dried with magnesium sulfated, filtered, and 
concentrated.  Column chromatography (15% acetone/hexanes) afforded 4.31 in 41% yield.  1H 
NMR (300 MHz, Chloroform-d) δ 5.09 (q, J = 7.7 Hz, 4H), 3.59 (t, J = 6.5 Hz, 2H), 2.26 (q, J = 
6.8 Hz, 2H), 2.14 – 1.86 (m, 12H), 1.65 (s, 3H), 1.62 (s, 3H), 1.57 (s, 9H).  13C NMR (75 MHz, 
Chloroform-d) δ 139.12, 135.49, 135.13, 131.47, 124.57, 124.37, 124.17, 120.03, 62.60, 40.01, 
39.93, 39.90, 31.68, 26.95, 26.82, 26.69, 25.91, 17.89, 16.42, 16.23, 16.20.  MS (EI) m/z 304; MS 





Representative procedure for the synthesis of alkyl-iodides 4.34a-c:  
 
7-iodo-2-methylhept-2-ene (4.34a): 
To a round bottom flask was added ethyl 5-bromovalerate (1.0 eq, 20 mmol) and acetone 
(30 mL).  Next, KI (2.0 eq, 40 mmol) was to the flask and the reaction was reluxed at 65°C for 20 
hr.  The acetone was the removed and the crude iodide was used directly without purification. 
To an oven-dried round bottom flask cooled under argon was added ethyl 5-iodovalerate 
(1.0 eq, 20 mmol) dissolved in 100 mL of anhydrous toluene.  The solution was then cooled to -
78°C where DIBAL (1.1 eq, 22 mmol) was added dropwise.  The reaction was allowed to stir for 
5 hours at -78°C and then was poured into an ice-cold 10% HCl(aq) solution.  The mixture was 
then filtered over a pad of Celite 545, extracted with 3 × 50 mL Et2O, washed with brine, dried 
with magnesium sulfated, filtered, and concentrated.  The crude aldehyde was used directly 
without purification. 
To an oven-dried round bottom flask is added (i-Pr)Ph3PI (1.1 eq, 22 mmol) dissolved in 
80 mL of anhydrous THF.  The mixture is cooled to 0°C where n-BuLi (2.5 M in hexanes, 1.1 eq, 
22 mmol,) is added dropwise.  The resulting orange solution is stirred for 1 hr at 0°C.  Next, 5-
iodopentanal (1.0 eq, 20 mmol) is diluted in 9 mL of anhydrous THF and added dropwise to the 
reaction mixture, which is allowed to stir for 16 hours coming to room temperature.  Upon 
completion of the reaction, saturated NH4Cl(aq) is added to the reaction vessel and stirred for 15 
minutes.  Following extraction with 3 × 50 mL hexanes, the organic layers were combined, 
washed with brine, dried with magnesium sulfate, and concentrated.  The crude reaction product 
was purified by column chromatography (100% Hexanes) to afford 4.34a in 64% yield.  1H NMR 
(300 MHz, Chloroform-d) δ 5.07 (tt, J = 8.7, 5.8, 1.4 Hz, 1H), 3.16 (t, J = 7.1 Hz, 2H), 1.96 (q, 
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2H), 1.80 (p, J = 14.6, 7.1 Hz, 2H), 1.66 (s, 3H), 1.57 (s, 3H), 1.40 (p, J = 7.4 Hz, 2H).  13C NMR 
(75 MHz, Chloroform-d) δ 132.17, 124.06, 33.32, 30.87, 27.08, 25.92, 17.90, 7.35.   
 
8-iodo-2-methyloct-2-ene (4.34b): 
Yield (30%). 1H NMR (300 MHz, Chloroform-d) δ 5.09 (dddt, J = 7.2, 5.8, 2.9, 1.5 Hz, 
1H), 3.18 (t, J = 7.1 Hz, 2H), 1.98 (q, J = 6.4, 6.0 Hz, 2H), 1.82 (p, J = 7.1 Hz, 2H), 1.68 (s, 3H), 
1.60 (s, 3H), 1.47 – 1.27 (m, 4H).  13C NMR (75 MHz, Chloroform-d) δ 131.79, 124.52, 33.71, 
30.37, 28.97, 27.97, 25.94, 17.91, 7.42.   
 
9-iodo-2-methylnon-2-ene (4.34c): 
Yield (47%). 1H NMR (300 MHz, Chloroform-d) δ 5.12 – 4.82 (m, 1H), 3.16 (t, J = 7.0 
Hz, 2H), 1.94 (q, J = 6.8 Hz, 2H), 1.80 (p, J = 7.0 Hz, 2H), 1.66 (s, 3H), 1.57 (s, 3H), 1.43 – 1.23 
(m, 6H). 13C NMR (75 MHz, Chloroform-d) δ 131.54, 124.77, 33.75, 30.62, 29.82, 28.37, 28.08, 
25.94, 17.89, 7.49.   
Representative procedure for the synthesis of homo-allylic alcohols 4.37 a-c: 
 
(E)-4,12-dimethyltrideca-3,11-dien-1-ol (4.37c): 
 To an oven-dried round bottom flask is added powdered molecular sieves and is cooled 
under argon.  The round bottom was then flamed-dried under vacuum and cooled under argon; 
this process was repeated 3 times.  Next, 3 mL of anhydrous THF was added to the round bottom 
flask which was sonicated under vacuum for 30 seconds and then the atmosphere was replaced 
with argon for 30 seconds; this process was also repeated 3 times.  Next, 2,3-dihydrofuran (stored 
over molecular sieves, 3.0 eq, 18 mmol) was added to the reaction vessel and the solution was 
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cooled to -78°C where t-BuLi (1.7 M in heptanes, 3.0 eq, 18 mmol) was slowly added dropwise 
over 5 – 10 minutes.  The reaction was stirred at -78°C for 10 minutes then placed in a 0°C ice 
bath and continued to stir for 1 hr.  Next, the reaction mixture was cooled back -78°C and 9-iodo-
2-methylnon-2-ene (1.0 eq, 5.7 mmol) in 2.5 mL of anhydrous THF (also sonicated as described 
above) was added to the reaction vessel.  The reaction was stirred for 20 hr slowly coming to 
room temperature and then poured into a beaker containing ice-cold 20 mL of saturated NH4Cl(aq) 
and 2 mL of NH4OH.  The mixture was allowed to stir for 20 minutes and then extracted with 3 × 
20 mL Et2O, the organic layers were combined, washed with brine, dried with magnesium sulfate, 
concentrated (at room temperature), and used immediately in the next step.  
 To an oven-dried round bottom flask is added NiCl2(PPh3)2 (0.05 eq, 0.3 mmol) dissolved 
in anhydrous benzene (17 mL).  The round bottom flask was sonicated under vacuum for 30 
seconds and then the atmosphere was replaced with argon for 30 seconds; this process was 
repeated 3 times.  Next, MeMgBr (3.0 M in Et2O, 2.9 eq, 17.4 mmol) was added slowly to the Ni-
catalyst solution and stirred for 30 minutes at room temperature.  Next, a solution of the newly 
alkylated-furan (1.0 eq, 5.7 mmol) was dissolved in benzene (15 mL) and deoxygenated by 
sonication as previously described.  After deoxygenation, the alkylated-furan solution was added 
slowly to the Ni-catalyst solution and the reaction was refluxed at 80°C for 12 hours.  The 
reaction is then cooled to room temperature and poured into a beaker containing 250 mL of 
saturated NH4Cl(aq) and 100 mL of Et2O.  The organic layer was isolated and the aqueous layer 
was extracted 3 × Et2O (50 mL).  The organic layers were pooled together, washed with brine, 
dried with MgSO4, filtered and concentrated.  Purification by flash chromatography using 20% 
EtOAc/hexanes as the eluent afforded the title compound in 69% yield.  1H NMR (300 MHz, 
Chloroform-d) δ 5.18 – 4.94 (m, 2H), 3.59 (t, J = 6.5 Hz, 2H), 2.26 (q, J = 6.8 Hz, 2H), 1.95 (q, J 
= 7.4 Hz, 4H), 1.66 (s, 3H), 1.60 (s, 3H), 1.57 (s, 3H), 1.31 – 1.14 (m, 8H).  13C NMR (75 MHz, 
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Chloroform-d) δ 139.46, 131.37, 125.06, 119.65, 62.70, 40.02, 31.68, 30.05, 29.45, 29.41, 28.22, 
28.13, 25.93, 17.86, 16.34.   
 
(E)-4,11-dimethyldodeca-3,10-dien-1-ol (4.37b): 
Yield (72%). 1H NMR (300 MHz, Chloroform-d) δ 5.08 (ddt, J = 7.1, 2.9, 1.5 Hz, 2H), 
3.58 (t, 2H), 2.25 (q, J = 6.6 Hz, 2H), 1.95 (h, J = 7.1 Hz, 4H), 1.66 (s, 3H), 1.60 (s, 3H), 1.56 (s, 
3H), 1.43 – 1.17 (m, 6H).  13C NMR (75 MHz, Chloroform-d) δ 139.36, 131.40, 125.00, 119.69, 
62.66, 39.98, 31.67, 29.94, 29.16, 28.18, 28.05, 25.91, 17.84, 16.30.   
 
(E)-4,10-dimethylundeca-3,9-dien-1-ol (4.37a): 
Yield (33%).  1H NMR (300 MHz, Chloroform-d) δ 5.08 (q, J = 6.3, 5.5 Hz, 2H), 3.58 (t, 
J = 6.6 Hz, 2H), 2.25 (q, J = 6.6 Hz, 2H), 1.95 (dt, J = 13.2, 6.7 Hz, 4H), 1.65 (s, 3H), 1.60 (s, 
3H), 1.57 (s, 3H), 1.45 – 1.19 (m, 4H).  13C NMR (75 MHz, Chloroform-d) δ 139.29, 131.48, 
124.89, 119.73, 62.67, 39.89, 31.66, 29.69, 28.08, 27.74, 25.91, 17.85, 16.28. 
Representative procedure for the synthesis of homo-allylic iodides 4.38a-c: 
 
(E)-11-iodo-2,8-dimethylundeca-2,8-diene (4.38a): 
 To a round bottom flask was added 4.37a (1 eq, 1.93 mmol), PPh3 (1.3 eq, 2.51 mmol) 
and imidazole (1.7 eq, 3.28 mmol) dissolved in dichloromethane (14 mL).  Next, the solution was 
cooled to 0°C with and ice-bath and I2 (1.3 eq, 2.51 mmol) was added to the reaction flask.  The 
reaction was allowed to stir 0.5 hr at 0°C then allowed to warm to room temperature and stirred 
for an additional 1.5 hr.  Upon completion of the reaction, 10% Na2S2O3 was added to the flask 
and stirred for 20 minutes.  The organic layer was isolated and the aqueous layer was extracted 3 
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× DCM (mL).  The organic layers were pooled together, washed with brine, dried with MgSO4, 
filtered and concentrated.  Purification by flash chromatography using hexanes as the eluent 
afforded the title compound in 61% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.08 (dtt, J = 
8.3, 5.8, 1.3 Hz, 2H), 3.09 (t, J = 7.4 Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 2.08 – 1.85 (m, 4H), 1.67 
(d, 3H), 1.58 (s, 6H), 1.47 – 0.98 (m, 4H).  13C NMR (75 MHz, Chloroform-d) δ 138.63, 131.48, 
124.93, 122.94, 39.71, 32.60, 29.65, 28.10, 27.60, 25.96, 17.91, 16.39, 6.42.   
 
(E)-12-iodo-2,9-dimethyldodeca-2,9-diene (4.38b): 
Yield (82%). 1H NMR (300 MHz, Chloroform-d) δ 5.22 – 4.68 (m, 2H), 3.09 (t, J = 7.4 
Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 1.95 (q, 4H), 1.67 (s, 3H), 1.57 (s, 6H), 1.45 – 1.13 (m, 6H).  
13C NMR (75 MHz, Chloroform-d) δ 138.67, 131.39, 125.04, 122.91, 39.79, 32.58, 29.96, 29.11, 
28.22, 27.88, 25.96, 17.90, 16.39, 6.43.   
 
(E)-13-iodo-2,10-dimethyltrideca-2,10-diene (4.38c): 
Yield (76%). 1H NMR (300 MHz, Chloroform-d) δ 5.16 – 4.98 (m, 2H), 3.09 (t, J = 7.4 
Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 2.04 – 1.85 (m, 4H), 1.66 (s, 3H), 1.57 (s, 6H), 1.45 – 1.13 (m, 
8H).  13C NMR (75 MHz, Chloroform-d) δ 138.68, 131.34, 125.08, 122.87, 39.81, 32.58, 30.07, 








Representative procedure for the synthesis of frame-shifted alcohols 4.39a-c; 
 
(2E,6E)-3,7,13-trimethyltetradeca-2,6,12-trien-1-ol (4.39a): 
An oven-dried round-bottom flask containing powdered molecular sieves was charged 
with (E)-11-iodo-2,8-dimethylundeca-2,8-diene (stored over sieves; 2.0 eq, 1.38 mmol) which 
was dissolved in 5 mL of anhydrous Et2O and cooled to -78°C.  Next, t-BuLi (1.7 M in pentane; 
3.0 eq, 2.06 mmol) was slowly added to the reaction flask and stirred for 1 hour at -78°C.  
Afterward, β-MeO-9-BBN (1.0M in Hexanes; 3.8 eq, 2.62 mmol) was slowly added to the 
reaction vessel followed by 2 mL of THF and the mixture was stirred for 16 hours slowly 
warming to room temperature.   
In a scintillation vial, (E)-tert-butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (1.0 eq, 
0.69 mmol) and Pd(dppf)Cl2 (0.15 eq, 0.10 mmol) are dissolved in 3mL of DMF.  Next, K3PO4 
(3.0 eq, 2.06 mmol) is added to the vial and after deoxygenating the solvent, the vinyl-iodide 
solution is added to the round-bottom flask containing the newly formed organoborane. The 
reaction mixture is allowed to stir for an additional 16 hours at 85°C after which it is poured into 
a separatory funnel containing water and Et2O and the aqueous layer was extracted  3 ×  5 mL 
Et2O.  The organic layers were combined and washed with water then brine, dried with 
magnesium sulfate, and concentrated.  The crude reaction product was run through a silica 
column (1% EtO2/Hexanes) to remove most of the impurities and any oxidizing species.  
In a scintillation vial, the semi-crude product was dissolved in 2.0 mL of THF, cooled to 
0°C, and TBAF (1.0 M in THF, 2.4 eq, 1.42 mmol) was added to the vial. The reaction was 
allowed to stir for 4 hours and then quenched with 10% NH4Cl(aq).  Next, the organic layer was 
removed, and the aqueous layer was extracted 3 × Et2O (5 mL).  The organic layers are 
combined, washed with brine, dried with MgSO4, filtered, and concentrated.  The crude reaction 
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product was purified by column chromatography using 20% Ethyl Acetate/Hexanes as the mobile 
phase to afford 4.39a in 46% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.45 – 5.30 (m, 1H), 
5.08 (tdq, J = 7.0, 4.2, 1.4 Hz, 2H), 4.12 (d, J = 6.9 Hz, 2H), 2.19 – 1.76 (m, 8H), 1.66 (dd, J = 
2.5, 1.3 Hz, 6H), 1.57 (s, 3H), 1.56 (s, 3H), 1.43 – 1.15 (m, 4H).  13C NMR (75 MHz, 
Chloroform-d) δ 139.99, 135.83, 131.44, 125.01, 123.79, 123.52, 59.60, 39.76, 39.72, 29.65, 
28.12, 27.79, 26.45, 25.94, 17.88, 16.47, 16.07.  MS (EI) m/z 250; MS (CI) m/z 249. 
 
(2E,6E)-3,7,14-trimethylpentadeca-2,6,13-trien-1-ol (4.39b): 
Yield (30% - 2 Steps). 1H NMR (300 MHz, Chloroform-d) δ 5.39 (tq, J = 7.0, 1.3 Hz, 
1H), 5.15 – 5.00 (m, 2H), 4.13 (d, J = 7.0 Hz, 2H), 2.16 – 1.97 (m, 4H), 1.92 (t, J = 6.7 Hz, 4H), 
1.66 (s, 6H), 1.57 (s, 3H), 1.56 (s, 3H), 1.40 – 1.13 (m, 6H).  13C NMR (75 MHz, Chloroform-d) 
δ 140.04, 135.92, 131.38, 125.08, 123.72, 123.50, 59.62, 39.86, 39.79, 29.98, 29.16, 28.22, 28.11, 




Yield (25% - 2 steps). 1H NMR (300 MHz, Chloroform-d) δ 5.39 (tq, J = 6.9, 1.4 Hz, 
1H), 5.16 – 5.01 (m, 2H), 4.12 (d, J = 6.9 Hz, 2H), 2.04 (s, 4H), 1.92 (t, J = 7.1 Hz, 4H), 1.65 (s, 
6H), 1.57 (s, 3H), 1.55 (s, 3H), 1.45 – 1.06 (m, 8H).  13C NMR (75 MHz, Chloroform-d) δ 
139.94, 135.90, 131.32, 125.09, 123.67, 123.50, 59.54, 39.86, 39.77, 30.06, 29.43, 29.39, 28.23, 






Representative procedure for the synthesis of pyrophosphates 4.11, 4.17, 4.21, 4.28, 4.40a-c: 
 
(2E,7E)-3,8,13-trimethyltetradeca-2,7,12-trien-1-yl diphosphate (4.11): 
To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS 
(2.5 eq, 0.25 mmol) in 0.5 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq, 
0.25 mmol) was added dropwise to the reaction.  Following the addition, the mixture is then 
placed in a 0°C ice bath and stirred for 5 minutes before being re-cooled back to -30°C.  Next, 
alcohol 4.9 (1 eq, 0.10 mmol) is dissolved in CH2Cl2 (0.2 mL) and added dropwise to the reaction 
mixture.  The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room 
temperature.  After the allotted time, brine is added to the reaction mixture and the organic layer 
was extracted.  The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic layers 
were combined, dried with magnesium sulfate, and concentrated.  The crude reaction product was 
used immediately in the following step.  
 To another oven-dried round bottom flask equipped with a magnetic stir bar was added 
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.3 mmol) dissolved in 1.3 mL of 
acetonitrile.  Next, a solution of crude allylic chloride dissolve in 0.9 mL acetonitrile was added 
dropwise to the reaction vessel.  The reaction was stirred for 3 hours at room temperature and 
then the solvent was removed by rotary evaporation at 34°C.  The residue was the dissolve in a 
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20 
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion 
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in 
a flask.  The resulting solution was lyophilized for 3-5 hours.  The resulting residue was then 
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15 
cm) using isopropanol:deionized  H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL 
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: 4 g) as the eluent.  In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions 
were collected.  Typically, fractions 12-18 were collected and the organic solvents were removed 
by rotary evaporation at 34°C.  The resulting solution was then lyophilized to afford 
pyrophosphate (4.11) as a white fluffy solid in 70% yield. 1H NMR (300 MHz, Deuterium Oxide) 
δ 5.40 (s, 1H), 5.11 (d, J = 7.4 Hz, 2H), 4.42 (d, J = 7.6 Hz, 2H), 2.08 – 1.79 (m, 8H), 1.65 (d, J = 
3.9 Hz, 3H), 1.62 (t, J = 3.0 Hz, 3H), 1.52 (d, J = 6.9 Hz, 6H), 1.47 – 1.28 (m, 4H).  31P NMR 
(122 MHz, D2O) δ -10.16, -13.91.  HRMS 409.1548 [M+2H]-, calculated 409.1545 (C17H31O7P2). 
 
(2E,7E)-3,8,12-trimethyltrideca-2,7,11-trien-1-yl diphosphate (4.17): 
Yield (43%).  1H NMR (300 MHz, Deuterium Oxide) δ 5.52 – 5.36 (m, 1H), 5.22 – 5.12 
(m, 1H), 5.09 – 4.98 (m, 1H), 4.44 (d, J = 7.0 Hz, 2H), 1.97 (td, J = 20.7, 19.5, 10.3 Hz, 8H), 1.70 
– 1.52 (m, 12H), 1.36 – 1.28 (m, 2H).  31P NMR (122 MHz, Deuterium Oxide) δ -10.22 (d, J = 
19.5 Hz), -14.05 (d, J = 18.7 Hz).  HRMS 395.1389 [M+2H]-, calculated 395.1389 (C16H29O7P2). 
 
(2E,6E,10E)-3,7,11,14-tetramethylpentadeca-2,6,10,13-tetraen-1-yl diphosphate (4.21):  
Yield (69%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (s, 1H), 5.17 – 4.97 (m, 3H), 
4.43 (s, 2H), 2.66 – 2.51 (m, 2H), 2.02 (d, J = 13.3 Hz, 6H), 1.91 (s, 2H), 1.82 – 1.46 (m, 
15H).31P NMR (122 MHz, Deuterium Oxide) δ -12.73 (d, J = 15.4 Hz), -14.42 (d, J = 12.9 Hz).  
HRMS 435.1705 [M+2H]-, calculated 435.1702 (C19H33O7P2). 
 
(2E,6E)-3,7,12-trimethyltrideca-2,6,11-trien-1-yl diphosphate (4.28): 
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Yield (73%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.40 (s, 1H), 5.13 (d, J = 12.2 Hz, 
2H), 4.41 (s, 2H), 2.08 (d, J = 12.2 Hz, 2H), 2.07 – 2.01 (m, 2H), 1.91 (q, J = 8.8, 7.5 Hz, 4H), 
1.67 (s, 3H), 1.63 (d, J = 7.5 Hz, 3H), 1.55 (s, 6H), 1.37 (dd, J = 14.8, 7.4 Hz, 2H).  31P NMR 
(202 MHz, Deuterium Oxide) δ -10.19 (d, J = 20.9 Hz), -13.99 (d, J = 22.1 Hz).  HRMS 
395.1389 [M+2H]-, calculated 395.1389 (C16H29O7P2). 
 
(2E,6E)-3,7,13-trimethyltetradeca-2,6,12-trien-1-yl diphosphate (4.40a): 
Yield (60%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.38 (s, 1H), 5.08 (d, J = 7.3 Hz, 
2H), 4.40 (s, 2H), 2.04 (s, 2H), 1.97 (s, 2H), 1.90 (s, 4H), 1.66 (d, J = 12.4 Hz, 3H), 1.59 (d, J = 
5.9 Hz, 3H), 1.51 (d, J = 8.8 Hz, 6H), 1.22 (s, 4H).  31P NMR (202 MHz, Deuterium Oxide) δ -
9.86 (d, J = 14.3 Hz), -13.78 (d, J = 12.2 Hz).  HRMS 409.1543 [M+2H]-, calculated 409.1545 
(C17H31O7P2). 
 
(2E,6E)-3,7,14-trimethylpentadeca-2,6,13-trien-1-yl diphosphate (4.40b): 
Yield (59%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.40 (s, 1H), 5.10 (s, 2H), 4.42 (s, 
2H), 2.07 (s, 2H), 1.99 (s, 2H), 1.91 (s, 4H), 1.64 – 1.57 (m, 12H), 1.26 – 1.17 (m, 6H).  31P NMR 
(202 MHz, Deuterium Oxide) δ -9.93 (d, J = 37.6 Hz), -13.92 (d, J = 23.5 Hz).  HRMS 423.1705 
[M+2H]-, calculated 423.1702 (C18H33O7P2). 
 
(2E,6E)-3,7,15-trimethylhexadeca-2,6,14-trien-1-yl diphosphate (4.40c): 
Yield (94%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.37 (d, J = 8.6 Hz, 1H), 5.05 
(dd, J = 13.0, 6.5 Hz, 2H), 4.40 (s, 2H), 1.93 (d, J = 29.2 Hz, 8H), 1.66 (s, 3H), 1.60 (s, 3H), 1.54 
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(s, 3H), 1.52 (s, 3H), 1.25 (s, 8H).  31P NMR (202 MHz, Deuterium Oxide) δ -9.81 (d, J = 15.6 
Hz), -13.66 (d, J = 13.2 Hz).  HRMS 437.1866 [M+2H]-, calculated 437.1858 (C19H35O7P2). 
 
(3E,7E,11E)-4,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-yl diphosphate (4.32): 
To an oven-dried round bottom flask equipped with a magnetic stir bar were added 
methanesulfonyl chloride (1.3 eq, 0.14 mmol), DMAP (1.5 eq, 0.16 mmol) and 0.6 mL of 
dichloromethane.  The mixture was cooled to 0°C and a solution of alcohol 4.31 in 0.2 mL of 
dichloromethane was added dropwise to the reaction vessel and allowed to stir for 3 hours.  
Hexanes were then added to the reaction vessel and the solution was filtered and concentrated.  
Next, Et2O was added to the crude product and was again filtered and concentrated.  The crude 
allylic chloride was then converted to pyrophosphate 4.32 following the same method described 
for 4.11.  Yield (71%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.06 (ddt, J = 26.0, 13.5, 7.3 
Hz, 4H), 3.82 (d, J = 7.3 Hz, 2H), 2.33 (t, J = 9.8 Hz, 2H), 2.18 – 1.82 (m, 12H), 1.61 (s, 3H), 
1.59 (s, 3H), 1.53 (s, 3H), 1.51 (s, 6H).  31P NMR (202 MHz, Deuterium Oxide) δ -12.10 (d, J = 
16.2 Hz), -14.13 (d, J = 19.0 Hz).  HRMS 463.2017 [M+2H]-, calculated 463.2015 (C21H37O7P2). 
 
General procedure for in vitro biochemical substrate screening:   
All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s 
laboratory at the University of Michigan by Elia Wright.  Preliminary evaluation of all 
pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansyl-
GCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO pH 7.8, 5 mM 
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).  
Protein prenylation was determined by monitoring the dansylated peptide using a continuous 
spectrofluorometic assay and all assays were performed in triplicate.  Upon prenylation of the 
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peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group 
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader.  Peptide in assay buffer was 
utilized as a negative control and the baseline fluorescence of the peptide was subtracted from the 
reaction signal. 
 
General procedure for in vitro GGTase-I inhibitor screening:   
The same assay as described above was used with the exception that 1 or 5 µM of GGPP 
















CHAPTER 5.   SYNTHESIS & BIOCHEMICAL EVALUATION OF ALKYNYL-TAGGED 
GERANYLGERANYL PYROPHOSPHATE ANALOGS 
 
5.1    Introduction 
 
Our laboratory has successfully utilized several alkynyl-FPP analogs as chemical tools to 
identify farnesylated proteins in cells (Figure 5.1A).31, 137  These alkynyl substrates can be used 
not only to identify farnesylated proteins, but also as a method to evaluate the analog-induced 
protein selectivity in cells through proteomic studies.137  While much work has been done to 
understand the reaction mechanisms of PTases, a great deal remains unknown about their in vivo 
function.138  The proteome is believed to be 100-1000 fold more complex than the genome, which 
predicts ~30,000 genes.  Thus, identification of prenylated proteins is difficult and the total 
number of prenylated proteins remains unknown. There are several techniques available to 
confirm prenylation of cellular proteins.139, 140  Unfortunately, these methods suffer from a 
number of setbacks such as the need for large samples and heavy sample modification.  The 
greatest pitfall of these methods is that they do not provide researchers with information about the 
modification of individual proteins.  An approach that can afford direct identification of a 
protein’s modification is radio-labeling proteins by incorporation of tritiated mevalonate or 
tritiated alcohols.140, 141  However, this approach is not readily adaptable to purification and MS 
analysis.  Another setback is that tritium is a weak emitter resulting in extremely slow detection 
via autoradiography (3 weeks – 2 months).140, 141  Therefore, a more direct and high throughput 
method would aid in uncovering the proteome’s mysteries. 
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To avoid these dilemmas, our laboratory has developed a “tagging-via-substrate” method 
that attempts to determine the extent of protein farnesylation in vivo.  This involves exposing the 
cells to an alkynyl-based FPP substrate that can be subsequently tagged with azido-biotin via 
click chemistry.78, 115, 137, 142   The biotinylated proteins can then be detected and identified via 
mass spectroscopy and western blotting (Figure 5.1C).  Click chemistry has many advantages 
such as being able to take place in aqueous media (e.g. the cell lysate) and it needs only mild 
reducing conditions in the presence of catalytic Cu(I).  These alkynyl-FPP analogs have provided 
us with valuable information about what proteins can be farnesylated and have proven to be 
valuable biochemical tools.  This tagging-via-substrate method combined with MS analysis 
technique was developed and greatly refined in or laboratory by Dr. Jiao Song. By using these 
alkynyl-FPP analogs, Dr. Song was able to identify over 190 farnesylated proteins which is by far 
the most extensive list to date.  
Thus, if the alkynyl-GGPP analogs show similar biochemical profiles to their FPP 
counterparts, then we would be able to develop chemical tools analogous to our in vivo FPP-tags 
(Figure 5.1B).  Therefore, we envisioned a similar alkynyl-based-tagging approach for 
geranylgeranylated proteins.  To better understand how the alkynyl-GGPP analogs might bind to 
GGTase-I, we overlaid these analogs with GGPP (Figure 5.2).  
The corresponding alcohols of the terminal alkynyl-FPP tags (Figure 5.1B , left) have 
been previously synthesized by Charron et al.; however, the pyrophosphates were not evaluated 
nor were they used in a robust screen such as our laboratory’s.143  While effective in our screens, 
the terminal alkynes were less efficient than the 7-substituted alkynyl-tags of FPP (Figure 5.1A, 
right).137  Therefore, the terminal alkynyl-GGPP tags were synthesized to compare their 
efficiency to the 7-substituted alkynyl-GGPP tags (Figure 5.1B).  Although 7-substituted GGPP 
analogs have been synthesized previously in the Gibbs laboratory and are able to act as substrates 
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of GGTase-I,144 7-substituted alkynyl-analogs had yet to be successfully synthesized and 
investigated.   
The final class of tags to be synthesized is alkynyl-triazoles (Figure 5.1B).  Evidence 
suggests that triazole containing analogs can act as substrates in the PTases (unpublished data).  
As mentioned previously, the ω-isoprene unit of GGPP is oriented nearly perpendicular to the rest 
of the molecule.  Triazoles could prove to be useful linkers in the synthesis of GGPP analogs by 
potentially allowing for the proper orientation of the alkynyl-tail within GGTase.  It is our goal 


















Figure 5.1.  Potential alkynyl pyrophosphate cellular probes for proteomic studies. (A) Currently 
utilized alkynyl FPP analogs as chemical tools to confirm alternative farnesylation in cells. (B) 
Proposed alkynyl GGPP analogs to be synthesized and tested as substrates with GGTase-I. (C) 












Figure 5.2.  Structural overlay of alkynyl-GGPP analogs with GGPP. (A) Compound 5.7 (Cyan) & GGPP (Green).  (B) Compound 5.6 (Magenta) 
& GGPP (Green). (C) Overlay of 5.6, 5.7, & GGPP zoomed in to the terminal isoprene unit. (D) Compound 5.14 (Cyan) &GGPP (Green).  (E) 
Compound 5.11 (Magenta) & GGPP (Green). (F) Overlay of 5.11, 5.14, & GGPP zoomed in to the terminal isoprene unit. (G) Compound 5.25 & 
GGPP. (PDB: 1N4P)
A) B) C) 




5.2    Synthesis of Alkynyl-Tagged Geranylgeranyl Pyrophosphate Analogs 
 
The synthesis of the alkynyl analogs began with the synthesis of the two terminal alkynes 
5.6 and 5.7 according to the procedures of Charron and colleagues.143  Briefly, alcohol 2.2 
underwent a NBS bromination to yield bromide 5.1.  Due to the instability of allylic bromides, 
bromide 5.1 was quickly purified using a very short silica column and used immediately in the 
following steps.  Allylic bromide 5.1 was then subjected to a mild copper catalyzed coupling with 
TMS-acetylene  as described by Bieber et al. to yield the protected product 5.2.145  Although 
reported as a single isomer by Charron et al., in our hands a mixture of the desired SN2 product 
and the SN2’ byproduct was obtained (7.7:2.3) and could not be separated with standard column 
chromatography.  Thus, 5.2 was taken on as a mixture of isomers and underwent THP-
deprotection with PPTS in ethanol followed by TMS-removal with TBAF at 0°C to produce 
alcohol 5.3.  To obtain the second terminal alkyne 5.5, the aforementioned allylic bromide 5.1 
underwent a displacement reaction with the TMS-propyne anion to yield the protected product 
5.4.  Following the same deprotection procedure used for the conversion of 5.2 to 5.3, 5.4 was 
converted in to the free alcohol 5.5.  Allylic alcohols 5.3 and 5.5 were then chlorinated via Corey-
Kim chlorination protocols and converted into pyrophosphates 5.6 and 5.7, respectively, using the 
method developed by Davisson et al.112, 113  
The second set of alkynyl-GGPP analogs to be synthesized was the triazole containing 
analogs 5.11 and 5.14.  To assemble these compounds we relied on the vastly used Cu-modified 
1,3-dipolar Huisgen cycloaddition (“Click” chemistry) between terminal azides and alkynes to 
generate 1,4-disubstituted 1,2,3-triazoles.118  This method has been widely employed in our 
laboratory to generate vast libraries of both GGTase-I and Icmt inhibitors.77, 106, 146  To begin the 
synthesis, previously synthesized iodide 4.26 was “clicked” with either di-alkyne 5.8 or 5.12.  
The triazole products obtained were first deprotected with PPTS to generate the free allylic 
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alcohols and further deprotected with TBAF to acquire the free terminal alkynes 5.10 and 5.13.  
In the past, our laboratory has had difficulties halogenating triazole-containing compounds.  
These difficulties have included low yields due to unwanted halogenations of the triazole-ring.  
Thus, in order to convert the allylic alcohols into pyrophosphates we first made the corresponding 
mesylates of 5.10 and 5.13.  The crude mesylates were used immediately in the 
pyrophosphorylation reaction developed by Davisson et al. to afford analogs 5.11 and 5.14.112, 113 
The synthesis of 7-propargyl GGPP (5.25) was accomplished in a similar manner as 
described by Placzek for the synthesis of 7-propargyl FPP.  First, cyclopropyl methyl ketone 
(5.15) was transformed into homoprenyl iodide 5.16 using the method of Biernacki and 
colleges.31, 147, 148  With 5.16 in hand, we then could utilize a strategy first developed by Wenkert 
et al. and later used in our laboratory for the synthesis of both frame-shifted FPP analogs.134, 149  
This unique transformation is based on the transforming carbon-oxygen bonds into carbon-carbon 
bonds and was previously discussed in Chapter 4 and utilized for the synthesis of the frame-
shifted GGPP analogs.  Compound 5.16 was first alkylated with 5-lithio-2,3-dihydrofuran 
according to the modified procedure discussed in Chapter 4.  Immediately reacting the alkylated 
dihydrofuran with NiCl2(PPH3)2 and MeMgBr afforded homogerianol (5.17) in 61% yield.  
Homogeraniol was then iodinated using standard Appel reaction conditions to generate homo 
allylic iodide 5.18 which underwent a subsequent lithium-halogen exchange in the presence of t-
BuLi.  Following the addition of CuCN to the reaction, organocuprate 5.19 was generated.  
Following a modified procedure of Placzek et al., addition of 5-lithio-2,3-dihydrofuran (4.36) to 
organocupurate 5.19 lead to a 1,2-metalate rearrangement to produce the higher order 
alkenylcuprate 5.20 which was coupled with TMS-propargyl bromide to generated 5.22.31, 150-152  
Homoallylic alcohol 5.22 was then iodinated in the same manner as 5.17 to produce iodide 5.23 
which was then converted into the organborane and coupled with vinyl-iodide 3.14 via a Suzuki 
reaction.120  After removal of the TMS and TBDMS groups with TBAF to generate 5.24, the 
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allylic alcohol was converted into the pyrophosphate (5.25) using the same procedure utilized to 
generate diphosphates 5.6 and 5.7.  It is important to note that only a small quantity of 5.24 was 
obtained; thus, the pyrophosphorylation was performed on a small scale and only a crude 31P 




Scheme 5.1.  Synthesis of terminal alkynyl-GGPP analogs.  (a) NBS, DMS, DCM, -40°C (crude 
purification) (a) i. TMS-acetylene, K2CO3, Na2SO3, Cu(I)I, DMF (27%-2 steps includes 
bromination) (c) i. PPTS, EtOH, 50°C, o/n; ii. TBAF, THF (21%-2 Steps)  (d) i. TMS-propyne, 
n-BuLi, THF, -78°C, 12 hr (49% - 2 steps includes bromination) (e) i. PPTS, EtOH, 50°C, o/n; ii. 





















Scheme 5.2.  Synthesis of triazole-containing alkynyl-GGPP analogs.  (a) NaN3, Na Ascorbate, 
CuSO4×5•H2O, DMF, then 5.6 or 5.9; (b) i. PPTS, EtOH, 50°C, o/n; (c) TBAF, THF; (d) MsCl, 




Scheme 5.3.  Synthesis of 7-propargyl GGPP.  (a) i. MeMgI, Et2O, 0°C, 1 hr; ii. 6M H2SO4(aq), 
30 min, 0°C (68%); (b) t-BuLi, Et2O, -78°C; (c) i. 5.16, THF, -78°C to r.t., 16 hr; ii. NiCl2(PPh3)2, 
MeMgBr, PhH, 75°C (61%); (d) Imidazole, PPh3, I2, 0°C (61%); (e) i. t-BuLi, Et2O, -78°C to 0°C 
then THF; ii) CuCN, Me2S, Et2O, -78°C to 0°C; (f) 4.36; (g) PBu3, Et2O, 5.21, 0°C to r.t.(8%); 
(h) Imidazole, PPh3, I2, 0°C (77%); (i) i. t-BuLi, Et2O, -78°C, ii. β-MeO-9-BBN, THF, -78°C 
warming to r.t, o/n; iii. 3.14, K3PO4, PdCl2(dppf), DMF, 85°C, 18 hr; (j) TBAF, THF, 0°C; (k) i. 









5.3    Biochemical Evaluation of Alkynyl-Tagged Geranylgeranyl Pyrophosphate Analogs 
 
Previously, Dr. Amanda Kryzsiak and Dr. Andrew Placzek of our laboratory synthesized 
a small library of alkynyl-FPP analogs (Figure 5.1A).31, 78, 80  Upon evaluation of these analogs, it 
was determined that these analogs are substrates of FTase and can farnesylate a wide range of 
dansyl-GCaaX peptides.  Dr. Jiao Song then utilized these alkynes in proteomic studies to 
identify ~192 farnesylated proteins via mass spectroscopy.137  
Based on these results, our goal was to synthesize a small library of alkynyl-GGPP 
analogs. These alkynyl analogs (5.6, 5.7, 5.11, 5.14, 5.25; Figure 5.1B) were evaluated for their 
biochemical activity in an in vitro continuous spectrofluorometric assay with GGTase and the co-
substrate CaaX-peptide dansyl-GCVLL.  All biochemical assays were performed in our 
collaborator Dr. Carol Fierke’s laboratory at the University of Michigan by Elia Wright.   
 Of the alkynes tested, only the terminal alkynes 5.7 displayed moderate substrate activity.  
At 1.5 hours with 10 µM analog, we observed 28 ± 0.004% RFI when compared to GGPP 
(Figure 5.3 and 5.4).  Terminal alkyne 5.6 also displayed substrate activity; however, it was a 
weaker substrate than 5.7.  Although analogs 5.11,5.14, and 5.25 do not appear to be substrates 
based on the bar graph in Figure 5.3, an endpoint point analysis indicates that these analogs may 
indeed be substrates, albeit very slow substrates (Figure 5.5).  It is important to note that due to 
small amounts of material, only a very crude 31P NMR could be obtained for 5.25.  Therefore, it 
could be beneficial if this compound is remade, fully characterized, and retested.  The saturated 

















Figure 5.3.  Bar graphs of substrate activity represented in RFI of alkynyl-GGPP analogs versus 
GGPP (+ control) with 5 µM dansyl-GCVLL and 50 nM GGTase-I.  Error bars represent mean ± 






















































































































































































*102 ± 5.8% 
*7.7 ± 0.17% 
*28 ± 0.37% 
*3.8 ± 0.30% 
*8.8 ± 1.6% 



















Figure 5.4.  Monitoring continuous changes in fluorescence of alkynyl-GGPP 
 analogs versus GGPP (+ control) at various concentrations (1 µM, 5µM, & 
10µM) with5 µM dansyl-GCVLL and 50 nM GGTase-I.  Experiments were 




































































Figure 5.5.  Endpoint assay results for slow alkynyl-GGPP analogs with 
5µM dansyl-GCVLL and 50 nM GGTase-I.  Experiments were performed 






5.4    Conclusions 
 
The goal of this chapter was to focus on the synthesis of a small library of alkynyl-GGPP 
analogs to utilize as potential chemical tools to evaluate GGTase-I via proteomics.  Previously, 
our lab synthesized alkynyl- FPP analogs that displayed interesting results in vivo and were later 
used to identify over 190 farnesylated proteins.137  Therefore, our laboratory aimed to expand this 
concept to include analogs that could aid in identifying geranylgeranylated proteins.  
The synthesis of the two terminal alkynes (5.6 and 5.7) was accomplished in accordance 
with the procedures of Charron and colleagues.143  The triazole containing alkynes were quickly 
generated using the previously synthesized intermediate 4.26 and commercially available 
dialkynes.  The triazole-containing analogs had to be pyrophosphorylated via the mesylate to 
avoid unwanted side reactions with NCS and the triazole ring.  The 7-propargyl GGPP analog 
(5.25) was more difficult to accomplish.  The synthesis was carried out in the same manner as 
previously developed by Dr. Andrew Placzek in our laboratory.31  The problematic step in this 
synthesis was the coupling of the vinyl-iodide 3.14, which resulted in very poor yields.  
We have successfully synthesized a small library of alkynyl-GGPP analogs.  Of the 
analogs synthesized, only the terminal alkyne, 5.7, showed moderate substrate activity.  Terminal 
alkyne 5.6 also demonstrated substrate activity, albeit it was a poorer substrate than 5.7.  Again, 
chain length seems to be an important factor.  Although our alkynyl-GGPP analogs did not live 
up to our expectations, it is important to keep in mind that our preliminary biochemical testing 
utilized only one CaaX sequence, dansyl-GCVLL.  It is possible that these analogs are more 
selective chemical tools and although most are weak substrates with dansyl-CVLL, they could 
potentially be strong co-substrates with other CaaX sequences.  In the future, these compounds 
will be tested as inhibitors of GGTase-I.  If no inhibitor activity is detected, an extensive in vitro 
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screening with a large library of dansyl-GCaaX sequences will determine if these analogs are 




5.5    Experimental Procedures Utilized for the Synthesis & Biochemical Evaluation of Alkynyl-
Tagged Geranylgeranyl Pyrophosphate Analogs 
 
General Experimental Procedures:  All reactions were performed with oven-dried or flame-
dried glassware and under dry argon gas.  All commercial reagents and solvents were used 
directly without subsequent purification.  For the organmetallic coupling reactions, anhydrous 
THF was freshly distilled from sodium and benzophenone.  All other anhydrous solvents were 
purchased from Acros Organics as extra dry solvents and were bottled over molecular sieves.  
Reactions were monitored by thin layer chromatography and visualized with one or more of the 
following: UV light, iodine, vanillin solution, potassium permanganate solution, 
dinitrophenylhydrazine solution, and/or phosphomolybdic acid solution.  All products were 
purified using flash chromatography silica gel 60 M purchased from Macherey-Nagel.  All 
reactions involving either triphenyl phosphine or triphenyl phosphine oxide were first dry-loaded 
with sodium sulfated before column purification.  NOTE: *Dry glassware is critical for the 
organometallic reactions in this publication.  This was accomplished by taking oven-dried 
glassware (dried for at least 24 hr and then cooled under argon) and flame drying the round 
bottom flask under vacuum.  The flask was then purged with argon and cooled to room 
temperature.  This process was repeated 3 times to produce a completely water free 
environment.*  **Deoxygenated solvents are extremely crucial for successful organometallic 
reactions in this publication.  In order to achieve completely deoxygenated solutions, the solvent 
was placed in a flame-dried round bottom and under vacuum was sonicated for 30 seconds and 
then purged with argon for 30 seconds.  This process was repeated 3 times to yield completely 
deoxygenated solvents.**  All NMR spectra were taken either on a 300 MHz Bruker ARX300 or 
a 500 MHz Bruker DRX500 spectrometer.  Low-resolution MS (EI/CI) were recorded with a 
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Hewlett Packard Engine and low-resolution MS (ESI) were taken on a Thermoquest LCQ.  All 






To an oven-dried round bottom flask equipped with a magnetic stir bar was added NBS 
(2.0 eq, 2.0 mmol) in 10 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.0 eq, 2.0 
mmol) was added dropwise to the reaction.  Following the addition, the mixture is then placed in 
a 0°C ice bath and stirred for 5 minutes before being recooled back to -30°C.  Next, alcohol 2.2 (1 
eq, 1 mmol) is dissolved in 5 mL of CH2Cl2 and added dropwise to the reaction mixture.  The 
mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room temperature.  
After the allotted time, brine is added to the reaction mixture and the organic layer was extracted.  
The aqueous layer was further extracted 3 × 10 mL CH2Cl2 and the organic layers were 
combined, dried with magnesium sulfate, and concentrated.  The crude reaction product was 
passed through a short plug of silica gel using 5%-10% EtOAc/hexanes as the eluent.  Bromide 
5.1 was used immediately in the next step.  
OH  
(2E,6E,10E)-3,7,11-trimethyltetradeca-2,6,10-trien-13-yn-1-ol (5.3): 
To an oven-dried round bottom flask is added powdered molecular sieves and is cooled 
under argon.  The round bottom was then flamed-dried under vacuum and cooled under argon; 
this process was repeated 3 times.  Next, ethynyltrimethylsilane (3.0 eq, 4 mmol) and 12 mL of 
anhydrous DMF were added to the round bottom flask.  To the round bottom flask was added 
K2CO3 (1.5 eq, 2.7 mmol), Na2SO3 (1.0 eq, 1.33 mmol), bromide 5.1, and Cu(I)I (0.05 eq, 
0.07mmol) sequentially and the reaction was stirred at room temperature for 12 hours.  The 
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reaction was quenched by the addition of 10% NH4Cl, the organic layer was isolated, and the 
aqueous layer was extracted 3 × CH2Cl2 (15 mL).  The organic layers were combined, washed 
with brine, dried with MgSO4, filtered, and concentrated.  The crude reaction product was 
purified by column chromatography using 3% Ethyl Acetate/Hexanes as the mobile phase to 
afford 5.2 in 27% yield (2-steps from 2.2). 
In a scintillation vial equipped with a magnetic stir bar, 5.2 (1.0 eq, 0.47 mmol) was 
dissolved in 5 mL of absolute EtOH and PPTS (0.1 eq, 0.05 mmol) was added to the vial.  The 
reaction mixture was heated to 75°C and stirred for 12 hours.  Next, the reaction was cooled to 
room temperature where it was poured into a separator funnel containing water and Et2O and the 
aqueous layer was extracted 3 × 10 mL Et2O.  The organic layers were combined, washed with 
water then brine, dried with magnesium sulfate, and concentrated.  The crude reaction product 
was then dissolved in 5 mL of THF and cooled to 0°C where TBAF (2.0 eq, 1.0 mmol, 1.0 M in 
THF) was added to the reaction flask.  The reaction was allowed to stir for 3 hours and then 
quenched with 10% NH4Cl(aq).  Next, the organic layer was removed, and the aqueous layer was 
extracted 3 × Et2O (10 mL).  The organic layers are combined, washed with brine, dried with 
MgSO4, filtered, and concentrated. The crude reaction product was purified by column 
chromatography using 20% Ethyl Acetate/Hexanes as the mobile phase to afford alcohol 5.3 in 
21 % yield (7.7:2.3; SN2:SN2’).  
1H NMR (300 MHz, Chloroform-d) δ 5.39 (t, J = 7.0 Hz, 2H), 
5.09 (t, J = 8.4 Hz, 1H), 4.13 (d, J = 6.5 Hz, 2H), 2.93 – 2.80 (m, 2H), 2.14 – 1.91 (m, 10H), 1.77 
(t, J = 1.1 Hz, 1H), 1.66 (d, J = 1.4 Hz, 6H), 1.58 (d, J = 1.4 Hz, 3H). MS (EI) m/z 246; MS (CI) 











An oven-dried round bottom flask equipped with a magnetic stir bar was charged with 1-
(trimethylsilyl)propyne (3.0 eq, 4.2 mmol) dissolved in 5.5 mL of anhydrous THF and cooled to -
78°C.  Next, n-BuLi (2.5 M in hexanes, 3.0 eq, 4.2 mmol) was slowly added to the mixture and 
the reaction was allowed to stir 1.5 hours.  After the allotted time, 5.1 (1.0 eq, 1.4 mmol) in 7 mL 
of THF was added dropwise to the reaction vessel at -78°C.  The reaction was allowed to stir for 
an additional 12 hours after which time the reaction was quenched by the addition of 10% NH4Cl.  
The organic layer was removed, and the aqueous layer was extracted 3 × Et2O (15 mL).  The 
organic layers were combined, washed with brine, dried with MgSO4, filtered, and concentrated.  
The crude reaction product was purified by column chromatography using 5% Ethyl 
Acetate/Hexanes as the mobile phase to afford 5.4 in 49% yield (2-steps from 2.2).  1H NMR 
(300 MHz, CDCl3) δ 5.33 (t, J = 6.4 Hz, 1H), 5.10 (dt, J = 12.8, 6.4 Hz, 2H), 4.60 (t, J = 3.3 Hz, 
1H), 4.29 – 3.41 (m, 4H), 2.33 – 1.90 (m, 11H), 1.79 (ddd, J = 20.6, 12.5, 8.6 Hz, 1H), 1.66 (d, J 
= 5.7 Hz, 4H), 1.62 – 1.42 (m, 11H), 0.14 – 0.00 (m, 9H).  13C NMR (75 MHz, Chloroform-d) δ 
140.44, 135.30, 133.54, 125.67, 124.15, 120.74, 107.57, 97.94, 84.68, 63.81, 62.44, 39.82, 39.79, 




The same procedure was used as in 5.3.  Yield (53%).  1H NMR (300 MHz, CDCl3) δ 
5.40 (td, J = 6.9, 1.1 Hz, 1H), 5.11 (dt, J = 12.5, 6.7 Hz, 2H), 4.13 (d, J = 6.9 Hz, 2H), 2.31 – 1.89 
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(m, 13H), 1.66 (s, 3H), 1.58 (s, 6H). 13C NMR (75 MHz, Chloroform-d) δ 140.04, 135.40, 
133.38, 125.71, 124.09, 123.49, 84.66, 68.53, 59.63, 39.75, 39.73, 38.61, 26.75, 26.48, 17.82, 
16.5, 16.23, 16.01.  MS (EI) m/z 260; MS (CI) m/z 261 [M++H]. 




To a scintillation vial equipped with a magnetic stir bar was added iodide 4.26 (1.0 eq, 
0.5 mmol) and 2.5 mL of DMF.  Next, NaN3 (3 eq, 1.5 mmol), sodium ascorbate (0.5 eq,.25 
mmol), and CuSO4·H2O (0.25 eq, 0.125 mmol) are added sequentially to the vial.  Alkyne 5.8 
(3.6 eq, 1.8 mmol) was then dissolved in 1.3 mL of DMF and added to the vial.  The reaction was 
heated to 70°C and allowed to stir for 36 hours. The reaction was then quenched with 10% NH4Cl 
and the aqueous layer was extracted 3 × EtOAC (10 mL).  The organic layers were combined, 
washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction product was 
purified by column chromatography using 25% Ethyl Acetate/Hexanes as the mobile phase to 
afford 5.9 in 70% yield.  1H NMR (300 MHz, Chloroform-d) δ 7.42 (s, 1H), 5.35 (ddd, J = 7.6, 
6.1, 1.4 Hz, 1H), 5.21 – 5.04 (m, 1H), 4.61 (dd, J = 4.4, 2.7 Hz, 1H), 4.24 (q, J = 6.4 Hz, 3H), 
4.01 (dd, J = 11.9, 7.3 Hz, 1H), 3.88 (ddd, J = 11.2, 7.3, 3.2 Hz, 1H), 3.60 – 3.42 (m, 1H), 2.95 (t, 
J = 7.1 Hz, 3H), 2.62 (td, J = 7.1, 4.1 Hz, 3H), 2.18 – 1.90 (m, 8H), 1.91 – 1.69 (m, 3H), 1.67 (s, 








Deprotection was accomplished using the same procedure as 5.3.  The crude reaction 
product was purified by column chromatography using 50 to 100% Ethyl Acetate/Hexanes as the 
mobile phase to afford 5.10 in 62% yield. 1H NMR (300 MHz, Chloroform-d) δ 7.40 (s, 1H), 5.46 
– 5.35 (m, 1H), 5.10 (t, J = 6.4 Hz, 1H), 4.26 (t, J = 7.0 Hz, 2H), 4.14 (d, J = 6.8 Hz, 2H), 2.93 (t, 
J = 7.1 Hz, 2H), 2.54 (td, J = 7.1, 2.6 Hz, 2H), 2.11 (t, J = 6.6 Hz, 1H), 2.03 (dd, J = 9.4, 6.8 Hz, 
2H), 1.97 (dt, J = 5.2, 3.0 Hz, 4H), 1.65 (s, 2H), 1.61 (s, 6H).  13C NMR (75 MHz, CDCl3) δ 
146.23 (s), 138.90 (s), 133.22 (s), 125.79 (s), 124.11 (s), 121.32 (s), 83.69 (s), 69.28 (s), 59.40 (s), 
49.61 (s), 39.41 (s), 36.22 (s), 28.19 (s), 26.12 (s), 25.09 (s), 18.90 (s), 16.34 (s), 15.95 (s). MS 
(ESI) m/z 302 [M++H]. 
 
(2E,6E)-3,7-dimethyl-10-(4-(prop-2-yn-1-yl)-1H-1,2,3-triazol-1-yl)deca-2,6-dien-1-ol (5.13): 
 Synthesis was accomplished following the same procedures as 5.9 and 5.10 to afford 5.13 
in 15% yield (2-steps).  1H NMR (300 MHz, Chloroform-d) δ 7.44 (s, 1H), 5.49 – 5.23 (m, 1H), 
5.06 (t, J = 6.5 Hz, 1H), 4.26 – 4.16 (m, 2H), 4.08 (d, J = 6.9 Hz, 2H), 3.84 – 3.55 (m, 2H), 2.11 – 
2.01 (m, 3H), 2.01 – 1.87 (m, 6H), 1.59 (d, J = 1.4 Hz, 3H), 1.52 (d, J = 1.5 Hz, 3H).  13C NMR 
(75 MHz, Chloroform-d) δ 143.44, 138.56, 133.07, 125.74, 124.09, 121.67, 80.27, 70.03, 59.18, 







5-iodo-2-methylpent-2-ene (5.16):  
An oven-dried round bottom flask equipped with a magnetic stir bar was charged with 
MeMgI (3.0 M in Et2O, 1.0 eq, 50.5 mmol) and an additional 150 mL of Et2O.  The mixture was 
then cooled to 0°C and cyclopropyl methyl ketone, 5.15,  (1.0 eq, 50.5 mmol) in 25 mL of Et2O 
was added dropwise to the reaction mixture and stirred for 1 hour at room temperature.  After the 
allotted time, 200 mL of 6 M H2SO4(aq) was cooled to 0°C in a beaker.  Next, the reaction mixture 
was very slowly poured into the acidic solution and allowed to stir for 45 minutes.  Next, the 
reaction was poured into a separator funnel and the organic layer was isolated.  The  aqueous 
layer was further extracted 2 × 100 mL Et2O.  The organic layers were combined, washed 2 × 100 
mL of saturated Na2S2O3, washed 1 × brine, dried with magnesium sulfate, and concentrated.  
The crude reaction product was purified by column chromatography 100% hexanes as the mobile 
phase to afford iodide 5.16 in 68% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.07 (tq, J = 7.1, 
5.7, 2.8, 1.4 Hz, 1H), 3.08 (t, J = 7.4 Hz, 2H), 2.69 – 2.36 (m, 2H), 1.68 (s, 3H), 1.59 (s, 3H).  13C 
NMR (75 MHz, Chloroform-d) δ 134.74, 123.26, 32.72, 25.93, 18.18, 6.36. 
   
(E)-4,8-dimethylnona-3,7-dien-1-ol (5.17): 
To an oven-dried round bottom flask is added powdered molecular sieves and is cooled 
under argon.  The round bottom was then flamed-dried under vacuum and cooled under argon; 
this process was repeated 3 times.  Next, 10 mL of anhydrous THF was added to the round 
bottom flask which was sonicated under vacuum for 30 seconds and then the atmosphere was 
replaced with argon for 30 seconds; this process was also repeated 3 times.  Next, 2,3-
dihydrofuran (stored over molecular sieves, 3.0 eq, 51.4 mmol) was added to the reaction vessel 
and the solution was cooled to -78°C where t-BuLi (3.0 eq, 51.4 mmol, 1.7 M in heptanes) was 
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slowly added dropwise over 5 – 10 minutes.  The reaction was stirred at -78°C for 10 minutes 
then placed in a 0°C ice bath and continued to stir for 1 hour.  Next, the reaction mixture was 
cooled back -78°C and 5.16 (1.0 eq, 17.14 mmol) in 7 mL of anhydrous THF (also sonicated as 
described above) was added to the reaction vessel.  The reaction was stirred for 20 hours slowly 
coming to room temperature and then poured into a beaker containing ice-cold 50 mL of 
saturated NH4Cl(aq) and 5 mL of NH4OH.  The mixture was allowed to stir for 20 minutes and 
then extracted with 3 × 50 mL Et2O, the organic layers were combined, washed with brine, dried 
with magnesium sulfate, concentrated (at room temperature), and used immediately in the next 
step.  
 To an oven-dried round bottom flask is added NiCl2(PPh3)2 (0.05 eq, 1.72 mmol) 
dissolved in anhydrous benzene (100 mL).  The round bottom flask was sonicated under vacuum 
for 30 seconds and then the atmosphere was replaced with argon for 30 seconds; this process was 
repeated 3 times.  Next, MeMgBr (3.0 M in Et2O, 2.9 eq, 99.4 mmol) was added slowly to the Ni-
catalyst solution and stirred for 30 minutes at room temperature.  Next, a solution of the newly 
alkylated-furan (1.0 eq, 17.14 mmol) was dissolved in benzene (50 mL) and deoxygenated by 
sonication as previously described.  After deoxygenation, the alkylated-furan solution was added 
slowly to the Ni-catalyst solution and the reaction was refluxed at 80°C for 12 hours.  The 
reaction is then cooled to room temperature and poured into a beaker containing 500 mL of 
saturated NH4Cl(aq) and 150 mL of Et2O.  The organic layer was isolated and the aqueous layer 
was extracted 3 × Et2O (50 mL).  The organic layers were pooled together, washed with brine, 
dried with MgSO4, filtered, and concentrated.  Purification by flash chromatography using 20% 
EtOAc/hexanes as the eluent afford 5.17 in 61% yield.  1H NMR (300 MHz, Chloroform-d) δ 
5.30 – 4.95 (m, 2H), 3.57 (p, J = 5.9, 4.8 Hz, 2H), 2.41 – 2.19 (m, 2H), 2.02 (tq, J = 10.4, 6.7, 5.3 
Hz, 4H), 1.73 (s, 1H), 1.64 (d, J = 1.5 Hz, 3H), 1.60 (d, J = 1.3 Hz, 3H), 1.56 (d, J = 1.3 Hz, 3H).  
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13C NMR (75 MHz, Chloroform-d) δ 138.91, 131.81, 124.30, 120.07, 62.50, 39.96, 31.63, 26.71, 




To a round bottom flask was added 5.17 (1 eq, 18.34mmol), PPh3 (1.3 eq, 23.84 mmol) 
and imidazole (1.7 eq, 31.17 mmol) dissolved in dichloromethane (70mL).  Next, the solution 
was cooled to 0°C with and ice-bath and I2 (1.3 eq, 23.84 mmol) was added to the reaction flask.  
The reaction was allowed to stir 0.5 hour at 0°C then allowed to warm to room temperature and 
stirred for an additional 1.5 hour.  Upon completion of the reaction, 10% Na2S2O3 was added to 
the flask and stirred for 20 minutes.  The organic layer was isolated and the aqueous layer was 
extracted 3 × DCM (50 mL).  The organic layers were pooled together, washed with brine, dried 
with MgSO4, filtered and concentrated.  Purification by flash chromatography using hexanes as 
the eluent afforded 5.18 in 81% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.08 (ddq, J = 8.5, 
5.4, 1.4 Hz, 2H), 3.09 (t, J = 7.4 Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 2.16 – 1.82 (m, 4H), 1.66 (s, 
3H), 1.58 (s, 6H).  13C NMR (75 MHz, Chloroform-d) δ 138.20, 131.66, 124.21, 123.14, 39.79, 
32.57, 26.62, 25.92, 17.92, 16.47, 6.25. 
 
(3Z,7E)-8,12-dimethyl-4-(3-(trimethylsilyl)prop-2-yn-1-yl)trideca-3,7,11-trien-1-ol (5.22): 
To an oven-dried round bottom flask was added powdered molecular sieves and is cooled 
under argon.  The round bottom was then flamed-dried under vacuum and cooled under argon; 
this process was repeated 3 times.  Next, iodide 5.19 (1.0 eq, 7.29 mmol) and 11 mL of anhydrous 
Et2O was added to the round bottom flask which was sonicated under vacuum for 30 seconds and 
then the atomosphere was replaced with argon for 30 seconds; this process was also repeated 3 
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times.  The solution was cooled to -78°C and t-BuLi (1.7 M in heptanes, 2.2 eq, 16 mmol) was 
added dropwise to the reaction mixture over a period of 5-10 minutes.  The solution was allowed 
to stir for 30 minutes at -78°C and for 1 hour at 0°C.  Next, THF (1.1 mL) was added to the 
reaction and it continued to stir for 1 hour at room temperature. 
In a second oven-dried round bottom flask was added powdered molecular sieves and is 
cooled under argon.  The round bottom was charged with CuCN (0.5 eq, 3.65 mmol) then flamed-
dried under vacuum and cooled under argon; this process was repeated 3 times.  Next, 7.3 mL of 
Et2O followed by dimethyl sulfide (9.1 mL) were added to the round bottom flask and sonicated 
as previously described.  The mixture was cooled to -78°C and the organo-lithium solution of 
5.19 was added dropwise.  The mixture was stirred for 15 minutes at -78°C and then 30 minutes 
at 0°C to furnish the corresponding organocuprate.  
To a third oven-dried round bottom flask was added powdered molecular sieves and is 
cooled under argon.  This flask was also flame-dried as described previously and then was 
charged with 2,3-dihydrofuran (1.0 eq, 7.3 mmol) and 1.5 mL of THF and sonicated a described 
above.  The solution was then cooled to -78°C and t-BuLi (1.7 M in heptanes, 1.0 eq, 7.3 mmol) 
was added dropwise over a 5-10 minute period.  The solution was then warmed to 0°C and stirred 
for 45 minutes.  After the allotted time, Et2O (6.7 mL) was added to dilute the organo-lithium 
solution which was then slowly added to the organocuprate solution at -78°C.  The reaction was 
stirred at this temperature for 15 minutes and then placed in a 0°C ice bath and allowed to slowly 
warm to room temperature over 16 hours.  Next, the mixture was cooled back down to 0°C and 
PBu3 (0.55 eq, 4.0 mmol) was added to the round bottom flask and stirred for 15 minutes.  
Following this addition, 5.19 (1.5 eq, 10.9 mmol) dissolved in 19 mL of Et2O and added to the 
reaction mixture which was allowed to warm to room temperature and stirred for 3 hours.  The 
reaction was quenched by the addition of 10% NH4Cl and the organic layer was isolated.  The 
aqueous layer was extracted 3 × Et2O (40 mL), the organic layers were combined, washed with 
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brine, dried with MgSO4, filtered, and concentrated.  The crude reaction product was purified by 
column chromatography using 20% Ethyl Acetate/Hexanes as the mobile phase to afford 5.20 in 
19% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.21 (t, J = 7.5 Hz, 1H), 5.16 – 4.96 (m, 2H), 
3.62 (t, J = 6.3 Hz, 2H), 2.98 (s, 2H), 2.30 (q, J = 6.6 Hz, 2H), 2.22 – 1.84 (m, 8H), 1.65 (s, 3H), 
1.58 (s, 6H), 0.11 (s, 9H).  13C NMR (75 MHz, Chloroform-d) δ 137.78, 135.68, 131.54, 124.49, 





 The synthesis or 5.21 was achieved using the same procedure utilized for 5.18.  The 
crude reaction product was purified by column chromatography using 0.5 to 1.0% Ethyl 
Acetate/Hexanes as the mobile phase to afford alcohol 5.21 in 77% yield.  1H NMR (300 MHz, 
Chloroform-d) δ 5.17 (t, J = 7.2 Hz, 1H), 5.14 – 5.03 (m, 2H), 3.12 (t, J = 7.4 Hz, 2H), 2.95 (s, 
2H), 2.61 (q, J = 7.3 Hz, 2H), 2.19 – 2.09 (m, 4H), 2.10 – 1.86 (m, 4H), 1.66 (s, 3H), 1.58 (d, J = 
2.1 Hz, 6H), 0.12 (s, 9H).  13C NMR (75 MHz, Chloroform-d) δ 137.09, 135.64, 131.52, 125.18, 




An oven-dried round-bottom flask containing powdered molecular sieves was charged 
with 5.16 (stored over sieves; 1.5 eq, 1.1 mmol) which was dissolved in 3.6 mL of anhydrous 
Et2O and cooled to -78°C.  Next, t-BuLi (1.7M in pentane; 3.0 eq, 1.64 mmol) was slowly added 
to the reaction flask and stirred for 1 hour at -78°C.  Afterward, β-MeO-9-BBN (1.0M in 
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Hexanes; 3.8 eq, 2.07 mmol) was slowly added to the reaction vessel and the mixture was stirred 
for 16 hours slowly warming to room temperature.   
In a scintillation vial, 3.14 (1.0 eq, 0.72 mmol) and Pd(dppf)Cl2 (0.3 eq, 0.22 mmol) are 
dissolved in 2.8 mL of DMF.  Next, K3PO4 (3.0 eq, 2.16 mmol) is added to the vial and after 
deoxygenating the solvent, the vinyl-iodide solution is added to the round-bottom flask 
containing the newly formed organoborane. The reaction mixture is allowed to stir for an 
additional 16 hours at 85°C after which it is poured into a separatory funnel containing water and 
Et2O and the aqueous layer was extracted 3 ×  20 mL Et2O.  The organic layers were combined 
and washed with water then brine, dried with magnesium sulfate, and concentrated.  The crude 
reaction product was run through a silica column (20% EtOAc/Hexanes) to remove most of the 
impurities and any oxidizing species.  
In a scintillation vial, the semi-crude product was dissolved in 5.0 mL of THF, cooled to 
0°C, and TBAF (4.9 eq, 3.5 mmol, 1.0 M in THF) was added to the vial. The reaction was 
allowed to stir for 4 hours and then quenched with 10% NH4Cl(aq).  Next, the organic layer was 
removed, and the aqueous layer was extracted 3 × Et2O (10 mL).  The organic layers are 
combined, washed with brine, dried with MgSO4, filtered, and concentrated. The crude reaction 
product was purified by column chromatography using 20% Ethyl Acetate/Hexanes as the mobile 
phase to afford alcohol 5.22 in 6% yield.  1H NMR (300 MHz, Chloroform-d) δ 5.49 – 5.40 (m, 
1H), 5.22 (t, J = 6.7 Hz, 1H), 5.18 – 4.98 (m, 2H), 4.15 (d, J = 7.0 Hz, 2H), 2.93 (d, J = 2.8 Hz, 
2H), 2.28 – 1.87 (m, 13H), 1.68 (s, 6H), 1.60 (s, 6H).  13C NMR (75 MHz, Chloroform-d) δ 
139.44, 135.47, 134.23, 131.48, 126.12, 124.46, 123.94, 123.85, 82.56, 68.34, 59.51, 39.85, 
39.39, 36.83, 26.87, 26.65, 26.36, 25.86, 19.84, 17.84, 16.46, 16.20. MS (EI) m/z 296 [M+-H2O]; 





Representative procedure for the synthesis of non-triazole containing pyrophosphates: 
 
(2E,6E,10E)-3,7,11-trimethylpentadeca-2,6,10-trien-14-yn-1-yl diphosphate (5.7): 
 To an oven-dried round bottom flask equipped with a magnetic stir bar was added NCS 
(2.5 eq, 0.24 mmol) in 0.5 mL of CH2Cl2 and cooled to -30°C where dimethyl sulfide (2.5 eq, 
0.24 mmol) was added dropwise to the reaction.  Following the addition, the mixture is then 
placed in a 0°C ice bath and stirred for 5 minutes before being recooled back to -30°C.  Next, 
alcohol 5.5 (1 eq, 0.096 mmol) is dissolved in 0.2 mL CH2Cl2 and added dropwise to the reaction 
mixture.  The mixture is then placed in a 0°C ice bath and stirred for 2.5 hours coming to room 
temperature.  After the allotted time, brine is added to the reaction mixture and the organic layer 
was extracted.  The aqueous layer was further extracted 3 × 5 mL CH2Cl2 and the organic layers 
were combined, dried with magnesium sulfate, and concentrated.  The crude reaction product was 
used immediately in the following step.  
To another oven-dried round bottom flask equipped with a magnetic stir bar was added 
tris (tetrabutylammonium) hydrogen pyrophosphate (3.0eq, 0.29 mmol) dissolved in 1.3 mL of 
acetonitrile.  Next, a solution of crude allylic chloride dissolve in 0.9 mL acetonitrile was added 
dropwise to the reaction vessel.  The reaction was stirred for 3 hours at room temperature and 
then the solvent was removed by rotary evaporation at 34°C.  The residue was the dissolve in a 
minimal amount of ion exchange NH3HCO3 buffer (700mg NH3HCO3, 1 L of deionized H2O, 20 
mL of isopropanol) and the resulting solution was passed through a Dowex AG 50 × 8 ion 
exchange column (2 × 8 cm) using the NH3HCO3 buffer as an eluent and 25 mL was collected in 
a flask.  The resulting solution was lyophilized for 3-5 hours.  The resulting residue was then 
redissolved in deionized watered and purified by cellulose flash column chromatography (3 × 15 
cm) using isopropanol:deionized  H2O:acetonitrile: NH3HCO3 buffer (500 mL : 250 mL : 250 mL 
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: 4 g) as the eluent.  In a beaker was collected 40 mL of eluent, then twenty-four 2.5 mL fractions 
were collected.  Typically, fractions 12-18 were collected and the organic solvents were removed 
by rotary evaporation at 34°C.  The resulting solution was then lyophilized to afford 
pyrophosphate (5.6) as a white fluffy solid in 84% yield. 1H NMR (500 MHz, Deuterium Oxide) 
δ 5.39 (s, 1H), 5.13 (d, J = 6.3 Hz, 2H), 4.41 (s, 2H), 2.33 – 1.98 (m, 12H), 1.95 (d, J = 6.1 Hz, 
1H), 1.66 (s, 3H), 1.56 (s, 6H).  31P NMR (202 MHz, D2O) δ -9.89, -13.73.  HRMS 419.1391 
[M+2H]-, calculated 419.1389 (C18H29O7P2). 
 
(2E,6E,10E)-3,7,11-trimethyltetradeca-2,6,10-trien-13-yn-1-yl diphosphate (5.6): 
Yield (91%).  1H NMR (500 MHz, Deuterium Oxide) δ 5.41 (s, 2H), 5.15 (s, 1H), 4.43 (s, 
2H), 2.26 – 1.84 (m, 10H), 1.73 (s, 1H), 1.66 (s, 3H), 1.62 (s, 3H), 1.57 (s, 3H).  31P NMR (202 
MHz, Deuterium Oxide) δ -10.08 (d, J = 37.0 Hz), -13.92 (d, J = 40.4 Hz).  HRMS 405.1237 

















To an oven-dried round bottom flask equipped with a magnetic stir bar was added 
methanesulfonyl chloride (1.3 eq, 0.15 mmol), DMAP (1.5 eq, 0.17 mmol) and 0.6 mL of 
dichloromethane.  The mixture was cooled to 0°C and a solution of alcohol 5.10 in 0.2 mL of 
dichloromethane was added dropwise to the reaction vessel and allowed to stir for 2.5 hours.  
Hexanes were then added to the reaction vessel and the solution was filtered and concentrated.  
Next, Et2O was added to the crude product and was again filtered and concentrated.  The crude 
allylic chloride was then converted to the pyrophosphate following the same method described 
for 5.6. Yield (80%). 1H NMR (500 MHz, Deuterium Oxide) δ 7.79 (s, 1H), 5.39 (d, J = 6.9 Hz, 
1H), 5.06 (s, 1H), 4.41 (t, J = 6.3 Hz, 2H), 4.29 (t, J = 6.3 Hz, 2H), 2.85 (t, J = 6.8 Hz, 2H), 2.58 
– 2.46 (m, 2H), 2.28 (s, 1H), 2.04 (dd, J = 12.9, 5.8 Hz, 4H), 1.99 – 1.93 (m, 2H), 1.90 (d, J = 6.5 
Hz, 2H), 1.66 (s, 3H), 1.51 (s, 3H).  31P NMR (202 MHz, Deuterium Oxide) δ -10.07 (d, J = 21.3 




 Yield (73%). 1H NMR (500 MHz, Deuterium Oxide) δ 7.84 (s, 1H), 5.41 (t, J = 6.7 Hz, 
1H), 5.07 (t, J = 6.8 Hz, 1H), 4.43 (t, J = 6.1 Hz, 2H), 4.32 (td, J = 6.7, 2.4 Hz, 2H), 3.65 (t, 1H), 
2.11 – 2.02 (m, 4H), 2.01 – 1.87 (m, 4H), 1.67 (s, 3H), 1.52 (s, 3H).  31P NMR (202 MHz, 
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Deuterium Oxide) δ -13.07 (d, J = 16.7 Hz), -14.29 (d, J = 17.3 Hz).  HRMS 446.1250 [M+2H]-, 
calculated 446.1246 (C17H27N3O7P2). 
 
General procedure for in vitro biochemical substrate screening:   
All biochemical evaluations were performed in our collaborator Dr. Carol Fierke’s 
laboratory at the University of Michigan by Elia Wright.  Preliminary evaluation of all 
pyrophosphate analogs were performed using GGPP analog (1, 5, or 10 µM), the peptide dansyl-
GCVLL (5 µM), recombinant mammalian GGTase-I (50 nM), 50 nM HEPPSO pH 7.8, 5 mM 
tris(2carboxyethyl)phosphine (TCEP), and 5 mM MgCl2 at 25°C in 96 well plates (Corning).  
Protein prenylation was determined by monitoring the dansylated peptide using a continuous 
spectrofluorometic assay and all assays were performed in triplicate.  Upon prenylation of the 
peptide, the activity was measured by an increase in fluorescence intensity of the dansyl group 
(λex = 340 nm, λem = 520 nm) in a POLARstar Galaxy plate reader.  Peptide in assay buffer was 




CHAPTER 6.   CONCLUSIONS & FUTURE DIRECTONS  
 
This work served as a preliminary study of the isoprene requirements and their effect on 
GGTase-I activity.  Several small libraries of aryl-modified, saturated, frame-shifted, and 
alkynyl-GGPP compounds were synthesized and evaluated as co-substrates with dansyl-GCVLL 
in a fluorescence-based assay.  Interestingly, the majority of our compounds displayed in vitro 
biochemical activity and provided us with interesting insights into GGTase-I binding (Figure 
6.1). 
 
6.1    Aryl-Modified GGPP Analogs 
 
Replacing the ω-isoprene unit with an aryl motif was well tolerated by the enzyme; 
however, the number of methylene spacers between the aryl group and the γ-isoprene unit was 
important.    When the number of methylene spacers was two, this yielded compounds that had 
substrate activity comparable to GGPP (2.6a, d, f; Figure 2.6).  The longer carbon chain allows 
the aryl-moiety to be positioned in a more spacious area of the exit grove (Figure 6.3, yellow).  
When the number of methylene spacers were decreased by one, there was diminished substrate 
activity, although these compounds still retained some ability to be turned over by the GGTase-I.  
One possible reason for the observations noticed with the shorter chain analogs (2.6b-d) could be 
that the aryl-analogs bind in such a way that the pyrophosphate head group is further away from 
the Zn2+ ion (i.e. bound deeper within the pocket).  Therefore, coordination to the zinc ion would 
be attenuated and in return the catalytic ability of the enzyme to transfer the isoprenoid chain 
would be diminished (Figure 6.2 & 6.4A).  
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Additionally, the aryl-group of the shorter chained analog (2.6b) is less flexible and 
modeling in the exit grove indicates a potential unfavorable interaction (Figure 6.3).  Due to the 
sp2 carbons being more electronegative than the hydrogen atoms, the benzene ring exhibits a 
negative potential on the pi face.  This could result in an unfavorable interaction with the 
electrons of the carbonyl backbone group of the neighboring P317β.  Alternatively, aligning the 
aryl-moiety of 2.6b (Figure 6.3, purple) with the ω-isoprene of GGPP (Figure 6.3, green) 
indicates that in this position the steric bulk of the aryl-motif would potentially be too great to fit 
into the narrow exit groove.  In order to alleviate these issues, the aryl-motif of 2.6b could rotate 
into an alternative pocket of the exit grove which would allow the analog to adopt a more 
extended conformation into a different pocket of the exit grove which may or may not affect 
product release (Figure 6.3, dashed circle). 
Surprisingly, the cyclohexyl analog (2.6c) also displayed substrate activity; in fact, it 
appeared to be a more efficient substrate than its aryl-counterpart (2.6b).  This led us to question 
whether or not the aryl-motif is beneficial or if it is simply a matter of hydrophobicity.  An 
alternative explanation could lie in the differences in flexibility between the two motifs and the 
product release of the prenylated protein.  In order for the product to be released from the 
enzyme, the isoprenoid group must rotate into an exit grove of the enzyme followed by the biding 
of a new molecule of the pyrophosphate analog.  The cyclohexyl motif is a much more flexible 
group; thus, it could be speculated that as the isoprenoid chain is shifting into the exit grove, the 
more flexible cyclohexyl group is able to undergo conformational changes in order to allow the 
isoprenoid shift to occur more efficiently (Figure 6.3, red).  The aryl-motif, which is a more rigid 
structure, could potentially hinder the ability of the isoprenoid chain to undergo this 
conformational shift into the exit grove.   
Another potential benefit of the cyclohexyl group of 2.6c is lack of aromaticity when the 
carbon chain is shorter than GGPP.  This would remove any potential unfavorable electronic 
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interaction between the carbonyl backbone of P317β and the pi face. It would be intriguing to 
synthesize a cyclohexyl-analog that contains two methylene spacers between the cyclic group and 
the γ-isoprene unit to determine if any additional activity could be gained by increasing the length 
of the isoprene chain (Figure 6.1).  In general, the length of the carbon chain seems to greatly 
influence whether or not the aromatic moiety is a beneficial modification.  
 
6.2    Saturated GGPP Analogs 
 
The saturated analogs revealed that GGTase-I can recognize and utilize compounds that 
contain only the α-isoprene unit; however, length of the analog has a significant effect upon 
substrate activity.  Generally, compounds that are the same length as GGPP display the greatest 
amount of substrate activity.  The attenuated activity of the shorter analogs could be due to the 
position of the isoprene in the binding pocket (Figure 6.4).  One possibility is that the carbon 
chain binds in the pocket in such a way that the carbon adjacent to the pyrophosphate head group 
is further away from the Zn2+ ion (Figure 6.4A, yellow) which could diminish catalysis.   
Analogs containing only the α-isoprene unit (3.3a-c) revealed that only α-isoprene is 
required for enzyme recognition and catalysis; however, only moderate substrate activity was 
observed.  Possible explanations for this observation include: 1) loss of potential pi interactions 
between the β, γ, and ω-isoprene units with aromatic groups aligning the binding pocket and/or 2) 
effects of changing hydrophobicity on the dansyl-fluorophore.  By taking a closer look at the 
binding pocket of GGTase-I, it is possible that the β and γ-isoprene units could interact with 
W275β via pi-pi interactions (Figure 6.4C).  Additionally, the γ and ω-isoprene units have the 
potential to have pi-pi interactions with Y176β and the ω-isoprene unit could have additional pi-
pi interactions with F52β, F53β, Y126β, W275β, and F324β.  Therefore, the lack of these 
interactions may result in the observed decrease in enzymatic catalysis by potentially lowering 
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the affinity of the enzyme for the saturated analogs.  On the other hand, the observation could be 
due to the nature of the pyrophosphate analogs.  The substrate assays were developed for the use 
of an isoprenoid chain with a dansyl-fluorophore.  Increasing the hydrophobic environment 
around the dansyl-fluorophore with an isoprenoid chain leads to an increase in fluorescence 
which can be easily measured.  This begs the question of whether or not the fluorescence 
change/intensity will be the same between a saturated analog and GGPP.  Thus, further studies 
need to done to address this issue and any definitive conclusions cannot be made until such 
experiments have been conducted.  One possible method is to use HPLC analyses which would 
allow us to quantify the amount of unprenylated peptide versus prenylated product which could 
then be related back to the change in fluorescence observed.   
The saturated analogs also revealed that incorporation of the ω-isoprene unit is very 
beneficial for substrate activity, but only when the carbon chain is the length of GGPP.  This 
modification yields a compound (3.16b) that was comparable to GGPP and indicated that the β- 
and γ- isoprene units are not essential for GGTase-I recognition and turn over.  However, by 
decreasing the length of the carbon chain by one (3.16a) resulted in a drastic decrease in enzyme 
activity.   Once again, this could potentially be due to pi-pi interactions.  As mentioned 
previously, the ω-isoprene unit has the potential to have pi-pi interactions with F52β, F53β, 
Y126β, Y176β, W275β, and F324β (Figure 6.4C).  By decreasing the carbon length by one 
methylene unit, this increases the distance between the ω-isoprene unit and four of the aromatic 
residues lining the binding pocket (F52β, F53β, Y126β, and F324β) (Figure 6.4B).  Therefore, 
the decrease in or lose of pi-pi interactions could account for the observed decrease in enzymatic 
activity.   
Interestingly, replacing the β-isoprene has little effect on substrate activity when the 
carbon chain is the length of GGPP.  Instead, the replacement of the β-isoprene has the most 
pronounced effect on compounds that are lacking in length.  As mentioned previously, the 
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attenuated activity of the shorter analogs could be due to the position of the isoprene in the 
binding pocket (Figure 6.2 & 6.4A).  Without the β-isoprene unit, perhaps it is more likely that 
the carbon chain binds in the pocket in such a way that the carbon adjacent to the pyrophosphate 
head group is further away from the Zn2+ ion (Figure 6.4A, yellow) which could diminish 
catalytic ability.  However, by reintroducing the β-isoprene unit back into the molecule, this could 
provide an additional pi-pi interaction between the β-isoprene unit and W275β (Figure 6.4C). 
Therefore, instead of binding deep in the pocket (Figure 6.3A, yellow) where the pyrophosphate 
group is further away from the Zn2+ ion, perhaps the added pi-pi interaction aids in the analogs 
binding in the correct orientation (i.e. the pyrophosphate head group is near the Zn2+).  Thus, for 
analogs which shorter carbons chains, this modification would be beneficial.  
 
6.3    Frame-Shifted GGPP Analogs 
 
The majority of the compounds in our frame-shifted GGPP library were determined to 
display substrate activity.  The information gained from these results can be helpful when 
designing new analogs.  Once again, the length of the carbon chain appears to be a major factor in 
determining substrate ability.  As mentioned previously, this is most likely due to the ω-isoprene 
unit having pi-pi interactions with F52β, F53β, Y126β, Y176β, W275β, and F324β (Figure 
6.4C).  Interestingly, compounds 1,2,2,1-OPP and 5,2,1-OPP have similar substrate abilities 
indicated that chain length is more important than flexibility.  It is possible that both molecules 
bind to the enzyme as shown in Figure 6.4B.  Both analogs increase the distance between the ω-
isoprene unit and four of the aromatic residues lining the binding pocket (F52β, F53β, Y126β, 
and F324β) (Figure 6.4B).  Therefore, the decrease in or lose of pi-pi interactions could account 
for the observed decrease in enzymatic activity and similar activities. 
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Additionally, increasing the number of methylene spacers between the α- and β- isoprene 
units from two to three seems to be very detrimental to substrate ability.  Preliminary docking of 
analogs 2,3,1-OPP (4.17, Figure 6.5B) and 3,3,1-OPP (4.11, Figure 6.5C) indicates that this 
modification could lead to potential unwanted steric interactions with C177β and C225β (Figure 
6.5B & 6.5C, dashed circles).  This could potentially explain their poor substrate ability.  By 
reverting back to the two methylene units between the α and β-subunits, analog 3,2,1-OPP (4.28)  
does not appear to have these steric interactions and regains minimal substrate activity (Figure 
6.5A).  It seems for analog 3,2,1-OPP the major factor is carbon chain length.  An analog 
synthesized by Dr. Andrew Placzek (2,2,1,1-OPP) where the number of methylene units between 
the α- and β- isoprene units was decreased to one was also determined to be a poor substrate of 
GGTase-I.  Thus, the position and orientation of the β-isoprene unit is crucial. 
This class of compounds also revealed the γ-isoprene unit is unnecessary for activity 
(4.40c; 6,2,1-OPP). This is perhaps not surprising when taken into consideration the majority of 
possible pi-pi interactions occur between the enzyme and the β and ω-isoprene units (Figure 
6.4C).  Moreover, converting the allylic pyrophosphate into a homo-allylic pyrophosphate 
produced an inhibitor.  This is most likely do to the decreased nucleophilicity of the non-allylic 
pyrophosphate.   It would be interesting to synthesized frame-shifted analogs with a carbon chain 
length of 16 such as 1,3,2,1-OPP, 2,3,1,1-OPP and 3,2,1,1-OPP (Figure 6.1).  Additionally, it 
would also be interesting to synthesize an analog in which all the isoprene units except the β-
isoprene are present (2,6,1-OPP) (Figure 6.1). These new analogs could provide further insight 







6.4    Alkynyl-GGPP Analogs 
 
 Unfortunately, the alkynyl-GGPP analogs did not show as much promise in our in vitro 
biochemical screening assays.  Looking at the transformations that occurs throughout the reaction 
pathway of GGTase-I could provide a possible understanding of why the triazole compounds did 
not behave as substrates.  Preliminary modeling of analog 5.11 in the catalytic site to GGTase-I 
indicates the possibility of an unfavorable steric interaction with C177β (Figure 6.6A, dashed 
circle).  This observation taken together with the fact that introduction of the triazole into the 
compound decreases the flexibility of the analog could hinder binding to GGTase-I.  
Additionally, due to increased rigidity, it is possible that the prenylated product cannot shift 
readily into the exit grove of GGTase-I which would hinder product releases (Figure 6.1).  It is 
also possible that the prenylated product may not fit into the exit grove (Figure 6.6B, orange).  
Moreover, analog 5.11 could adopt an alternate conformation with in the exit grove (Figure 6.6B, 
violet).  This alternative position allows for favorable, stabilizing interactions between the 
triazole nitrogens and the hydroxyl group of Y40β and the backbone carbonyl of P317β.  Such 
stabilizing interactions could result in attenuated product release.  
Only the terminal alkyne (5.7) showed moderate substrate activity; however, as 
mentioned previously, it’s important to note that these compounds were only screened with one 
dansyl-GCaaX sequence.  Using combinatorial screening in the past, our laboratory has 
demonstrated that some modified FPP and GGPP analogs act as selective substrates.  These 
substrates only modify a very limited amount of CaaX sequences.73, 144  Thus, it is possible these 
analogs are substrates of GGTase-I but they are not a co-substrate with dansyl-CVLL.  Therefore, 
all these compounds will be evaluated more extensively in the future with combinatorial assays in 
which several libraries of dansyl-CaaX peptides will be screened.  These screens will provide us 
with a good indication of whether or not our substrates are global or selective prenyl donors.  
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Additionally, compounds that do not display substrate activity will be tested in a similar 
fluorescence-based assay to determine if these analogs are inhibitors of GGTase-I.  Finally, we 
also anticipate screening these analogs in a combinatorial screen and/or inhibitor screen with 
FTase.  These screens will provide insight into the differences and/or similarities of isoprene 
requirements of FTase and GGTase-I leading to a deeper understanding of the dynamic roles 




























Figure 6.2.  Structure of GGPP and CVLL or CVIL bound in the β-subunit of GGTase-I. A) 
Overlay of GGPP (magenta) and CVLL (ligh purple) and prenylated CVIL (blue).  B) Overay of 
prenylated CVIL (blue) in the catalytic site and prenylated CVIL in the exit grove (green) of 




Figure 6.3.  Aryl-modified analogs bound in the exit grove of GGTase-I.  Overlay of analog 2.6a 
(yellow, homobenzyl), 2.6b (purple, benzyl), 2.6c (red, cyclohexyl), & GGPP (green).  





















Figure 6.4.  Analyzing the distances between the Zn2+ ion or aromatic residues in the binding 
pocket of GGTase-I with isoprenoid chains.  A)  Shorter carbon chain analogs (yellow) that could 
bind deep in the GGTase-I pocket. B) Bound isopreind that is one carbon shorter than GGPP 





































Figure 6.5.  Analyzing the affects of increasing the number of carbons between the α and β-
isoprene units to three carbons. Overlay of GGPP (blue ) and A) 3,2,1-OPP (green), B) 2,3,1-OPP 
(purple) and C) 3,3,1-OPP (pink).  Potential unfavorable steric interactions are shown in dashed 












Figure 6.6.  Triazole-containing alkynyl-GGPP analogs bound in GGTase-I.  A) Overlay of 
analog 5.11 (orange) with GGPP (magenta) bound in the catalytic site.  B)  Overlay of analog 
5.11 (orange) and GGPP (green) bound in the exit grove of GGTase-I.  Alternative binding mode 
of analog 5.11 is also shown (violet).  Unfavorable steric interactions shown dashed circles (PDB: 
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